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Abstract 
Ordered mesoporous silica materials disclosed over the past two decades have 
been extensively used  in many applications as nanocarriers for delivering various 
therapeutic/ diagnostic agents, due to their ease of synthesis and surface 
functionalization, tunable pore size, and pore structure, high surface area, pore 
volume and controllable morphology. Currently, many research attempts have 
focused on the synthesis of mesoporous silica nanoparticles (MSN). Significant 
progress has been achieved to date. However, specific biomedical applications, for 
example, in the design of tablet formulations, as safe adjuvants in vaccine delivery 
and in combined cancer therapy should be developed further to explore the potential 
of this family of interesting materials.  
The aim of this project is to develop novel and facile approaches to prepare 
monodispersed MSN with finely controllable pore size and morphology for 1) to 
developing floating tablets, and 2) to gain insight into the role of particle morphology 
on hemocompatibility and adjuvanticity, and 3) to study the efficiency of combined 
therapy for cancer treatment. The main achievements obtained in this thesis are 
listed below. 
In the first part, novel floating tablets are designed using MSN for enhancing the drug 
delivery performance of both hydrophobic and hydrophilic drugs compared to 
conventional floating tablets. The drug released was tested from floating tablet, 
where the water soluble drug loaded MSN containing floating tablet show a 
sustained release than a conventional tablet. More importantly, dissolution 
improvement for the hydrophobic drug was achieved, an issue that was not solved 
with a conventional floating tablets. 
In the second part, asymmetric MSN with controllable head-tail structures were 
successfully synthesised. The tail length (~25-170 nm) and tail coverage on head 
particles are adjustable with varying the reaction time and tetraethyl orthosilicate 
(TEOS). Furthermore the head particle is tunable (solid silica to porous silica). The 
synthesised particles were tested for hemocompatibility. Furthermore, we applied the 
smooth solid silica spheres and head-tail MSN for uptake and activation efficiency in 
dendritic cells (DCs) and macrophages. Compared to solid head particles or MSN 
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with fully covered, dendritic large pores, asymmetrical HTMSN show surprisingly 
higher hemocompatibility towards red blood cells. Further, HTMSN were analyzed 
for immunoadjuvant activity. Interestingly, we found that asymmetrical HTMSN 
exhibit a higher level of uptake and in vitro maturation of antigen presenting cells 
compared to spherical head particles. 
In the third part, multifunctional core-shell-structured dendritic mesoporous silica 
nanoparticles with a fullerene doped silica core and a dendritic silica shell with large 
pores have been successfully prepared. The designed dendritic silica spheres with 
fullerene core (FD) have a particle size of ~110 nm and pore size of ~25 nm, which 
can be easily modified with octadecyl group. The prepared FD with big pore size 
after hydrophobic modification (FD-C18) shown good loading efficiency of big 
antibody (anti-pAkt). The FD-C18 has high cell internalization compared to FD, which 
was confirmed by ICPOES test and confocal and, the particle are less toxicity to 
breast cancer cell line (MCF-7) up to 160 ug/mL. The FD-C18 showed significant cell 
inhibition of ~ 85 % in combined therapy, while pure antibody shown only negligible 
cytotoxicity in breast cancer cell line (MCF-7). 
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Chapter 1 
 Introduction 
1.1 Significance of the work 
From past three decades, traditional polymer based floating tablets have been used 
for the delivery of hydrophilic and hydrophobic drugs. [1, 2] However, a conventional 
formulation cannot help in enhancement of bioavailability of hydrophobic drugs, 
which further hinders clinical applications. Thus, the quest to find an appropriate 
method for the formulation of floating tablet with improved drug solubility and 
controlled drug release still persists. Recently mesoporous silica nanoparticles 
(MSNs) have been extensively studied as one class of the most promising 
nanocarriers in biomedical applications, including cell imaging, diagnosis, vaccine, 
gene/antibody/drug delivery.[3-6] Increasingly, porous nanomaterials with adjustable 
pore sizes have been successfully applied in solubility enhancement[7-9] and 
controlled drug release.[10] By understanding the effect of pore size on the drug 
release and solubility enhancement a modified floating tablet in combination with 
polymer and MSNs can be developed for effective drug release. 
On the other hand, with parallel to the pore size, silica nanoparticle shape is also 
playing an important role in bio-applications. Recent studies have shown the 
advantage of silica nanoparticles shape in tumor cell targeting, [11] bimodal drug 
delivery. [12, 13] However, the influence of asymmetric silica nanoparticle shape on 
hemocompatibility and adjuvant effect remains unclear. Therefore, systemic 
synthesis of series of asymmetric silica nanoparticles and its influence on 
hemocompatibility and adjuvant effect should be explored for developing a safe and 
potent nanocarrier. 
There are tremendous studies in the synthesis and application of large pore silica 
nanoparticles in cancer therapy.[14] In addition, combination of chemotherapy and 
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photodynamic therapy for cancer treatment has also been reported.[15] However, 
chemotherapeutics drugs have limitations such as toxicity to normal cells, and 
multidrug resistant. In this context, silica nanocarrier with therapeutic proteins and 
photosensitizer delivery is required for effective treatment of cancer.  
 
1.2 Research objective and scope 
This research aims to develop novel floating tablets with improved solubility of 
hydrophobic drug and controlled release for hydrophilic drugs. This thesis does not 
only focus on the development of floating tablets, but also provides some guidelines 
for the synthesis of symmetric and asymmetric large pore silica nanoparticles. The 
synthesised materials were applied in the field of formulation, vaccines, and cancer 
therapy. The sentence is not very clear.The objectives of this project are specified as 
follows:  
a) To fabricate floating tablets from mesoporous silica nanoparticles, and to confirm 
the significance of MSN in drug release. 
b) To synthesise silica nanoparticles with varied tail lengths and testing the 
hemocompatibility and immunoadjuvant property. 
c) To synthesise dendritic mesoporous silica nanoparticles for combined therapeutic 
protein and photosensitizer for cancer treatment. 
 
1.3 Structure of the thesis 
This thesis is written according to the guidelines of the University of Queensland. 
The chapters in this thesis are presented in the following sequence: 
Chapter 1 Introduction  
This chapter includes a brief overview of the background of this research work 
including aims and significance of the work. 
Chapter 2 Literature review 
This chapter presents a detailed review of the contributions made by mesoporous 
silica nanoparticles in drug delivery systems. In addition, a detailed review on the 
contribution of particle shape and pore size of MSN in biological application. 
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Chapter 3 Methodology 
This chapter summarizes the strategies utilized in the whole PhD project, including 
material synthetic methods for small and large pore MSN, and the techniques for 
material characterizations and biological evaluations.  
Chapter 4 Floating tablets from mesoporous silica nanoparticles 
In this chapter we reported the preparation of floating tablets using MCM-41. Floating 
tablets were prepared with a specific pore size of MSN which has a significant 
solubility enhancement of hydrophobic drug and sustain release of hydrophilic drug. 
This chapter was published in Journal of Material Chemistry B.  
Chapter 5 Asymmetric silica nanoparticles with tunable head-tail structures 
enhance hemocompatibility and maturation of immune cells 
In this chapter we reported the synthesis of novel head-tail MSN using emulsion 
system. We achieved to synthesize various lengths of tail over head by changing the 
parameters like TEOS amount, reaction time and the head amount. The particles 
were tested for hemocompatibility and uptake efficiency into APC and inducing the 
maturation of APC cells.  
Chapter 6 Dendritic mesoporous silica nanoparticles: Combined therapeutic 
protein and fluorescence-image guided photosensitizer for cancer treatment 
In this chapter we reported the synthesis of novel dendritic particles with big pore 
size with a fullerene core and its advantage in cancer treatment. We have shown the 
advantage of big pore size dendritic particles with fullerene core in combined protein 
and photodynamic therapy in cancer treatment.  
Chapter 7 Conclusions and recommendations 
Conclusion and major contributions of this work are highlighted and 
recommendations for future works are presented. 
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                 Chapter 2 
                            Literature Review 
This chapter reviews the exiting studies on silica based nanoparticles (SiNPs) for 
pharmaceutical and biomedical applications. It begins with a brief introduction to 
current nanomaterials that have been widely used in medicine and the applications 
of silica nanoparticles in formulations, cancer therapy, photodynamic therapy and 
vaccines.  
2.1 Nanoparticles for application in medicine 
Many of the conventional organic drug delivery systems (such as liposomes, 
micelles and polymers) have reached the later stages towards clinical applications 
(Figure 2.1) and few of them have even received U.S. Food and Drug Administration 
(FDA) approval (Table 2.1).  The conventional nanocarriers developed so far have 
few major drawbacks hindering the clinical translation of laboratory-developed 
nanocarriers: 1) inherent toxicity, 2) cost and scalable fabrication. A variety of 
inorganic delivery systems with special morphologies and chemophysical properties 
are emerging due to the limitations of conventional nanocarriers. Among various 
inorganic materials, gold nanoparticles reached the clinical stage which are used in 
drug delivery, hyperthermia based treatment and detection.[1] Next to gold, a wide 
variety of silica nanoparticles such as solid, mesoporous, hollow silica nanoparticles, 
dendritic, asymmetric have been developed for biomedical applications to carry 
therapeutic drug/ gene/ protein/ peptide delivery, cell imaging agents.  In addition, 
silica based nanoparticles with tunable pore structures and particles size, surface 
area demonstrated excellent biocompatibility and safety profile at the cellular and 
animal level. These unique properties endow them with advantages to load and 
deliver various therapeutic agents to the targeted site.[2-4] Recently, the first silica 
based diagnostic nanoparticles called C-dots have received the FDA approval for 
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stage I clinical trials to use in melanoma patients. This proves the important step 
towards real application of silica nanoparticles. 
 
2.2 Silica nanoparticles in solubility enhancement and controlled 
drug release 
2.2.1 Enhancement of drug solubility using traditional method  
Bottom up and top down approaches are basically used for enhancement of drug 
solubility. The bottom up approach involves a controlled precipitation process in 
which the drug is dissolved in a solvent and this solvent solution is then added to a 
non-solvent medium resulting in precipitation of drug into amorphous or crystalline 
form. However, the main disadvantage of bottom up process is removal of the harsh 
organic solvents used in the process. Hence, this approach is not the preferable 
approach in enhancing the drug solubility.[5]  
Top-down approach includes techniques such as milling and homogenization.[6, 7] 
The most preferable method for milling is wet milling process, where the drug is 
dispersed in surfactant solution and subjected to milling process. In homogenization 
process drug is broken down to small size by exposing to high energy. [8]The 
sample preparation is very similar to wet milling process which involves preparation 
of dispersion medium containing drug and stabilizer.[8]  The advantage of 
homogenization process is reduction in time, microbiological issues and less 
contamination then milling process.[9] The major disadvantage of top-down 
approach is that it is time, energy consuming, and degradation due to mechanical 
stress.[10] In addition, special equipment are required for generating high energy for 
milling.[11] Due to the limited success achieved to date by nanotechnology 
approach, there is a need for the development of general technique to further 
increase the solubility of hydrophobic drugs. 
2.2.2 Enhancement of drug solubility using various approaches 
The hydrophobic drugs for example, low aqueous solubility hinder the ability of the 
drugs to be administered through the intravenous and oral routes. The solubility of 
drug is highly important for having high bioavailability while administering the drugs 
through oral route. According to the Biopharmaceutical classification system (BCS), 
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drugs are classified into four groups based on their solubility in gastrointestinal fluid 
and permeability through gastro intestinal tract (GIT). The four classes are: class I- 
high soluble and high permeable, Class II- low soluble and high permeable, class III- 
high soluble and low permeable, and class IV-low soluble and low permeable. The 
poor solubility in aqueous gastrointestinal fluid cause low oral bioavailability. 
Especially for class II drugs, low bioavailability is due to its poor solubility and 
dissolution in the aqueous solution. The solubility of drugs was enhanced by 
converting the pure drug to its salt form by conjugating with chlorides, carbonate, 
maleate, citrate etc. Many formulations with drug-salt conjugates have been 
commercially available such as Diclofenac sodium, chlorphenaramine maleate, 
etc.[12]  
Common methods for solubility enhancement are complexation of drug molecules 
within the cavity of cyclodextrin (CD). Various kinds of CD are currently available 
such as α-CD, β-CD, γ-CD, Hydroxypropyl β-CD, etc. Till date several dosage forms 
have been developed using CD to enhance the solubility of drugs such as Piroxicam, 
Itraconozole, Hydrocortisone, etc.[13] Co-solvents have also been used for 
enhancing the solubility of hydrophobic drugs. The most commonly used co-solvents 
are propylene glycol, ethanol, glycerine, polyethylene glycol, and Dimethylsulfoxide 
(DMSO), etc.[12] The conventional strategies applied for solubility enhancement face 
the problems of precipitation, toxicity and altered pharmacological activity [14, 15] 
and also this techniques cannot be applied for all hydrophobic drug molecules. 
2.2.3 MSNs as solubility enhancers 
Utilizing the inorganic mesoporous materials for enhancing the solubility of poorly 
soluble drugs is a rapid growing area in pharmaceutical research. The pore size is 
one of the most important factors of MSNs for its application in catalysis and drug 
delivery. The pore size of MSN was controlled by changing the synthetic conditions 
or by grafting process such as atomic layer deposition [16] and chemical vapour 
deposition (CVD)[17] and, vacuum assisted vapour deposition (VVD)[18] process. 
The pore size of MCM-41 was controlled by adjusting the pH of the synthesis mixture 
from pH 11.5 to 10.0 resulting in pore size variation from 3.8 nm to 5.3 nm. This pH 
variation during synthesis causes change in the electrostatic charge distribution 
which affects the interaction of micelle head group resulting in pore expansion. The 
Chapter 2 
   Literature Review 
 
- 9 - 
 
MCM-41 obtained by this process has different morphology based on the pH of the 
synthesis mixture.[19] Incorporation of drug molecules into pores of MSN will leads 
to drug size reduction at nanoscale range leading to high surface area and also 
converting from crystalline to non-crystalline form.[20] These effect leads to 
enhancement of drug solubility. The enhancement of drug solubility by MSN has 
been studied in MCM-41, MCM-48 and SBA-15 materials. The list of hydrophobic 
drugs used for solubility enhancement using inorganic nanoparticles is listed in Table 
2.1.[21] 
Table 2.1 Poorly soluble drugs studied on mesoporous materials. Reported from the 
reference.[21]  
Drug Solubility 
(mg/ml) 
BCS class Carrier Drug loading capacity 
(wt. %) 
Atazanavir 4.0–5.0 II NFM-1, AMS-6,  
STA-11 
28.2,31.5,32.8 
Carvedilol 0.583 II SBA-16, MCM-41,TiO2, 
Hydroxycarbonate, 
apatite 
25.0,25.0,22.8,22.5 
Celecoxib 0.003 II Carbon 28.5 
Ezetimibe 0.0085 II SBA-15 17.9 
Fenofibrate 0.25 II SBA-15, MCM-41 20.0,21.5 
Flurbiprofen 0.008 II FSM-16 30.0 
Furosemide 0.25 IV TCPSi, TOPSi 41.3 
Glibenclamide 0.004 II SBA-15 22.5 
Griseofulvin 0.009 II TCPSi, TOPSi 16.5, 17.3 
Ibuprofen 0.049 II MCM-41 2.5-37.1 
Indomethacin 0.0009 II Syloid 244, MCM-41, 
3DOM 
25-50 
Itraconazole 0.0096 II SBA-15 11.2 
Lovastatin 0.0004 II Mesoporous carbon 25.6-36.3 
Telmisartan 0.0035 II MCM-41, SBA-15 27.5 
Carbamazepine 0.018 II SBA-15 22.5 
Cinnarizine 0.75 II SBA-15 20.7 
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2.2.4 Nanomaterial for controlled drug release 
Since 2001, when MCM-41 was first proposed as drug-delivery system[22-24] silica-
based materials, such as SBA-15[25, 26] or MCM-48[27] and some metal-organic 
frameworks have been discussed as drug carriers and controlled-release systems. 
Recently several groups have reported drug storage and controlled delivery from 
MSNs. The advantages of the relatively large pore diameter and pore channels 
allowed easy accessibility as well as interesting release characteristics for the uptake 
and release of the drugs. 
In 2001, Maria-vellet and co-workers tested the ibuprofen release from MCM-41 with 
larger and small pore size. Interestingly, 68% of drug released was achieved from 
larger pore size and 55% from small pore size at 24 h.[22] The same group used a 
series of periodic mesoporous organosilica with same structural symmetry (p6mm) 
and similar morphology but different pore size (from 2.5 to 3.6 nm).[28] An increase 
in drug release was observed with relatively increase in pore size. These advances 
highlight the considerable potential of nanoporous materials with controlled pore size 
for high controlled drug delivery performance. 
In addition to the pore size effect, surface chemistry is another key factor affecting 
the drug release.[29, 30] Mesoporous silica shows a high density of silanol groups, 
which can be used to obtain functionalized surfaces by grafting organic silanes. In 
the case of unmodified MSNs, it consists only silanol groups which simply form weak 
hydrogen bonds with the drug. Hence, they are not strong enough to hold drug which 
leads to burst release. In light of its potential application in the area of sustained drug 
delivery, attempts have been made to introduce functional groups on the pore 
channel walls. Balas et al., reported amino functionalized MCM-41 and SBA-15 
mesoporous silica-based materials containing alendronate for bone repair or 
regeneration.[31] After 24 h in an aqueous alendronate solution, the amino-modified 
materials showed a drug loading almost 3 times higher than that of the unmodified 
materials. The adsorption of alendronate molecules on the amino-modified materials 
was 22 and 37% in SBA-15-NH2 and MCM-41-NH2, respectively. These alendronate 
loads are significantly larger than those obtained for the modified materials: 8 % in 
SBA-15 and 14 % in MCM-41. The work demonstrates that the amount of drug 
Chapter 2 
   Literature Review 
 
- 11 - 
 
adsorption can be modulated through modification of the surface of the pore walls 
through organic molecules. The control release of the drug can also be achieved by 
modifying the surface with hydrophobic species. The effect of organic modification 
on highly water soluble (captopril) drug release was studied. A well-defined, 
controlled drug release was achieved by tailoring the surface properties of 
mesoporous silica materials by regulating the degree of silylation.[32] Therefore, it 
can be concluded that the surface characteristics of the mesoporous carrier system 
play an important role in drug delivery profiles.  
2.2.5 Floating tablet preparations 
Control of placement of drug delivery system (DDS) in a specific region of the GI 
tract offers numerous advantages, especially for drugs: 1) exhibiting an absorption 
window in the GI tract, 2) drugs which are insoluble or undergoes degradation at 
high pH, and 3) disease which need a local effect for effective treatment.[33, 34] 
Over the last there decades, various approaches have been pursued to increase the 
retention of an oral dosage form in the stomach, including floating systems, swelling 
and expanding systems, bio adhesive systems,[35] modified-shape systems, high 
density systems, and other delayed gastric emptying devices. Among these floating 
delivery system is considered as an effective technique. The polymer and sodium 
bicarbonate are the two key ingredients used in the design of low density gastro 
retentive drug delivery system. Floating drug delivery systems were first described 
by Davis in 1968.[36] Since then several approaches have been used to develop an 
ideal floating delivery system. The design of floating technique has been used in 
making captopril (highly water soluble drug) tablets by changing the metolose 
(polymer) concentration.[37] The drug release decreased as the polymer 
concentration increases. However, 100% of drug released at 8th h at the highest 
polymer concentration. Mina Ibrahim and co-workers studied the drug release from 
ciprofloaxacin floating tablet with polymers HPMC K15M and sodium alginate.[38] 
The release profile of the drug was studied systematically by varying the ratios of two 
polymers. Tablet containing HPMC K15M (21.42%, W/W), Na alginate (7.14%, w/w) 
was showed the satisfactory results with 95% drug release at 12 h.  Many 
researchers formulated floating tablets for hydrophilic drugs, but very few have 
addressed the issue of solubility for hydrophobic drugs to formulate them as a 
floating tablet. In the polymer based designs controlling the release of highly water-
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soluble drug is limited. Moreover, drug and polymer are generally physically mixed 
which does not aid in enhancing solubility of inherently insoluble drugs.  
2.3 Silica nanoparticles in cell imaging and photosensitiser carrier 
Molecular imaging is the visualization, characterization, and measurement of 
biological processes at the molecular and cellular levels in humans and other living 
systems, which is very important to gain better understanding on mystery of life.[39] 
The functionalized fluorescent nanoparticles based cell imaging and sensing 
technique is of great interest because they are fast responsive, highly stable, in situ 
and in real time.[40]  
2.3.1 Silica particles in imaging 
There are two principal approaches to synthesize dye-doped SiNPs: the Stöber 
method and reverse microemulsion method. The Stöber method is simple and 
efficient approach to synthesise monodispersed solid SiNPs with a broad range of 
diameters from 50 nm to 2µm. Van Blaaderen and coworkers for the first time 
synthesised stable dispersions of monodispersed colloidal silica spheres containing 
dye or fluorophores according to general procedures and dispersed in polar and 
apolar solvents.[41] Wiesner and co-workers at Cornell University further extended 
this approach to develop water-soluble, non-toxic fluorescent core-shell silica 
nanoparticles (C dots) in a size range of 20-30 nm.[42] The C dots are biological 
probes shown enhanced dye quantum efficiencies, brightness and bio stability and 
reduced energy transfer effects, because of the restricted rotational mobility of 
organic dyes entrapped in the core of the C dots and the protection from molecular 
quenchers and solvent effects.[43] Bawendi and Frangioni group have studied the 
size effect on effective clearance, and they found that particle diameter between 3- 
7nm will have balanced reasonable circulation time and efficient clearance.[44] In 
2009, the authors developed poly(ethylene glycol) (PEG) modified C-dots (~7nm) 
which showed efficient renal clearance in mice compared with unmodified C 
dots.[45] Moreover, the C dots modified with the cyclic arginineglycine-aspartic acid 
(cRGD) peptide and radiolabeled with 124I showed its selective tumor targeting and 
real-time multimodal imaging in both small and large animal models.[46] The C dots 
received FDA investigational new drug approval for a first-in-human clinical trial in 
2011. For the trial conducted with C dots, administered under the FDA’s IND 
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guidelines showed that particles are safe for human use and leave no trace after 
renal excretion.  The researchers are organising to test the silica based inorganic 
nanoparticle in melanoma patients in developing an approved diagnostic agent. 
The second method to prepare dye-doped SiNPs is a water-in-oil reverse 
microemulsion method, which involves water, surfactant and oil. The hydrolysis and 
condensation of silica precursors and the formation of nanoparticles with dye trapped 
inside occur at the interface of surfactant stabilized water droplet inside the oil 
phase, to form fluorescent SiNPs. By changing the charge and packing properties of 
the surfactant in the micelles, water to surfactant ratio or the amount of free water 
and ammonium hydroxide concentration, the diameter of spherical monodispersed 
SiNPs can be adjusted from 20 to 500 nm.[47, 48] Monodispersed SiNPs with the 
diameters of 30-60 nm was achieved by microemulsion method. However, the 
dispersity of  SiNPs was not better in the Stöber method. However, the utilization of 
large amount of surfactants required extensive washing steps, which limits the 
potential of microemulsion method for industrial/mass production. At the beginning, 
the reverse microemulsion method can only be used to incorporate inorganic dyes, 
but the resultant inorganic-dye-doped SiNPs have limited fluorescence intensity, 
because inorganic dyes have lower quantum yields compared with organic 
fluorophores.[49-51] Organic dye doped SiNPs are difficult to prepare using reverse 
microemulsion method due to hydrophobic properties of the organic dyes compared 
with the hydrophilic surface of the SiNPs. In 2004, Tan and co-workers reported a 
modified microemulsion method to successfully incorporate the organic dye into 
SiNPs.[52] Since then, various single-dye doped SiNPs and multiple-dye 
incorporated SiNPs can be generated using this method.[53] Multiple dyes 
synchronously encapsulated in SiNP will help in fluorescence resonance energy 
transfer (FRET) mediated large stokes shifting fluorescence resonance probes. 
Hybrid SiNPs doped with PbSe quantum dots (QDs) have also been reported for cell 
imaging using the microemulsion method.[54] The toxicity of QDs was reduced by 
single or multiple coating of silica shell, which further enhanced the water-solubility.  
Huo et al., developed an hybrid fluorescent SiNPs with uniform particle size of ~ 10 
nm by micelle templating approach, with significant improved stability.[55] In 
addition, Wang et al., utilized similar approach to obtain an ultra-small, highly stable 
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and sensitive dual nanosensor for imaging intracellular oxygen and pH in cytosol.[56] 
Furthermore, the dual fluorescent dyes doped SiNPs was developed by Wolfbeis et 
al., using same approach. The nanosensors are pH-sensitive which have capacity of 
sensing pH value and oxygen in cellular cytosol.[57] Furthermore, hollow 
mesoporous silica nanoparticles (HMSNs) with a large cavity inside and mesopores 
in the silica walls have also been reported for optical imaging, positron emission 
tomography (PET), magnetic resonance imaging [58] and ultrasound imaging in both 
in vitro and in vivo models.[59] 
2.3.2 Silica particles in photodynamic therapy 
Photodynamic therapy is an alternative tumor ablative oncological intervention. 
Essentially, it involves the administration of a photosensitizer [58] followed by local 
illumination of the tumor with light of a specific wavelength to activate the PS. The 
excited PS then transfer its energy to molecular oxygen, thus generating cytotoxic 
reactive oxygen species (ROS), such as singlet oxygen (1O2) that can oxidize key 
cellular macromoleculer leading to tumour cell ablation (Figure 2.1).[60] 
 
 
Figure 2.1 A typical photodynamic reaction. Reproduces from reference.[60] 
For application in photodynamic therapy Stöber silica nanoparticles and mesoporous 
silica nanoparticles are frequently used. These nanoparticles are often used as a 
vector for PDT due to its flexible synthesis procedure, chemical inertness, 
transparency of the matrix to light absorption and porosity. The effectiveness of PDT 
depends on the production of reactive oxygen species (1O2) within the cell. The 
efficacy of the photodynamic treatment strongly depends on the type, concentration 
and intracellular localization of the photosensitizer. Some of the most common 
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photosensitizers that have been approved for use in humans are indicated in Table 
2.2. 
Table 2.2 List of photosensitisers approved for human use. 
Photosensitizer Type of disease Country 
(5-ALA) Actinic Keratosis U.S., EU 
5-aminolevulinate Basal cell carcinoma  
Photofrin Barrett‘s displasia U.S., Canada, EU, UK 
Photofrin Cervical cancer Japan 
Photofrin Endobronchialcancer Canada, Most EU Countries, Japan, U.S. 
Photofrin Esophageal cancer Canada, Most EU Countries, Japan, U.S. 
Photofrin Gastric cancer Japan 
Photofrin Papillary bladder cancer Canada 
Foscan Head and neck cancer EU, Norway, Iceland 
Verteporfin Age-related Macular 
Degeneration 
Canada, Most EU Countries, Japan, U.S. 
In 2003, Kopelman first used amino-propyltriethoxysilane reagent for the initiating the 
hydrolysis polycondesation of tetramethylorthosilicate for the high efficient 
encapsulation of meso meta-tetral(hydroxyphenyl)chlorine (m-THPC) into silica 
nanoparticles. To characterise the 1O2 formation, anthracene-9,10-dipropionic acid 
(ADPA) was used. The same group published the encapsulation of methylene blue 
to vectorize it and protect it from degradation. In 2003, Prasad group prepared 
ORMOSIL nanoparticles for the entrapment of 2-devinyl-2-(1-hexyloxyethyl)-
pyropheophorbide (HPPH), a photosensitizer which is in phase I/II clinical trials for 
treating esophageal cancer.[61] The entrapped PS was found to generate 1O2 
efficiently upon irradiation. In a subsequent study the same group covalently 
conjugated PS iodobenzylpyrophenophorbide to ORMOSIL nanoparticles, to avoid 
premature release. Another type of PS phthalocyanine 4 Pc4, PpIX [62] and 
mTHPC[63] was also encapsulated in ORMOSIL nanoparticles by method 
developed by Prasad group, which has improved solubility, stability and delivery into 
A-375 cells compared to free drug.[64] 
Other type of silica nanoparticles have been used for the encapsulation of PS. Wei 
and collaborators[65] prepared hollow SiNP by careful hydrolysis of N-(β-
aminoethyl)-α-aminopropyl triethoxysilane by ammonia for successful encapsulation 
Chapter 2 
   Literature Review 
 
- 16 - 
 
of hypocrelline A into hollow SiNP. These particles were found to have good light 
and thermal stability. The same collaborator[66] reported the preparation of 
hypocrelline A nanoparticles by reprecipitation followed by encapsulation using N-(β 
aminoethyl)-α-aminopropyl triethoxysilane to form 110 nm silica nanovehicles. These 
particles have also shown superior light stability and singlet oxygen generation ability 
than bare PS. Qian et al. reported the synthesis of ultra small (25 nm) MSN with high 
dispersity for encapsulation of PpIX.[67]  These nanoparticles induced high cell 
death via necrotic pathway (HeLa cell line) upon photoexcitation with 532 nm light for 
8 min. 
Encapsulation of PS into MSN may leads to leaching from the nanocarrier, leading to 
reduced efficiency. Zhang et al., developed multifunctional core shell structured 
nanoparticles composed of FITC doped silica core and PS, hematoporphyrin 
covalently linked to MSN shell. [68] The particles exhibited excellent photo-oxidation 
efficiency and cell imaging ability. Teng et al., synthesised folate conjugated 
phospholipid-capped PpIX-loaded and FITC-sensitized MSN for targeted intracellular 
delivery of the nanocarriers.[69] The developed nanocarrier has high cell uptake and 
efficiency in decreasing cell toxicity than free PpIX. The developed nanocarrier 
decreased 65 % of tumour volume in nude mice bearing melanoma tumours after 
irradiating the carrier with laser at 630 nm. Another dual delivery using MSN 
composite was fabricated by zhao et al., for the combined delivery of carboxy 
aluminium phthalocyanine (AlC4Pc) for photodynamic therapy (PDT) and small Pb 
nanosheets for photothermal therapy (PTT).[70] While the PS was covalently 
conjugated to MSN, the Pb was coated on the surface of MSN via electrostatic 
interaction. The cell viability of HeLa cells was dropped to 35 % upon treatment with 
functional nanocomposites, which was significantly higher than individual treatment.  
Yang et al., precisely synthesised various morphologies of MSN by changing the 
amount of organic PS (Ce6) molecules covalently doped in the silica matrix.[71] The 
shape of  MSN was transformed from spherical to rod shape with increase in Ce6 
amount. A chemotherapeutic drug doxorubicin was physically adsorbed into the 
mesopores. Among different shape particles, the Ce6 loading efficiency and uptake 
into cancer cell was high in rod shape particle with an aspect ratio of 4.6. Moreover, 
the synergistic effect of PS/DOX was found to be much higher than single therapy. 
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Some nanoscale materials act as a PS due to its ability to generate ROS upon 
exposed to lazer light because of its optical absorption properties. Fullerenes are 
one class of PS discovered in 1985, with spherical shape and composed of 60 (C60) 
or 70 (C70) carbon atoms (Figure). The diameter of fullerene is very small, thus 
making it’s less likely to be taken up by the macrophages cells. Fullerenes absorb 
light in the ultraviolet [72] or blue region of electromagnetic spectrum to form long-
lived triplet state and generate ROS upon illumination. Fullerenes are photostable 
and highly resistant to photo bleaching[73] and undergo both Type I and Type II 
reactions in producing both free radicals and 1O2. The major disadvantage of 
fullerene is its poor biodegradability, solubility. This short comes have been solved 
by PEG modifications, encapsulation in liposomes,[74] micelles[75] or chitosan.[76] 
Liu and others developed theranostic hybrid system in which 
diethylenetriaminepentaacetic acid (DTPA) was attached to the terminal group of 
PEGylated C60 (C60-PEG-DTPA).[77] This complex was conjugated to gadolinium to 
form C60-PEG-DTPA-Gd. Upon light irradiation, following intravenous injection of 
complex to tumor bearing mice, there was a drastic reduction in tumour volume due 
to the PDT effect. In another study, malonic acid C60 derivatives (DMA-C60) modified 
with DSPE-PEG2000-maleimide was conjugated to Asn-Gly-Arg  peptide, to form a 
novel tumor-targeting drug delivery system.[78] The presence of targeted peptide 
shown enhanced cell uptake and strong cell inhibition on MCF-7 cell line. 
2.4 PDT in Combination therapy for cancer treatment 
Combination therapy is a common practice in many medical disciplines. Previously 
small molecule drugs are the most commonly used for cancer treatment, such as 
hydrophobic anticancer drug of doxorubicin,[79] hydrophobic drug of tamoxifen[80] 
and curcumin.[81, 82] However, pharmaceutical drugs have evident drawbacks of 
non-specific toxicity to normal cells and multi-drug resistance (MDR). Therefore, new 
drugs with better safety and high specificity are required. Currently, genetic and 
protein-based biomolecules have attracted much attention as new therapeutics due 
to its advantages.  
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2.4.1 Anti-oxidant agents 
Buettner and co-workers demonstrated that in the presence of iron, ascorbate 
combined with photofrin/ PDT enhanced the production of radicals and decreased 
cell survival of various cancer cell lines.[83] Other authors studied the effect of the 
combination with benzoporphyrin/PDT in HL60 cells. They concluded that the 
addition of ascorbate to cells, followed by photosensitization would strongly enhance 
the toxicity of cells.[84] Melnikova et al., demonstrated a remarkable reduction of 
tumor after injection of alpha-tocopherol analogue in combination with 
mTHPC/PDT.[85]  
2.4.2 Chemotherapeutic agents 
Chemotherapeutic agents are divided into two categories according to their direct 
and indirect effect on DNA. Drugs which directly act on DNA are composed of 
alkylating agents, antitumor antibiotics and inhibitors of topoisomerases. 
Cisplatin, oxaliplatin and carboplatin are commonly used drugs to treat different 
cancers. However, their good clinical efficacy is hindered by severe adverse effects. 
Lottner et al.,[86] developed a new approach for the combination of cisplatin and 
PDT. The authors have synthesized different hematoporphyrin based platinum 
derivatives bearing phototoxic ligands for photodynamic effect. The authors 
evaluated the cytotoxicity and phototoxicity of some of these derivatives against 
bladder cancer and normal urothelial cells. Carboplatin a less nephrotoxic analogue 
of cisplatin, has been employed in combination of 9-hydroxypheophorbide alpha (9-
HPbD)/PDT to treat head and neck cancer cell lines in vitro.[87] 
Among the antitumor antibiotics, doxorubicin is commonly used in the treatment of a 
wide range of cancer such as haematological malignancies, carcinomas and soft 
tissue sarcomas. Casas et al.,[88] evaluated the interaction between 5-ALA/PDT and 
doxorubicin in mice bearing transplantable mammary adenocarcinomas. Treatments 
with two cytotoxic drugs in common clinical use did not cause any reduction of the 
murine tumors tested. Tumor explants of doxorubicin-treated mice were first 
subjected to 5-ALA/PDT in vitro and then re-implanted into test animals that showed 
strong inhibition of tumour growth in combined treatment. The authors assigned the 
observed enhancement of PDT to the weakening of cellular defence mechanisms by 
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the pre-treatment involving free radical generation by doxorubicin. Canti et al.,[89] 
investigated the combination of PDT, with disulfonated aluminium phthalocyanine 
(AlS2Pc) and lazer light, and doxorubicin on mice bearing murine leukemia and 
lymphoma. Low chemotherapy doses were ineffective, but the combination of 
doxorubicin and AlS2Pc/PDT had improved clinical implications. 
Shiah et al., [90] studied the antitumor activity of (N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymer and Adriamycin conjugates in 
combination therapy. Combination therapy and PDT of P-ADR and P-Mce6 exhibited 
high therapeutic efficacy against human ovarian OVCAR-3 carcinoma xenografts. 
The cytotoxic and antitumor effects of doxorubicin in combination with mTHPC)/PDT 
have also been verified both in vitro (murine hepatoma cells) and in vivo (murine 
liver)[91]. The anticancer efficacy of doxorubicin in combination with methylene 
blue/PDT has been investigated in a drug-resistant mouse tumor model [92]. 
Nanoparticle-mediated combination treatment resulted in enhanced tumor 
accumulation of both doxorubicin and methylene blue, significant inhibition of tumor 
cell proliferation, increased induction of apoptosis and improved animal survival.  
Jianquan et al., [93] developed one strategy delivery system for targeting anticancer 
prodrug with both chemo and photodynamic therapeutic actions. The prodrug can 
enter folate receptor positive cancer cells and kill the cells via intracellular release of 
active drug form. The combined effect of chemotherapy and PDT increased the 
therapeutic efficacy of the DOX-fullerene combined prodrug. Guangbao et al., [71] 
synthesised mesoporous silica nanorods and spheres, which was intrinsically doped 
with photosensitizer, chlorine e6(Ce6) and loaded with DOX. The significance of 
combined therapy was successfully realized in both in vitro cellular experiments and 
in vivo animal studies. Compared with combination therapy using free drugs, the 
nanoparticle formulation had longer retention times in the tumor and thus offered 
improved therapeutic outcome. Yannan et al., [94] prepared well dispersed hollow 
silica fullerene-DOX nanoparticles with the particle size of ~50 nm. Hollow silica 
nanoparticles has shown high drug loading capacity and improved photodynamic 
activity compared with solid silica nanoparticles. Moreover, the combined of chemo-
photodynamic therapy demonstrated excellent performance in cancer cells leading to 
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high cell apoptosis. Multifunctional hollow mesoporous silica nanocages for cancer 
cell detection and the combined chemotherapy and photodynamic therapy was 
studied.[95] In vitro cell assays demonstrated that the nanocages could be used as 
probes for fluorescence imaging and biocompatible carrier for loading and delivery of 
chemotherapeutic drugs DOX and photosensitizer hematoporphyrin. 
2.4.3 Protein therapeutics for cancer therapy 
Multidrug resistance is the most important impediment for the successful use of 
chemotherapeutic drugs. The drawback of multidrug resistance has led to the 
development of safe and effective therapeutic system. Among several, protein 
therapy has been significantly improved, especially in the last decade. In this part, 
the classification of protein therapeutics for cancer therapy will be summarized.  
2.4.3.1 Enzymes 
The use of enzyme proteins as therapeutics is very promising because of their high 
targeted binding affinity and specificity. An enzyme catalytic activity allows for rapid 
conversion of multiple target molecules into product. These unique properties make 
enzymes promising therapeutic agents [96] and use as a therapeutic agent since the 
beginning of twenty century.[97]  
Intracellular delivery of proteins with enzymatic activities can help to catalysing a 
chemical reaction in cancer cells. One of the examples is ribonuclease A (RNase A), 
which is a mature enzyme, as secreted by exocrine cells in the bovine pancreas.[98] 
After intracellular delivery of RNase A, it initiates the degradation of mRNA and tRNA 
and stops protein synthesis, thus strongly influence cell functions and cause 
deleterious effects on cell viability.[99] In addition, type-1 ribosome-inactivating 
protein, saporin-S6 (also known as saporin) has also have similar properties of 
RNase A. It is widely distributed among plant genera, and confirmed to specifically 
remove A4324 adenine residue in 28S rRNA in the 60S subunit of rat ribosome, so 
that it can damage ribosomes irreversibly and inhibit protein synthesis. The high 
enzymatic activity, stability and resistance to conjugation to blood protease, makes 
saporin-S6 a useful tool for cancer treatment.[100] A variety of nanocarriers have 
been studied for the delivery of enzymatic protein for cancer therapy. For instance, 
hydrophobic modified, negatively charged silica nanoparticles (SiNP) were used to 
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immobilize RNase A on the surface and deliver it into human breast cancer cells 
(MCF-7) for cell growth inhibition. A dose dependent cytotoxicity was observed for 
the SiNP-RNase upon incubation with MCF-7.[101] 
2.4.3.2 Targeting proteins 
Proteins or peptides can be conjugated to nanoparticles with the help of electrostatic 
forces, hydrogen bonds and disulphide bonds, to form 3-dimensional (3-D) rough 
and flawy structures, which can help in targeted interaction of proteins with other 
molecules.[102] The targeting proteins will specifically interact with molecules inside 
or on the surface of cancer cells to block the cell functions. Monoclonal antibodies 
(mAbs) with high binding specificity have been widely used in numerous ways, and 
grown to be the largest class of human medicine within the top ten best-selling 
drugs. The delivery of monoclonal antibody  (antipAkt) into cytosols of cancer cells 
has been reported.[101] In addition, the delivery of functionalised mesoporous silica 
entrapped anti-CTLA4 IgG mAb induced much greater extent of therapeutic 
response than the same given alone.[103]. Alternatively, cytotoxic drug conjugated 
peptides can also be used for cancer treatment. One example is application of 
mRNA for targeting SSTR3 and SSSTR5 receptors (appears to express in some 
cancers). However, this lead to some inconclusive and controversial results. AN-238 
a targeted cytotoxic SST analogue, which consist of DOX, 2-pyrrolino-DOX was 
developed for effective cell growth inhibition in multiple cancer cell lines.[104]  
Yuting et al., [105] reported a successful delivery of the anti-pAKt antibody 
conjugated to hydrophobic modified rough silica nanoparticles to MCF-7 cell lines. 
The rough silica nanoparticles with high loading of anti-pAKt antibody demonstrated 
high efficiency of intracellular delivery of therapeutic protein in cancer cells and 
caused significant cell growth inhibition. Xin et al., [106] synthesised multifunctional 
upconversion nanoplaform with combined PDT and gene therapy for effective cancer 
killing. Combining PDT and gene therapy both delivered by upconversion 
nanoparticles also served as an imaging tool for real time tracking. Utilizing 
multifunctional nano-complex with both SiRNA, photosensitizer (Ce6) an effective 
cancer killing was achieved. MSN as a codelivery system has also been designed for 
co-delivering of chemotherapeutic drug and SiRNA silencing ABC transporters gene 
MDRI,[107] chemotherapeutic drug and SiRNA silencing Bcl-2 gene,[108] and 
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chemotherapeutic drug and surfactant chemosensitizer.[109] The co-delivery of Bcl-
2- SiRNA and DOX, has increased the anti cancer activity 132 times higher 
compared to pure drug.[108] 
2.5 Hemocompatability of MSNs 
Mesoporous silica nanoparticles have been put forward as the prominent drug 
delivery system which was proven by several studies conducted in the last decade. 
However, there are a few concerns regarding its hemocompatability in scientific 
community. Silica is reported to have LD50 of 1.5 mg/kg for intravenous 
administration in rats while LD50 of 3.16 g/kg for oral administration in rats proposing 
its safety. However, considering numerous variants such as particle size, porosity, 
shape, surface functionalization and structure within the mesoporous silica family, it 
is not surprising to encounter several conflicting results, making the biocompatibility 
assessment of these materials a subject of intense debate.[110] 
The influence of aminopropyl, mercaptoproplyl, and carboxyethyl-tetheraed modified 
SBA-15 on hemolysis was studied by comparing with unmodified SBA-15 and 
modified amorphous silica (a-SiO2). a-SiO2 showed high hemolysis than unmodified 
SBA-15 at an incubation time of 24 h. While aminopropyl, mercaptoproplyl, and 
carboxyethyl-tetheraed modified SBA-15 showed less hemolysis at low 
concentration. However, at high concentration of 750 µg/ml aminomodified SBA-15 
showed 50 % hemolysis.[111] On the other hand, in the other study it was shown 
that the MSN functionalized with organic groups has less or reduced hemolytic 
activity. [112] 
Impact of shape and pore size of MSN on serum proteins adsorption and RBCs 
hemolysis was evaluated, where MSNs with the particle size of  67 and 68 nm and 
pore size of 2 and 3 nm were found to be less toxic than porous rod with an aspect 
ratio of 3.[113] In the same study they have shown that MSN with the aspect ratio of 
4 and 8 displayed lower hemolysis than the MSN with an aspect ratio of 2. Similarly 
silica nanoparticle design dependent hemocompatibility effect was studied using 
various aspect ratios mesoporous SiO2. Mesoporous SiO2 with high aspect ratio of 4 
and 8 demonstrated lower hemolysis activity than spherical or lower aspect ratio (2) 
mesoporous SiO2.[114] However, the amine modified SiO2 caused rapid hemolysis 
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for all types of nanoparticles irrespective of aspect ratio. In another study the 
interaction effect of MSN with different morphologies on RBCs was studied where it 
was found that the higher aspect ratio MSN demonstrated lower hemolysis at a 
concentration of 250 and 500 µg/ml than spherical and lower aspect ratio MSN 
particles.[115] 
The influence of MSN size, pore ordering and pore integrity on hemocompatibility 
was studied by comparing solid silica spheres with porous MSN of various 
sizes.[116] It was found that small silica nanoparticles (SS NP) with the diameter of 
24 nm caused high hemolysis compared to SS NP with the diameter of 37, 142 and 
263 nm. It was found that the mesoporous silica nanoparticles (MS NP) with the 
diameter of 24 nm were caused less hemolysis than the SS NP with the diameter of 
24 nm. Overall, compared to SS NP with similar size, MS NP caused reduced 
hemolysis activity. Furthermore, the haemolytic activity of MS NP with particle size of 
25 and 42 nm increased when the ordered pores was collapsed. However, the 
haemolytic activity of MS NP with particle size of 25 and 42 nm was decreased after 
polyethylene glycol modification. Additionally, Slowing et al. demonstrated that 
haemolytic effect of amorphous silica is higher than MSN.[117] The author further 
demonstrated that the haemolytic activity of amorphous silica can be supressed after 
amino modification. 
As research efforts towards the synthesis of various MSNs and their potential 
applications in biological and medicine have intensively continued, concerns 
regarding the potential toxicity of the engineered nanomaterials in human health and 
on the environment have also been raised. Shami et.al.,[118] investigated the 
biological responses of various extracted murine tissues, including lung, liver, kidney, 
spleen, and pancreas after exposing to 200 µg/ml calcined SBA-15 and MCM-41 
particles for hours. The results showed that the murine tissues did not exhibit any 
changes in their microscopic structures and bioenergetics after exposure to both 
type of MSNs.  The results show that calcined MSNs have very promising 
biocompatibility when administered at reasonable dose. Tang and co-workers[119] 
investigated the biodistribution and excretion of different MSNs in mice, after 
injecting the tail veins of mice with rod-like fluorescein-conjugated MSNs possessing 
different aspect ratios of 1.5 and 5. MSNs were found in both urine and feces 
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samples, there were detected in lower amounts in the kidney and liver, suggesting 
that the MSNs could be more rapidly excreated via renal uptake than hepatic 
digestion. 
2.6 Mesoporous silica nanoparticles in vaccine 
The current vaccine challenges comprise the induction of strong immunoprotective 
responses in the host in a safe manner and at lower cost. MSN with a highly ordered 
pore structure have been used as an antigen carrier due to the interesting properties 
like antigen protection and targeting antigen to antigen presenting cells [120]. Mody 
et al., summarized the immunomodulatory properties of different nanoparticles such 
as aluminium salts, chitosan, ISCOMs, liposomes, and polymeric and silica 
nanoparticles (SPs).[121] Luciana et al., compared the adjuvant effect of SBA-15 
with the licenced adjuvant Al(OH)3 and IFA. SBA-15 has high immunogenicity and 
improved immune response than the licenced adjuvant. Moreover, SBA-15 
stimulated mutually high TH1 and TH2 immune response. In vitro assays with 
macrophages demonstrated that SBA-15 has high phagocytic uptake and least cell 
integrity.[122] Helen et al.[123] compared the activation of human monocyte derived 
dendritic cell after exposing to AMS-6, calcined and cyanopropyl functionalized SBA-
15 (SBA-15 PrCN). SBA-15 at the highest concentration showed similar immune 
regulatory effect on MDDCs as AMS-6 for CD86. In contrast, SBA-15 PrCN did not 
cause statistically significant changes on MDDCs. In addition, SBA-15 at the highest 
concentration also induced a significant increased number of cells producing IL-4 
and IL-13 and generated a mixed response of both TH1 and TH2 cytokines. Xiupeng 
et al.[124] studied the hollow mesoporous silica (HMS) in generating antitumor 
immunity, promoting memory response and stimulating TH1 antitumor immunity in 
vivo. HMS nanospheres markedly improved the population of CD4+ and CD8+ 
effector memory T cells in the bone marrow. Moreover, plain HMS nanospheres 
showed greatly inhibited tumor growth compared with alum and without adjuvant. In 
addition, plan HMS stimulated both TH1 and TH2 immunity than commercial adjuvant 
alum. Jaeyun et al., studied the injectable pore forming scaffolds based on 
mesoporous silica rods (MSR), and tested their efficacy in modulation of immune 
cells and potentials as a vaccine platform to provoke adaptive immune 
response.[125] MSR with the aspect ratio (AR) of 88 X 4.5 µm and 37 X 3.2 µm in 
Chapter 2 
   Literature Review 
 
- 25 - 
 
length and diameter were studied for immune response. In which higher AR particle 
has 2.5 fold more host immune cells residing in the structure than lower AR MSRs. 
MSR in conjugation with antigen, recruited more dendritic cells and high cell surface 
expression of CD86+ and MHCII+, as compared to bare MSR particles. Mice 
immunized with full MSR vaccine showed significant proliferation of Thy 1.2+ cells 
and generated a high CD4+ CXCR5+ T helper cell clonal expression and TFH 
differentiation.[125] 
Smith et al., systematically studied the influence of particle size on targeting dendritic 
cells (DCs). They have demonstrated that particle size less than 20-30 nm can reach 
DCs directly. A scheme below shows the SPs delivery draining into lymph nodes 
(Figure 2.2). On the other hand, particle size above 20 nm can be phagocyted by 
and uptake by DCs is shown below.[126]  
In addition to the particle size, the surface charge of the nanoparticles can also affect 
the immune response. A positive charge on the particle surface leads to an effective 
macrophage and DC uptake due to the negative charged DCs surface.[128] Foged 
et al.,[129] observed that nanoparticles with the particle size of 500 nm has high DCs 
uptake, and further concluded that the uptake of nanoparticles with the particles size 
> 500 nm can be enhanced with amino modification. Weiwei et al., studied the effect 
of surface modification of mesoporous silica micro rod scaffold on immune cell 
activation and infilteration.[130] PEG and PEG-RGD modified MSR particles were 
tested for immune cell adhesion, cell infiltration and Nlrp3 inflammasome production. 
PEG modified MSR induced high CD86 expression than RGD modified MSR. 
Moreover, PEG-MSR induced high IL-1b expression than RGD-MSR nanorods. 
PEG-RGD modified MSRs displayed decreased inflammatory effect as compared to 
PEG-MSR. 
The role of other important parameters of particles in modulating the immune 
response is not thoroughly understood. Several recent in vitro studies have provided 
evidence that particles shape will also plays an important role in modulating 
interaction with the APC, and T cells. Kumar et al.[131] conducted a comparative 
study of spherical and rod shape particles of different size in modulating an immune 
response. It has been reported that spherical particle of 193 nm, rods-376 and 
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Figure 2.2 Delivery of silica nanoparticles based nanovaccines (20-200 nm particle 
size) by parental (A) and mucosal (B) routes. Reproduces from the reference.[127] 
spherical-521 nm produced both Th1 (IgG-2a) and Th2 (IgG-1) type immune 
response. However, rods-1530 failed to develop IgG-2a antibody titres. Sphere-193 
produced significantly increased level of IFN-γ as compared to other groups. 
Bingbing et al., [132] prepared rod shaped aluminium hydroxide nanoparticles with 
the length of 810, 592 and 451 nm, and studied the influence of shape and 
crystallinity for NLRP3 inflammosome activation, cytokine production, and adaptive 
humoral immunity response. Rod shape nanoparticles induced significantly high IL-1 
beta than the commercial adjuvant Alum. All lengths of rods generated MHC-II 
expression and induced significant expression of costimulatory molecules (CD40, 
CD80 and CD86), which was significantly higher than Alum. Wang et al., [133] in 
2012 studies the effect of silica nanoparticle pore size, geometry and particle size on 
immunological properties by injecting the nanoparticles orally into Balb/C mice using 
Bovine serum albumin (BSA) as model adjuvant. The three silica nanoparticles with 
the particle size of 130(S1), 430(S2), nm and 1-2(SBA-15) µm was used in the study 
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with an average pore size of 4, 60 and 7 nm, respectively. The IgG antibody in the 
plasma after oral vaccination of BSA loaded S1, S2, SBA-15 was in the order of 
S1>S2>SBA-15. 
Kenichi et al., [134] studied the influence of gold nanoparticle size and shape on 
immunological responses in vitro and in vivo for the production of antibodies for West 
Nile virus (WNV). Where they prepared spherical (20 and 40 nm diameter), rod (40 
×10 nm) and cubic (40 ×40 × 40 nm) as adjuvant and coated with WNV protein. The 
40 nm spherical particle induced highest level of WNV specific antibodies than rod 
and cubic particles. In contrast, uptake of the rod shape nanoparticles was more 
efficient than the spherical and cubic particles. Meanwhile, spheres and cube shape 
particles induced significantly high inflammatory cytokine production, TNF-alpha, IL-
6, IL-12 than rods. In another study, Zhen et al.[135] studied the shape effect of 
glycol-nanoparticles (GNP) on macrophage cellular uptake and immune response. It 
was found that spherical GNP was internalized more by RAW 264.7 macrophages 
than cylindrical GNP. It was found that all the GNP irrespective of shape stimulated 
higher secretion of the inflammatory cytokines compared to the control group. 
2.7 Synthesis of mesoporous silica nanoparticles  
2.7.1 Synthesis of small pore mesoporous silica nanoparticles 
Mesoporous silica nanoparticles (MSNs) are inorganic silica nanoparticles composed 
of silica with uniform particle size and ordered mesopores. [136] The first MSNs were 
discovered by Mobile researchers in 1992 which was named as Mobile Crystalline 
Materials (MCM-41) for catalysis.[137] MCM-41 materials were prepared by using 
two different surfactants-dodecyltrimethylammonium bromide (C12TAB) and 
hexadecyltrimethylammonium bromide (C16TAB) to achieve a pore size of 2.5 nm 
and 1.8 nm, respectively. MSN whose attributes include high surface area, 
adjustable pore size and particle size, easy surface modification which leads to its 
application in adsorption of therapeutic molecules, catalysis activity, sensor and 
various other fields.[138-145] The use of MSN in as a drug carrier was first reported 
by Maria Vallet-Regi et al., in delivering Ibuprofen.[22] They have demonstrated that 
the drug release appeared to be pore size dependent and thus demonstrated the 
application of MCM-41 as drug carrier. Szegedi at al., [146] also reported the loading 
of ibuprofen into different amounts of 3-aminopropyltriethoxysilane (APTES) modified 
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MCM-41. Amino modification resulted in high degree of ibuprofen loading and slow 
release into dissolution medium. 
2.2.1 Synthesis of small pore mesoporous silica nanoparticles 
Mesoporous silica nanoparticles (MSNs) are inorganic silica nanoparticles composed 
of silica with uniform particle size and ordered mesopores. [5] The first MSNs were 
discovered by Mobile researchers in 1992 which was named as Mobile Crystalline 
Materials (MCM-41) for catalysis.[6] MCM-41 materials were prepared by using two 
different surfactants-dodecyltrimethylammonium bromide (C12TAB) and 
hexadecyltrimethylammonium bromide (C16TAB) to achieve a pore size of 2.5 nm 
and 1.8 nm, respectively. MSN whose attributes include high surface area, 
adjustable pore size and particle size, easy surface modification which leads to its 
application in adsorption of therapeutic molecules, catalysis activity, sensor and 
various other fields.[7-14] The use of MSN in as a drug carrier was first reported by 
Maria Vallet-Regi et al., in delivering Ibuprofen.[15] They have demonstrated that the 
drug release appeared to be pore size dependent and thus demonstrated the 
application of MCM-41 as drug carrier. Szegedi at al., [16] also reported the loading 
of ibuprofen into different amounts of 3-aminopropyltriethoxysilane (APTES) modified 
MCM-41. Amino modification resulted in high degree of ibuprofen loading and slow 
release into dissolution medium. Tang et al., [22] reported dimethyl silyl (DMS) 
modified mesoporous silica for loading ibuprofen by adsorption method. The 
adsorption capacity of ibuprofen was dependent on the amount of silanol groups. 
Later on, MCM-41 have been used as a nanocarrier for various types of 
pharmaceutical drugs such as hydrophobic anticancer drug doxorubicin, [23] 
hydrophobic camptothecin [24] and curcumin. [25] Arean et al., [26] investigated 
effect of amino and carboxyl functionalized MCM-41 on loading of cisplatin. Their 
investigation has shown that modified MCM-41 showed a superior loading efficiency 
than unmodified one. Ambrogi et al., [27] reported furosemide loaded drug delivery 
system for oral administration. The results demonstrated dissolution enhancement 
and complete drug release within 90 min at the absorption region. The advantage of 
MCM-41 helped in the invention of variety of inorganic silica nanoparticles such as 
SBA-15[28], MSU-1[29], KIT-6[30], FSM-16[30], FDU family [31] and many more are 
synthesized till date. MCM-48 is another important type of MSNs which has attracted 
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Figure 2.3 The scheme shows the leading nanocarriers for drug delivery and their 
general stages of development. The top row shows the representative conventional 
nanocarriers such ad liposomes, micelles, dendrimers, and polymers. The bottom 
row shows novel inorganic nanocarriers such as carbon nanotubes, quantum dots, 
iron oxide, gold, and mesoporous silica nanoparticles.[3] 
much attention in biomedical applications. [32, 33] These materials have hexagonally 
arranged tubes, with diameter ranging from 20-100 Å. The discontinuous hexagonal 
pore channels are considered to be helpful for fast molecular transport and easy 
molecular accessibility. 
Tang et al., [151] reported dimethyl silyl (DMS) modified mesoporous silica for 
loading ibuprofen by adsorption method. The adsorption capacity of ibuprofen was 
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dependent on the amount of silanol groups. Later on, MCM-41 have been used as a 
nanocarrier for various types of pharmaceutical drugs such as hydrophobic 
anticancer drug doxorubicin,[152] hydrophobic camptothecin[153] and 
curcumin.[154] Arean et al., [155] investigated effect of amino and carboxyl 
functionalized MCM-41 on loading of cisplatin. Their investigation has shown that 
modified MCM-41 showed a superior loading efficiency than unmodified one. 
Ambrogi et al., [156] reported furosemide loaded drug delivery system for oral 
administration. The results demonstrated dissolution enhancement and complete 
drug release within 90 min at the absorption region. The advantage of MCM-41 
helped in the invention of, variety of inorganic silica nanoparticles such as SBA-
15[157], MSU-1[158], KIT-6[159], FSM-16[159], FDU family[160] and many more are 
synthesized till date. 
MCM-48 is another important type of MSNs which has attracted much attention in 
biomedical applications.[161, 162] These materials have hexagonally arranged 
tubes, with diameter ranging from 20-100 Å. The discontinuous hexagonal pore 
channels are considered to be helpful for fast molecular transport and easy 
molecular accessibility. The synthesis of MCM-48 was rather complicated in 1990s, 
where cationic-anionic co-surfactants were utilized as templates and high 
temperature and long reaction time was involved. Moreover, the particle sizes of 
MCM-48 were greater than1µm, which were not suitable for biomedical applications. 
In 2010, Kim et al., [163] reported a facile approach to synthesize mono-dispersed 
spherical MCM-48 MSN with cubic Ia3d mesostructure by modified Stöber method 
Table 2.3 Representative drug delivery carriers on the market or in clinical trial. [3] 
Nanocarrier 
platform 
Delivered 
therapeutic 
agent 
Stage (Date) in 
development 
Drug name Indications 
Liposome Doxorubicin Approved 
((November 17, 
1995) 
Doxil Kaposi's 
sarcoma, 
recurrent 
breast cancer, 
and ovarian 
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cancer[17] 
Polymeric 
micelles 
Paclitaxel Phase II clinical 
trial 
Genexol-PM Non-small- cell 
lung cancer[18] 
Albumin 
(protein-drug 
conjugate) 
Paclitaxel Approved (January 
7th, 2005) 
Abraxane Metastic breast 
cancer[19] 
Gold Recombinant 
human 
tumor necrosis 
factor 
(rhTNF) 
Phase II clinical 
trial 
AurImmune
™ 
Pancreatic 
cancer, 
melanoma, 
soft tissue 
sarcoma, 
ovarian, 
and breast 
cancer[20] 
Silica cyclic 
arginineglycine
aspartic acid 
(cRGD) 
peptide, and 
124I 
Phase I clinical 
trial 
C dots Human 
melanoma[2] 
utilizing triblock copolymer Pluronic F127 as a particle size designer. The particle 
sizes can be controlled within the range of 70-500 nm by adjusting the amount of 
F127. Moreover, the pore diameter was also precisely controlled from 2.3 to 3.3 nm 
by using different alkyl chain surfactants. The monodispersed spherical MCM-48 
MSN was applied for enzyme responsive controlled release and pH responsive 
neutraceuticals.[164, 165] 
In addition, SBA-15 was also used for biomedical applications. SBA-15 was 
synthesised in strong acidic condition using amphiphilic triblock copolymers 
EO20PO70EO20 [Pluronic P123, EO refers to poly (ethylene oxide), PO refers to 
poly(propylene oxide)] as structure directing agent.[157] The pore size of SBA-15 is 
usually 6 nm in diameter, larger than the pore size of MCM-41. The size of SBA-15 
was reduced with time, and there was a successful development of different shapes 
such as ellipsoid, sphere and rod.[166, 167] Popova et al., [168] conducted a 
Chapter 2 
   Literature Review 
 
- 32 - 
 
comparative study of sulfadiazine loading into MCM-41 and SBA-15 nanoparticles. In 
vitro studies showed slower release rate of sulfadiazine from carboxylic modified 
MCM-41 and SBA-15 than parent particles. Most of the SBA-15 is still far away from 
ideal candidates for biomedical applications due to its big particle size. 
2.7.2 Synthesis of large pore symmetric and asymmetric silica nanoparticles 
(SiNPs). 
2.7.2.1 Synthesis routes of solid SiNPs and modifications 
In 1968, StÖber et al. introduced the synthesis of mono-dispersed solid SiNPs by 
hydrolysis and condensation of silicon alkoxides in a mixture of alcohol and water 
using ammonia as a catalyst.[169] The silica nanoparticles size was adjusted from 
50 nm to 2 µm, by changing the ammonia concentration. Silica nanoparticles 
synthesized by StÖber method have been used for various applications. Non-viral 
silica nanoparticles mimicking virus surface topology have been synthesised by 
inducing surface roughness on the surface of StÖber spheres and tested for gene 
efficacy.[170] In addition, non-viral silica nanoparticles were modified with n-ODMS 
for therapeutic protein delivery.[105, 171] A modified StÖber method, C dots have 
been synthesized for diagnostic applications and have reached stage I human 
clinical trials.[42, 46] 
2.7.2.2 Synthesis of large pore dendritic symmetric silica nanoparticles 
In the recent times, symmetric dendritic silica micro/ nanoparticles with centre-radial 
pore structures, a kind of newly created porous materials, have attracted 
considerable attention owing to their unique open three dimensional dendritic 
superstructures with large pore channels and highly accessible internal surface 
areas compared with conventional MSN. Great attention has been paid to this family 
of materials due to their unique properties. Different research groups have come with 
an innovative different synthesis conditions for the generation of centre radial 
structures. 
Okuyama et al.[172] introduced oil in water emulsion system to synthesise dendritic 
spherical MSNs using octane as the oil phase, styrene monomers and CTAB as a 
dynamic templating agent, lysine as a base, TEOS as silica source, 2,2-azobis (2-
methylpropionamide) dihydrochloride as an initiator and water (Figure 2.4A). The 
TEM image of calcined sample was shown in Figure 2.4B. 
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Figure 2.4 A) Schematic formation mechanism of oil in water system introduced by 
Okuyama et al. and B) TEM image of the obtained dendritic MSNs. Reproduced from 
the reference. [172] 
Polshettiwar et al.[173] reported the synthesis of dendritic silica nanoparticles with 
centre radial wrinkle structure through a microemulsion system composed of 
cyclohexane as an oil phase, pentanol as a co-solvent, and water as a dispersion 
phase, CTAB as a structural directing agent, TEOS as a silicone source and urea as 
a base catalyst under microwave-assisted hydrothermal conditions. The internal 
surface area of fibrous silica nanospheres (KCC-1) is easily accessible which can be 
clearly seen from the TEM image (Figure 2.5B). The proposed mechanism for the 
formation of radial wrinkle structure is the arrangement of silicates molecules in the 
space available between the self-assembled template molecules to aggregate along 
the free radial and restricted tangential directions. The application of KCC-1 was 
shown by shili et al., where hydrophobic Fe3O4 was adsorbed on to the fibrous 
mesoporous silica nanoparticles (FMSN) structure of KCC-1. Further DOX was 
successfully entrapped within the mesopores of Fe3O4-FMSN composite and 
investigated the intracellular drug delivery, fluorecsence and therapeutic effect. DOX-
Fe3O4-FMSN composite shown pronounced cytotoxic effect in L929 fibroblast cells 
than free DOX at high concentration. [174] Later, Atabaev et al., synthesised 
multifunctional core shell mesoporous silica with fibrous morphology with slight 
modifications of the procedure reported by Polshettiwar. The multifunctional 
Fe3O4@SiO2 composites are spherical morphology with clearly distinguishable 
magnetic core and mesoporous silica shell. The size of the Fe3O4@SiO2 NP was 
tuned by changing the time, TEOS or urea concentration by keeping the other 
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parameters constant. The Fe3O4@SiO2 composite with the fluorescent property, at 
concentration >125 ppm significantly reduced the cell viability of L-929 cells. [175] 
Magnetic fibrous monodispersed core-shell Fe3O4/SiO2/KCC-1 structures were 
successfully synthesised by surfactant template microemulsion formation process. 
The BET surface area and pore volume were 213 m2/g and 0.45 cm3/g, respectively, 
which were considerably large. Fe3O4/SiO2/KCC-1 have shown good methylene blue 
adsorption capacity.[176]   
                             
Figure 2.5 A) SEM and (B) TEM images of KCC-1. Reproduced from the reference. 
[173] 
Later, Yang’s[177] group and Lee’s[178] group also synthesised KCC-1 type of 
particles by employing similar microemulsion systems under more mild experimental 
conditions. Lee group systematically investigated and demonstrated that wrinkled 
silica nanoparticles were formed in a bicontinuous microemulsion phase of the 
winsor III system (Figure 2.6). Moreover, increasing the chain length of the co-
solvents can also alter the phase behaviour by varying the relative solubility of 
surfactants in oil and water phases, which results in the increase of interwrinkle 
distances in the dendritic particles. 
Zhao., at al[179] group developed a new oil-water biphase stratification approach to 
achieve 3-D dendritic MSN with tuneable multigenerational and central-radial 
mesoporous channels. They used CTAC as surfactant, TEA as base catalyst, TEOS 
as silica source, and water in lower phase and upper oil phase includes 
cyclohexane, 1-octadecene, decahydronapthalene. The pore size in each generation 
was adjusted from 3-13 nm by changing the concentration of hydrophobic solvent 
and TEOS in the upper oil phase (Figure 2.7). The particle formation mechanism 
was explained by interfacial emulsion funnelling gradient assembly and growth 
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process. They further extended the approach to synthesise functional core-shell 
materials with different shapes of cores.  
                                   
Figure 2.6 Schematic representation of influence of cyclohexane volume on silica 
nanoparticles and respective TEM images. Reproduced from reference.[178] 
Chun Xu et al.[180] introduced core-cone structures by using chlorobenzene-water 
system, in which CTAC as a surfactant, TEA as a base catalyst and TEOS as silica 
source. The formed particles are shown in Figure 2.8, which has a pore size ~ 45 nm 
and particle size of 175 ± 12 nm (Figure 2.8). Meka et al.[181] synthesised amino-
functionalized hollow dendritic MSN by inducing APTES in the chlorobenzene-water 
systems under more diluted CTAC concentration. From the TEM (Figure 2.9d) the 
hollow cavity diameter is of 173 ± 29 nm and the large opening pore is of 20 nm. 
                                 
Figure 2.7 TEM (a,b,c) and SEM (d,e,f) images of three generations of pore 
structures. Reproduces from reference. [179] 
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Figure 2.8 A picture of dahlia (A), TEM images at low magnification (B) and high 
magnification (A) and an ET slice (D) of core cone particles. Reproduces from 
reference.[180] 
 
Figure 2.9 SEM images at low magnification and high magnification (a, b) and TEM 
(c) images and ET slice (d) of A-HDMSN. Reproduced from reference. [181] 
2.7.2.3 Synthesis of asymmetric silica nanoparticles 
Asymmetric nanoparticles with polymeric, inorganic and polymeric-inorganic hybrid 
composition have attracted much attention in diverse fields because of their unusual 
behaviour that cannot be observed for isotropic particles. Precise design of 
asymmetric nanoparticles promises a wide range of application in displays, sensors 
and drug delivery systems. 
Zhao et al., [182] synthesised multifunctional dual-compartment Janus mesoporous 
nanocomposites of upconversion nanoparticles (UCNP) @Sio2@mSio2@PMO 
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containing UCNP@SiO2@mSiO2 nanospheres and periodic mesoporous 
organosilica (PMO) single crystal nanocubes using novel anisotropic island 
nucleation and growth approach. The asymmetric Janus nanocomposites have a 
uniform size of ~300 nm with a unique dual independent mesopores with different 
pore sizes of 2.1 and 3.5-5.5 nm (Figure 2.10). The Janus nanocomposite possess 
an excellent NIR to UV-vis upconversion optical property from the UCNP and dual 
drug loading capacity. A mechanism is proposed to explain the heterogeneous 
nucleation process, where the mesostructured CTAB/ silicate micelles can be 
assembled and nucleated on the surface of the UCNP@SiO2@mSiO2 through a 
heterogeneous nucleation process. Once the nucleation sites are formed the growth 
manner of PMO is determined by the hydrolysis environment of 1,2-bis 
(triethoxysilyl) ethane (BTEE) and the mesostructure of the obtained PMO. There 
observations are consistent with the classical island growth mode of Volmer-Weber. 
                                     
Figure 2.10 Synthesis procedure for the dual-compartment Janus mesoporous silica 
nanocomposites UCNP@SiO2@ mSiO2&PMO by anisotropic island nucleation and 
growth method. Reproduced from reference. [182] 
The same group synthesised asymmetric single hole nanocages by using dense 
SiO2 spherical nanoparticles as a seed. [183] By using CTAB as mesostructure 
template and BTEE as a silica source, periodic mesoporous organosilica could be 
nucleated and encapsulated on dense SiO2 by novel anisotropic encapsulation 
method to form eccentric core@ shell nanocomposite. The unique asymmetric 
nanocages have a particle size of 100-240 nm, with uniform mesopores of 3-10 nm 
and controllable eccentric hollow cavity of 35-170 nm (Figure 2.11). The obtained 
single hole mesoporous nanocages was further functionalized with upconversion 
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nanoparticles (UCNP). The obtained nanocages were used for codelivery of 
doxorubicin and bovine serum albumin. The formation of asymmetric nanocages was 
because of asymmetric growth of PMO growth on dense SiO2. 
                                                           
Figure 2.11 TEM images (A-C) of the morphology evolution of the eccentric 
nanocomposites. TEM images of Janus UCNPs@SiO2 and PMO and the eccentric 
hollow structured nanocomposites. Reproduced from reference. [183] 
Kuroda et al.,[184] reported the asymmetric capping of mesoporous silica with 
phenylsilsesquioxane, where they added phenyltriethoxysilane (PTES) to the 
colloidal dispersion of silica and surfactant composite nanoparticles (CMSS). It was 
first report on asymmetric modification to produce janus nanoparticles. It was 
proposed that PTES acts as an oil phase, and the hydrolysed PTES slowly move 
and deposit on the surface of CMSS (located in water phase). Here, it was also 
proposed that CMSS can be located at the interface of water and oil droplets as an 
emulsifier; hence, nucleation and growth essentially occur on one side of CMSS. 
Suteewong et al., synthesised multicompartment mesoporous silica nanoparticles 
with branched shape using CTAB as structure directing agent, ammonia as a base 
catalyst, and mixed organosilica precursor via one pot synthesis method. 
Multicompartnat epitaxial growth was controlled by varying the ethyl acetate 
concentration in the reaction system.[185] First, it was shown that increase in 
ethylacetate concentration lead to an increase in hydrolysis rate and a pH drop. This 
pH drop was drawn to decrease in the acid dissociation constant and was increased 
from 91mM to 457mM by keeping ammonium hydroxide and APTES constant.  
Novel multifunctional magnetic mesoporous janus particles with controlled aspect 
ratio was developed by a simple one step synthesis approach by Zhang et al.[186] 
The janus structures with controlled aspect ratios were prepared by varying the 
molar ratios of silica source (TEOS) to iron oxide. The formation of ordered 
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mesoporous architecture on iron oxide particles was the self-organization of low-
ordered aggregates on colloidal surface and eventual growth along both axis and 
radial direction. 
 
2.8 Conclusion  
Mesoporous silica has received considerable attention and emerging as an 
alternative carrier system to deliver the therapeutic cargo or diagnostic aids into the 
specific disease/ targeting site because of their tuneable pore size, high surface 
area, large pore volume, and ease of functionalization. Although there have been 
tremendous efforts in the synthesis of mono-dispersed SiNPs for various 
applications, more efforts are still needed to develop novel mono-dispersed SiNPs 
with desired pore size and morphology. As this Ph.D. thesis is combination of 
synthesis and development of silica nanoparticles and its morphology advantage in 
biomedical field, chapter 2 mainly focus on the broad picture over synthesis and 
applications. Current synthetic approaches for symmetric and asymmetric silica 
nanoparticles with small and large pores have been discussed. Later, 
physiochemical parameters especially the influence of pore size and morphology 
were discussed concerning biomedical applications of nanomaterials, such as 
solubility enhancement, controlled drug release, hemocompatibility, combination 
therapy, and vaccines. 
 The novel designed SiNPs are expected to expand their capacity in various 
biomedical applications. Tuning the morphological characteristics of particle is an 
essential parameter and that helps to load the desired cargo into the silica. 
Particularly, conventional floating tablet formulation failed to enhance the solubility of 
hydrophobic drugs and control release the hydrophilic drugs. Thus, it is necessary to 
develop simple method for the design of floating tablets with improved performance. 
For example, SiNPs with desired pore size is expected to have much higher 
solubility enhancement of hydrophobic drugs and controlled release of hydrophilic 
drugs. Thus chapter 4 of the thesis addresses this issue. In another example, better 
understanding on the hemocompatibility of asymmetric SiNP not only allows a better 
estimation of the potential risk, but also helps to find a balanced point between 
efficacy and safety. Chapter 5 of this thesis investigates the morphology influence of 
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symmetric and asymmetric SiNP on hemocompatibility. Furthermore, large pore 
dendritic silica nanoparticles are synthesized using different methods, but the 
combination of photosensitiser and large biomolecules in cancer therapy was not 
studies. So far all the designed combined therapy is in combination with 
chemotherapeutic and photosensitizers.  However, the chemotherapeutic caused 
various side effects. Thus it is necessary to develop smart combination approach for 
cancer treatment. Chapter 6 of the thesis address this issue and demonstrates the 
effect of protein and photodynamic therapy in cancer treatment. 
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                                     Methodology 
 
 
This chapter summarizes the strategies utilized in the whole PhD project, including 
synthetic methods for small pore MCM-41, dual pore head-tail MSN, large pore 
dendritic MSN and the techniques for material characterizations and biological 
evaluations. 
 
3.1 Material synthesis 
Mono-dispersed MSN with various pore size and morphologies are synthesised by 
the hydrolysis and condensation of silicon alkoxides in either aqueous solution using 
ammonia as a catalysis or in oil in water emulsion system using TEA as a catalyst.  
 
3.1.1 Synthesis of monodispersed MCM-41 and preparation of floating tablets 
with drug loaded MCM-41 
MCM-41 was synthesized according to an approach reported in our previous work 
with slight modifications. [1] In a typical synthesis, 1.0 g of CTAB was dissolved in 
480 g of deionized water under stirring at room temperature followed by the addition 
of 3.5 mL of NaOH (2 M). The temperature of the solution was raised and kept at 80 
°C. To this solution, 6.7 mL of TEOS was added. The mixture was continuously 
stirred for additional 2 h. The resultant products were collected by filtration and dried 
at room temperature. The templates were removed by calcination at 550 °C for 5 h. 
The floating tablets were prepared by a direct compression method. Weights of each 
ingredient were taken according to Table S2, Table S3 for each formulation. Micro-
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crystalline cellulose (MCC, bulking agent) was added in order to maintain the same 
weight of each tablet in different formulations. All the ingredients were mixed 
homogeneously with mortar and pestle for 10 min. Zinc stearate (a lubricant) was 
added at last to the mixed powders and then mixed further for 3 min. Finally, the 
powder was fed manually into die with spatula of a single punch tablet punching 
machine, equipped with concave punches (10 mm diameter). The hardness of the 
tablets was adjusted to 50 N by adjusting the punches and the hardness was 
measured by using Erweka hardness tester. 
 
3.1.2 Synthesis, functionalization and dye tagging of head-tail nanoparticles 
Uniform nonporous silica nanoparticles with a smooth surface were synthesized 
using a well-known method developed by Stöber et al. [2] Typically, absolute ethanol 
(50 ml) was mixed with deionized water (3.8 ml) and ammonium hydroxide solution 
(2 ml, 28%,) at 35 ˚C. Then, TEOS (2.8 ml) was added to the solution under vigorous 
stirring. After 6 hours, the as-synthesized nanoparticles were separated by 
centrifugation, and washed with ethanol and deionized water. The final product was 
obtained by drying at 100 ˚C overnight. 
In a typical synthesis, 60 mg of silica spheres of ~200 nm size were dispersed in 6 
ml of milliQ water, and 0.035 g Triethanolamine (TEA), by sonication for 15 min. 
Then, 4 ml of CTAC (25 wt%) solution was added into the solution and kept at 60 ˚C 
at a stirring speed of 400 rpm for 1 h. After stirring for 1 h, 8.75 ml of chlorobenzene 
and, TEOS was added into the above solution. The reaction was continued at 60 ˚C 
for 12 h. Particles were collected by centrifugation at 15,000 rpm, washed with water 
and ethanol twice and dried at 50 ˚C overnight. The particles are calcined at 550 ˚C 
for 5 h to remove CTAC. We studied the influence of TEOS amount, reaction time 
and head amount on the morphology by varying the reaction time, TEOS volume and 
head amount.  
Amino silane was grafted onto the surface of stöber spheres, HTMSN0.41-12-60, 
HTMSN1.25-12-60, HTMSN1.25-12-400, to create positive charge particles. 200 mg of 
particles was suspended in 30 ml of toulene, and sonicated for 10 min, and then 0.19 
ml APTES was added and the mixture was refluxed at 110 ˚C for 20 h. The product 
Chapter 3 
Methodology 
- 60 - 
 
were collected by centrifugation and washed twice with ethanol and water and dried 
at 50 ˚C for overnight. 
50 mg of amino modified particles were suspended in 20 ml of ethanol with 
sonication for 10 min. Afterwards, 5 mg of FITC was added and stirred the 
suspension for overnight in dark. FITC tagged particles were collected by 
centrifugation followed by several times washing with ethanol to remove the free dye. 
 
3.1.3 Synthesis of dendritic silica nanoparticle with fullerene core 
Uniform SSF nanoparticles was synthesized according to literature method.[3] In a 
typical synthesis, 16 mg of C60 fullerene were well dispersed in toluene using 
sonication. The dispersed fullerene solution was mixed and stirred for 30 min, with 
microemulsion solution composed of cyclohexane (20 ml), 1-hexanol (8 ml), distilled 
water (2 ml), and Triton X-100 (6.8 ml). After 30 min, 400 µl of TEOS solution was 
added and stirred for another 30 min before addition of ammonium hydroxide (28 wt 
%, 2.4 ml). The mixture was continuously stirred at room temperature for 24 h. 40 ml 
of ethanol was added to break the microemulsion and the particles were collected 
using 20,000 rpm and washed with ethanol twice. 
FD nanoparticles were synthesised according to literature with slight modification. In 
a typical synthesis, 60 mg of SSF were dispersed in 6 ml of milliQ water, and 0.035 g 
Triethanolamine (TEA), by sonication for 15 min. Then, 4 ml of CTAC (25 wt%) 
solution was added into the solution and kept at 60 ˚C at a stirring speed of 400 rpm 
for 1 h. After stirring for 1 h, 8.75 ml of chlorobenzene and, TEOS was added into the 
above solution. The reaction was continued at 60 ˚C for 12 h. Particles were 
collected by centrifugation at 20,000 rpm, washed with water and ethanol twice and 
vacuum dried overnight. 
 
3.2 Characterisation 
3.2.1 X-ray diffraction 
Small-angle XRD patterns of MCM-41 were recorded on a German Bruker D4 X-ray 
Diffractometer (40 kV, 30 mA) with Ni-filtered Cu Kα (λ = 0.15418 nm) Radiation at a 
scanning rate of 0.2˚ min-1 from 0.5˚ to 5.0˚. The interplanar spacing is calculated 
based on the following Bragg equation: 2dhkl sinθ = nλ where dhkl is the interplanar 
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distance between a set of parallel planes described by the Miller indices (hkl) (nm), λ 
is the wavelength of Cu Kα ray (nm), θ is the angle of incident beam (˚), and n is 
integer determined by a given order. 
 
3.2.2 Thermogravimetric analysis  
Thermogravimetric analysis (TGA) is used to calculate the loading of curcumin and 
captopril in MCM-41 and also the fullerene amount in solid silica spheres. Around 5-
10 mg of drug loaded nanoparticles was loaded in an aluminium pan and heated 
from 25 to 900°C at a heating rate of 1.5 °C min-1 at an air flow of 20 mL min-1. TGA 
was conducted using a TGA/DSC 1 Thermogravimetric Analyzer (Mettler-Toledo 
Inc). 
 
3.2.3 Transmission Electron Microscopy (TEM) 
Transmission electron microscopy is an important tool for structure determination 
(TEM). In this thesis all the (TEM) images were obtained using JEOL 1010 operated 
at 100 kV, JEOL 2100 at 200 kV or FEI Tecnai F30 operated at 300 kV. The samples 
for TEM measurements were prepared by dispersing the powder samples in ethanol, 
after which they were dispersed and dried on carbon film on a Cu grid. 
 
3.2.4 Scanning Electron Microscopy (SEM)  
The morphologies of the samples MMNSs were observed using a JEOL6610 
scanning electron microscope (SEM) operated at 5 kV. Samples were dispersed on 
a carbon tape. 
 
3.2.5 Nitrogen sorption 
Nitrogen adsorption/desorption isotherms were measured at 77 K by using a 
Micromeritics ASAP Tristar II 3020 system. The samples were degassed at 473 K 
overnight on a vacuum line. The pore size distribution curve was derived from the 
adsorption branch of the isotherm using the Barrett– Joyner–Halanda (BJH) method. 
The Brunauer–Emmett–Teller (BET) method was utilized to calculate the specific 
surface areas. The total pore volume was calculated from the amount adsorbed at a 
maximum relative pressure (P/P0) of 0.99. 
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3.2.6 Attenuated Total Reflectance (ATR)-Fourier transform infrared (FTIR) 
spectroscopy 
Attenuated total reflectance (ATR)-Fourier transform infrared (FTIR) spectroscopy 
was utilized to trace functional group modifications of different SiNPs. The powder of 
samples was simply added onto the crystal to obtain optimal contact. The surface 
functional groups, for example, methyl groups, were investigated by ATR-FTIR. 
ATR-FTIR spectra were collected using the Thermo S nt ™ N ol t™ 6700 FT-IR 
spectrometers. Each spectrum was obtained using dried powder against a 
background measured under the same condition. For each spectrum, 128 scans 
were collected at a resolution of 4 cm-1 over the range 400–4000 cm-1. 
 
3.2.7 Dynamic light scattering (DLS) 
Dynamic light scattering (DLS) is a non-invasive, well-established technique for 
particle size characterization of proteins, polymers and colloidal dispersions. The 
Brownian motion of particles or molecules in suspension causes laser light to be 
scattered at different intensities. Analysis of these intensity fluctuations yields the 
velocity of the Brownian motion and hence the particle size using the Stokes-Einstein 
relationship. The hydrodynamic sizes of particle samples in this PhD project were 
measured using DLS measurements on a Malvern NanoZS zetasizer at 25 ◦C in 
ethanol or water solutions. 
 
3.2.8 Inductively Coupled Plasma-Optical Emission Spectroscopy (ICP-OES)  
Inductively coupled plasma-optical emission spectrometry (ICP-OES) is an analytical 
technique used for the detection of trace metals. It uses the inductively coupled 
plasma to produce excited atoms and ions that emit electromagnetic radiation at 
wavelengths characteristic of a particular element. The intensity of this emission is 
indicative of the concentration of the element within the sample. In this PhD project, 
ICP-OES technology was utilized to quantify the silicon concentrations in cells after 
treatment of nanoparticles with cells. The MCF-7 cells were incubated with the FD, 
FD-C18 nanoparticles for 4 hours, then washed with PBS and harvested with trypsin. 
After washing with PBS and centrifugation, cell lysis buffer was added to allow 
dissolution of cells under sonication process. The supernatants (containing cell 
components) were discarded after centrifugation, and the precipitates were washed 
with PBS, followed by drying at 50C for 12 h. After 12 h, 1M sodium hydroxide 
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solution was added and incubated for 24 h to completely dissolve silica 
nanoparticles. The dissolved silica solution was diluted and measured using ICP-
OES with a Vista-PRO instrument (Varian Inc, Australia). 
 
3.3 Biological assays 
3.3.1 MTT assay 
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) cell 
proliferation assay measures cell proliferation rate and conversely, when metabolic 
events lead to apoptosis or necrosis, reduction in cell viability. The yellow tetrazolium 
MTT is reduced by metabolically active cells, in part by the action of dehydrogenase 
enzymes, to generate reducing equivalents such as NADH and NADPH. The 
resulting intracellular purple formazan can be solubilized by DMSO and quantified by 
spectrophotometric means. The cell growth inhibition by delivering nanocarriers was 
tested in multiple cell lines, including HeLa, MCF-7, and RAW 264.7 cell lines. One 
day before the test, 5000-8000 cells were seeded in each well of 96-well plates. The 
nanoparticles were dispersed in culture medium supplemented with 10% FBS and 
1% penicillin-streptomycin and added into each well. After the incubation at 37 °C for 
24, MTT reagent was added and further incubated for 4h. Finally, DMSO was added 
to the wells analysed the plates by setting the absorbance at 540 nm using a 
Synergy HT Microplate Reader. Results were compared to cells not exposed to 
nanoparticles. 
 
3.3.2 Confocal Laser Scanning Microscopy (CLSM)  
Laser scanning confocal microscopy (CLSM) has become an invaluable tool for a 
wide range of investigations in the biological and medical sciences for imaging thin 
optical sections in living and fixed specimens ranging in thickness up to 100 
micrometres. It is a technique to obtain high resolution optical images with selected 
depth. CLSM is normally equipped with 3-5 laser systems with a precise control in 
wavelength and excitation intensity. These microscopes coupled with 
photomultipliers are capable of detecting fluorescence emission ranging from 400 to 
750 nm. In this thesis, all the confocal images of fixed cells were observed under a 
confocal microscope (LSM Zeiss 710). 
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3.3.3 Flow cytometry  
Flow cytometry is a laser-based, biophysical technology employed in cell counting, 
cell sorting, biomarker detection and protein engineering, by suspending cells in a 
stream of fluid and passing them by an electronic detection apparatus. It allows 
simultaneous multi-parametric analysis of the physical and chemical characteristics 
of up to thousands of particles per second. 
In this thesis, the intracellular uptake of fluorescent silica nanoparticles was 
quantified using a FACS LSR II flowcytometer (BD Biosciences).
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This chapter reports a design of novel floating tablets using mesoporous silica 
nanoparticles for enhancing the drug delivery performance of both hydrophobic and 
hydrophilic drugs compared to conventional floating tablets. This work has been 
published in Journal of Material Chemistry B, 2014; 2, 8298-8302. 
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4.1 Introduction 
Since the first report of ordered mesoporous materials in the early 1990s,[1] great 
attention has been paid to this family of materials due to their unique properties (e.g., 
easy synthesis, tunable structures, controllable surface chemistry)[2, 3] and a broad 
range of applications.[4-6] Recently, mesoporous silica nanoparticles (MSNs) have 
attracted enormous interest in drug delivery.[7] The large surface area and high pore 
volume of MSNs render a high efficiency to load cargo molecules, while the 
adjustable pores with a range of sizes can be used to control the drug release in a 
sustainable manner.[8, 9]  MSNs have been demonstrated as targeted delivery 
systems to tumor cells[10, 11] and as stimuli-responsive systems.[12-14] MSNs have 
also been used in developing oral tablets because the oral route is still the preferable 
route of drug administration.[15, 16] However, there is no report on using MSNs in 
localised drug delivery for the upper region of gastrointestinal tract (GIT), i.e., 
stomach.  
High residence time and local drug release in stomach is prerequisite for the drugs 
with narrow absorption window in upper GIT, and poor solubility or degradation in 
small intestine.[17] Various approaches have been developed for retaining a dosage 
form in stomach.[18, 19] Among these floating delivery system is considered as an 
effective technique.[20-22] A successful example of floating drug delivery systems is 
floating tablets.[23] Traditionally, floating phenomenon in floating tablets is achieved 
by using swellable polymers or polymer mixtures and gas generating agents.[17] 
However, for polymer based floating systems, controlling the release of highly water-
soluble drug is limited.[24] Moreover, drug and polymer are generally physically 
mixed which does not aid in enhancing solubility of inherently insoluble drugs. In light 
of the advantages of MSNs in solubility enhancement[25] and controlled drug 
release,[26] it is hypothesised that a floating tablet based on MSNs will provide 
unprecedented benefits to address the limitations of conventional polymer based 
floating tablets. 
In this communication, we report the first example of novel floating tablets based on 
MSNs for the localised drug release. As shown in Scheme 4.1A, MCM-411 type 
MSNs are chosen as drug carriers. Hydroxypropylmethylcellulose (HPMC) is chosen 
as a gelling agent due to its non-toxic nature, easy compression and swelling 
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properties, which is widely used in oral and topical pharmaceutical formulations. 
Sodium bicarbonate is used as a gas generating agent. The floating tablet is 
prepared by blending drug loaded MSNs, HPMC and sodium bicarbonate (Scheme 
4.1B) and compressing into tablet (Scheme 4.1C) using a single punch tablet 
compression machine. Curcumin and captopril are chosen as model hydrophobic 
and hydrophilic drugs respectively to demonstrate the application of novel MSNs 
based floating tablet. The resultant tablets showed extensive floating behaviour (>12 
h) with improved dissolution rate and enhanced solubility for curcumin while 
extended release in case of captopril (Scheme 4.1D), providing a leap forward 
towards new application of mesoporous materials in localized oral drug delivery.     
 
Scheme 4.1 Schematic representation of floating tablets made from drug loaded 
MCM-41, polymer and sodium bicarbonate (A). After blending and compression (B), 
captopril (white coloured) and curcumin (yellow) floating tablets are obtained (C), 
which can float in stomach >12 h (D). 
 
4.2 Results and discussion 
MCM-41 type MSNs were used in this study and prepared according to published 
methods [27] with slight variations (see ESI†). Calcined MCM-41 with two different 
pore sizes (2.1 and 1.7 nm) were used and the pore size adjustment was performed 
by a reported vacuum-assisted vapour deposition (VVD) process [25] (ESI†).  The X-
ray diffraction (XRD) patterns (Figure 4.S1A, ESI†) of calcined MCM-41 before and 
after VVD process both showed three well resolved peaks at 2θ of 2.68, 4.76 and 
5.42˚, which can be indexed as 100, 110, and 200 reflections of an ordered two 
dimensional hexagonal mesostructure. For MCM-41 after VVD process, the intensity 
of 110 and 200 peaks was decreased due to the decreased scattering contrast 
between the pore and silica walls. [28] This is evidenced from the N2 adsorption-
desorption analysis. Comparing the isotherms of calcined MCM-41 before and after 
VVD process (Figure 4.S1B, ESI†), the capillary condensation step shifted to a lower 
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relative pressure range after VVD treatment, reflecting a pore size reduction from 2.1 
to 1.7 nm (Figure 4.S1C, ESI†), in accordance with our previous results. [25] The 
surface areas and pore volumes are summarised in Table 4.S1 (see ESI†). 
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) 
were used to study the nanostructure of MCM-41. SEM images of two MCM-41 
materials showed a spherical morphology with particle sizes of ~120 nm (Figure 
4.S2c and d, ESI†). TEM images of both materials showed stripe-like or hexagonal 
pattern (Figure 4.S2a, b, ESI†), typical of MCM-41 materials.[29] Because MSNs 
have not been used in the formulation of floating tablets, screening tests were 
conducted to optimise the floating tablet formulation by increasing the amount of 
MCM-41. The compositions of floating tablets (F0-FD) are shown in Table 4.S2, 
ESI†. F0 is conventional polymer based, while FA-FD has a silica weight ratio of 42, 
55, 58, and 62%, respectively. All tablets floated in simulated gastric fluid (SGF, pH 
1.2) longer than 12 h. The silica content after 12 h of floating test decreased as the 
amount of silica increased (Figure 4.S3B, ESI†). FA with the initial silica ratio of 42% 
has the highest retention ratio of 80%. An initially larger MCM-41 content is 
beneficial for a higher dosage form, while the silica content remained in the tablet 
after floating is important to reduce the unwanted entry of drug into intestine. 
Consequently, the silica content of 42% was chosen as the optimised ratio (FA) in 
the following studies.  
SEM was also used to investigate the morphology of floating tablets. A typical cross-
section SEM images of FA is presented in Figure 4.1a, showing a homogenous 
distribution of MCM-41 particles in the tablet. The HPMC (see SEM image in Figure 
4.S2e, ESI†) and other ingredients cannot be seen in the tablet, suggesting a 
homogenous distribution of all ingredients. After 12 h of floating test, the SEM image 
of F0 prepared without silica nanoparticles revealed a porous structure (Figure 4.S2f, 
ESI†). The pores are generated by entrapped CO2 produced by the reaction of 
sodium bicarbonate with HCl in the gastric juice (pH 1.2). In contrast, the SEM image 
of FA prepared in the presence of MSNs after floating for > 12 h  still showed 
homogeneously distributed MCM-41 nanoparticles in the polymer matrix (Figure 
4.1b), suggesting that HPMC play a dual role of gelling agent to entrap both gas and 
MSNs throughout the dissolution process. 
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In order to prepare a drug loaded floating tablet, curcumin (Cur) was separately 
loaded into two calcined MCM-41 with different pore sizes by a rotary evaporation 
method (see ESI†). Curcumin loaded MCM-41 samples were characterised by 
thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), XRD and 
N2 adsorption-desorption. TGA (Figure 4.S4, and Table 4.S1, ESI†) showed that the 
weight percentage of curcumin was 20.0% and 20.9% in Cur-MCM-41(1.7nm) and 
Cur-MCM-41(2.1nm) respectively.  
 
Figure 4.1 Cross sectional SEM images of (a) floating tablet with MSNs and (b) after 
12 h of dissoution study. 
Sharp diffraction peaks were observed in 2θ range of 5-40˚ for both pure curcumin 
and the physical mixture of curcumin and MCM-41 as observed from wide-angle 
XRD patterns (Figure 4.S5A, ESI†). Pure MCM-41 showed no diffraction peaks in 2θ 
range of 5-40˚, indicating its amorphous nature. After loading curcumin into MCM-41, 
no obvious diffractions of curcumin were observed, suggesting that the drug has 
been successfully loaded as nano-aggregates into the pore channels of MCM-41 in 
an amorphous state. This conclusion is further confirmed by DSC analysis. The DSC 
curve (Figure 4.S5B, ESI†) of pure curcumin showed a sharp endothermic peak at 
172 ˚C corresponding to its melting point. After loading curcumin into MCM-41 this 
peak showed very week intensity, suggesting that the crystallinity of curcumin has 
been significantly reduced after loading inside the pore channels. 
Figure 4.S6A (ESI†) showed the nitrogen adsorption/desorption isotherms of Cur-
MCM-41(1.7nm) and Cur-MCM-41(2.1nm) were typical type IV with clear capillary 
condensation steps in the relative pressure (P/P0) range of 0.2-0.4. The details of 
surface area, pore volume, and pore size are given in Table 4.S1, ESI†. After 
loading curcumin, the surface area and the pore volume decreased. However, the 
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pore size remained the same for Cur-MCM-41(1.7nm) and Cur-MCM-41(2.1nm) 
even after loading curcumin (Figure 4.S6 B, ESI†). It is suggested that due to the 
hydrophobic nature of curcumin, the drug molecules tend to repel from the 
hydrophilic silanol groups on the surface and exist as isolated nano-aggregates 
inside the pore channels, thus the pore size after loading is not changed.  
A hydrophilic drug (captopril) was also loaded into MCM-41 with a pore size of 2.1 
nm by a wetting impregnation method. The N2 sorption isotherm and pore size 
distribution curve of MCM-41 after drug loading was shown in Figure 4.S7, ESI†. 
After drug loading the BET surface area decreased from 946 to 534 m2/g, the pore 
volume from 0.66 to 0.38 cm3/g, and pore size from 2.1 to 1.7 nm (Table 4.S1, 
ESI†). These data suggest that the drug molecules were introduced into the 
mesopores. From the TGA analysis (Figure 4.S8, ESI†) it is confirmed that the 
weight percentage of captopril loaded is 16.4. Because captopril is hydrophilic in 
nature, the drug molecules may locate preferentially adjacent to the hydrophilic 
surface silanol, leading to a decrease pore size.  
The drug loading is further confirmed by Fourier transform infrared (FTIR) studies 
(Figure 4. S9, ESI†). FTIR spectra for the pure captopril showed peaks at 2880, 
2955 and 2987 cm-1, corresponding to asymmetrical C-H stretching vibration of 
captopril anion, and the characteristic bands at 2569, 1745, 1584 and 1475 cm-1 
could be attributed to S-H, C=O of COOH group, C=O of amide and quaternary 
carbon atom respectively. A sharp peak at 3745 cm-1 can be observed for MCM-41, 
which is attributed to the isolated silanol groups and water molecules. The FT-IR 
spectrum of captopril loaded MCM-41 sample shows weak shoulder at 2959 cm-1 
which is attributed to symmetrical CH3 stretching mode of captopril and a band at 
1749 cm-1 due to the COOH group on captopril.[30] The C=O of amide can be clearly 
observed at 1646 cm-1, this shift is attributed to the weak interaction with the silanol 
groups on the surface of MCM-41. The signal from isolated silanol disappears for 
captopril loaded MCM-41. The corresponding peaks of the pure drug were observed 
in the Cap-MCM-41 particles, confirming that the drug was loaded effectively. 
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Figure 4.2 The morphology of floating tablet at different time points. (F1) Cur-MCM-
41(1.7nm), (F2) Physical mixture of curcumin and MCM-41, (F3) Pure curcumin, (F4) 
Cur-MCM-41(2.1nm). All the formulations contain polymer and sodium bicarbonate. 
The in-vitro drug release profile of floating tablets was performed in SGF, pH 1.2 at 
37 ºC using Rosette rise apparatus (RRA) to mimic the environment of stomach 
(Figure 4.S10, ESI†).[31] Four different formulations were studied to show the 
importance of MSNs and its pore size in the release profile of curcumin (Table 4.S3, 
ESI†). The total weight of tablets for four formulations and the amount of curcumin in 
each tablet are the same. F1 and F4 are made with polymer and drug loaded MCM-
41 with the pore size of 1.7 nm and 2.1 nm, respectively. F2 is the physical mixture 
of MCM-41 (2.1nm), polymer and drug. F3 is made of polymer and drug in the 
absence of MSNs. Figure 4.2 showed the morphology of floating tablets (F1-F4) at 
different time points of dissolution study. The diffusion of dissolution medium into the 
tablets was clearly visible at 1 h as evidenced by the volume change. However, there 
was no disintegration of tablets suggesting effective binding ability of HPMC and 
MSNs. 
The release profiles of curcumin loaded floating tablet F1-F4 are shown in Figure 
4.3. The release rate of F4 Cur-MCM-41(2.1nm) was similar to conventional floating 
tablet F3. There is no significant difference in the release profile of F2 (floating tablet 
made from physical mixture) compared to F3 and F4. The dissolved curcumin from 
floating tablets was less than 19% at 20 h in three groups (F2-F4). Remarkably, the 
cumulative percentage drug release of F1 Cur-MCM-41(1.7nm) was twice that of 
conventional floating tablet at 20 h (42.8%). The solubility of a substance is a 
function of its particle size according to the Ostwald-Freundlich equation.[25] After 
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loading curcumin into MSNs, the size of curcumin is dependent on the pore size of 
MSNs. The enhanced solubility of curcumin in F1 can be attributed to the use of 
MSNs with a carefully chosen pore size of 1.7 nm, which has been demonstrated 
before with the highest solubility enhancement. Additionally, it is noted that when 
curcumin was physically mixed with MSNs there was no improvement in release 
kinetics, indicating the encapsulation of curcumin into the nanopores is important for 
the solubility enhancement. 
For captopril floating tablets, two formulations were prepared. F5 was made from 
drug loaded MCM-41, while F6 using HPMC polymers in the absence of MCM-41 
(Table 4.S4, ESI†). As expected for F6 batch, 60% of captopril was released within 
the first 6 h, and almost 100% release was observed at 8 h (Figure 4.4). This 
observation indicates that in the case of conventional polymer based floating tablets, 
swelling of HPMC allows quick exposure of the drug molecules to dissolution 
medium, causing fast release of captopril into the SGF. While for floating tablet F5 
made with MCM-41, a sustained drug release of captopril was observed reaching 
100% only after 24 h. At all time points the release rate of floating tablet F5 was 
slower than that of conventional tablet F6. Because the drug molecules are pre-
loaded inside the nanopores, the dissolution medium has to diffuse through two 
barriers: the polymer matrix to induce the gelation of HPMC and the nanopores in 
order to dissolve the drug molecules. Consequently, the floating tablet made from 
MSNs gives rise to more control over hydrophilic drugs. 
 
Figure 4.3 The release profile of curcumin from floating tablets. (F1) Cur-MCM-
41(1.7nm), (F2) Physical mixture of curcumin and MCM-41, (F3) Pure curcumin and 
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(F4) Cur-MCM-41(2.1nm). All the formulations contain polymer and sodium 
bicarbonate. 
 
 
Figure 4.4 The release profile of captopril from floating tablet. (F5) Cap- MCM-41, 
(F6) Pure captopril. All the formulations contain polymer and sodium bicarbonate. 
 
4.3 Conclusion 
In conclusion, we have successfully prepared a new generation of floating tablets 
using MSNs as a key formulation ingredient. With this finding, the advantages of 
mesoporous materials can be further integrated into floating tablets with fine control 
over the sustainable release of water-soluble drugs and, more importantly, 
enhancing the solubility of poorly water-soluble drugs, an issue that cannot be solved 
by conventional floating tablet technology. Our success has paved the way for 
formulation improvement in localised drug release. 
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Supporting information  
Materials and Methods 
4.S1. Preparation of MCM-41 particles 
MCM-41 material was synthesized using the method reported by Yang et al., with 
slight modifications.1In a typical synthesis, 1.0 g of CTAB was dissolved in 480 g of 
deionized water with 3.5 ml of NaOH (2 M) under stirring at 80˚C. Then, 6.7 ml of 
TEOS was added into the mixture and kept under continuous stirring for an 
additional 2 h. The resultant product was collected by filtration and dried at room 
temperature. The surfactant templates were removed by calcination at 550˚C for 5 h. 
The procedure for step wise pore size reduction of MCM-41 was followed according 
to literature.2 MCM-41 material (0.8 g) was held on the porous disc and TEOS was 
placed in the bottom chamber. The VVD apparatus is placed in the vacuum oven 
(175 Torr) at 60˚C for 24 h. TEOS vapour molecules can only pass through the 
porous disc and the mesoporous silica placed on the top of the disc. The vacuum 
(175 Torr) helps in continuous contact between mesoporous silica and TEOS vapour 
generated from the bottom chamber, so that TEOS molecules can be adsorbed on 
the silica surface. After 24 h of the VVD process, the mesoporous silica materials 
adsorbed with TEOS was calcined at 550˚C for 5 h. 
 
4.S2. Loading of curcumin and captopril 
Curcumin loading 
Curcumin was loaded into MCM-41 with two different pore sizes 2.1 and 1.7 nm 
using Rotavapor technique. To rotavapor flask (RF) containing 80 mg of silica 
material, 20 mg of curcumin was added followed by addition of 5 ml of methanol. 
This suspension was sonicated for 2 min in ultrasonic bath and the RF was affixed to 
the rotavapor assembly and methanol was slowly evaporated at 50˚C. The solvent 
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evaporation procedure was continued for another 30 min to ensure complete solvent 
removal. The obtained samples were denoted as Cur-MCM-41(1.7nm), Cur-MCM-
41(2.1nm). 
 
Captopril loading 
The captopril loading was done by wetting impregnation method. Initially 217.29 mg 
of drug was dissolved in 10 ml of water. To the drug solution 200 mg of MCM-41was 
added and kept for stirring at room temperature for 24 h. The drug loaded MCM-41 
were separated from the solution by filtration and kept in vacuum overnight. The 
obtained sample was denoted as Cap-MCM-41. 
 
4.S3. Characterization  
TEM images were taken using a JEOL 2100 microscope operated at 200Kv. The 
samples were prepared by dispersing MCM-41 in ethanol, and then transferred to a 
copper grid with dropper. SEM images were taken using a JEOL 7800 accelerating 
voltage operated at 1Kv.  SEM samples were prepared by cutting thin cross 
sectional layer of the tablet and placed on carbon tape mounted on the stage. X-ray 
diffraction (XRD) patterns were recorded on a German Bruker D8 X-ray 
diffractometer with Ni-filtered Co Kα radiation (λ=1.79 A). The XRD patterns were 
obtained at 40 kV and 30 mA with a step size of 0.01˚. Nitrogen adsorption-
desorption isotherms were measured at -196˚C by using a Micromeritics Tristar II 
3020 system. The drug loaded samples were degassed at 50˚C overnight on a 
vacuum line and pure MCM-41 is degassed at 180˚C for 6 h. The Brunauer-Emmett-
Teller (BET) method was utilized to calculate the specific surface area. The pore size 
distribution curves were derived from the adsorption branches of the isotherms using 
the Barrett-Joyner-Halanda (BJH) method. The total pore volume was calculated 
from the amount adsorbed at a maximum relative pressure (P/P0). 
Thermogravimetric analysis (TGA) and Differential Scanning Calorimetry (DSC) 
measurements were performed by TGA/DSC Thermogravimetric Analyser (Mettler-
Toledo Inc) with a heating rate of 2˚C /min in air flow. Erweka hardness tester was 
used to measure the hardness of the tablet. 
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4.S4. Preparation of tablets 
Preparation of floating tablets without and with curcumin 
The floating tablets were prepared by a direct compression method. Weights of each 
ingredient were taken according to Table S2, Table S3 for each formulation. Micro-
crystalline cellulose (MCC, bulking agent) was added in order to maintain the same 
weight of each tablet in different formulations. All the ingredients were mixed 
homogeneously with mortar and pestle for 10 min. Zinc stearate (a lubricant) was 
added at last to the mixed powders and then mixed further for 3 min. Finally, the 
powder was fed manually into die with spatula of a single punch tablet punching 
machine, equipped with concave punches (10 mm diameter). The hardness of the 
tablets is adjusted to 50 N by using Erweka hardness tester. 
 
Preparation of captopril tablets 
The floating tablets were prepared by direct compression method. Weights of each 
ingredient are taken according to Table S4, for each formulation and mixed 
homogeneously with mortar and pestle for 10 min. Zinc stearate was added to the 
final mixed power and mixed for additional 3 mins. Finally, the powder was fed 
manually into die with spatula of a single punch tablet punching machine, equipped 
with concave punches (10 mm diameter). The hardness of the tablets is adjusted to 
50 N by using Erweka hardness tester. 
 
4.S5. Determination of MSNs content in the tablet 
The amount of silica content in tablet after floating for 12 h in dissolution medium 
was determined. The floating tablet F0 to FD was used in this test. F0 was prepared 
without silica nanoparticles. After 12 h, the water content was removed by freeze 
drying overnight. The obtained dry tablet was kept in furnace at 500˚C for 5 h. The 
decomposition of all the ingredients except silica was below 500˚C (Melting point of 
HPMC K100M-260˚C, Sodium bicarbonate-50˚C, zinc stearate-120-130˚C, Silica-
1600-1725˚C). This was confirmed by the control formulation F0. Thus the weight 
after thermal treatment is attributed to the silica retained in the tablet after floating 
test.  
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4.S6. Dissolution studies 
Dissolution studies for curcumin 
The dissolution test was performed in rosette rise apparatus for maintaining sink 
condition as  reported by Gohel et al.3,4 The tablet was placed in a beaker (100 ml) 
modified at the base with inverted v shaped glass tube, containing 70 ml of HCl 
(0.1M) containing 0.8% tween 80, maintaining at 37˚C, stirred at 50 rpm. The burette 
was mounted on the top of the beaker to deliver the dissolution medium at a flow 
rate of 2 ml/min. At the same time 2 ml of medium was drained out of the beaker. At 
regular time interval 1 ml of sample was collected from the beaker and replaced with 
the same volume of fresh medium. Collected samples were filtered through 0.2 µm 
membrane filter and analysed spectrophometrically at 424 nm.  
 
Dissolution studies for captopril 
The dissolution test was performed in 200 ml of HCl (0.1M), maintaining at 37˚C, 
stirred at 50 rpm.5 At regular time interval 2 ml of sample was collected and replaced 
with the same volume of fresh medium. Collected samples were filtered through 0.2 
µm membrane filter and analysed spectrophometrically at 216 nm.  
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Supplementary Figures and Tables 
  
 
Figure 4.S1 XRD patterns (A) of a) Calcined MCM-41 with 2.1 nm b) Calcined MCM-
41 subjected to VVD process with 1.7 nm,  N2 adsorption-desorption isotherms (B) of 
calcined MCM-41 and MCM-41 subjected to VVD cycle and BJH pore size 
distribution plots (C) of calcined MCM-41 and MCM-41 subjected to VVD cycle.  
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Figure 4.S2 Transmission electron microscope (TEM) image (a) of MCM-41(1.7nm), 
(b) MCM-41 (2.1nm); Field-emission scanning electron microscope (FE-SEM) image 
(c) of MCM-41(1.7nm), (d) MCM-41 (2.1nm), (e) HPMC K100M, (f) Cross-section 
image conventional floating subjected to 12 h of dissolution study. 
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Figure 4.S3 A) The chemical structure of HPMC polymer. B) The amount of MSNs 
remained in floating dosage form after 12 h of dissolution study analysed by TGA.  
 
 
 
 
 
Chapter 4 
Floating tablets from meoporous silica nanoparticles 
- 84 - 
 
 
Figure 4.S4 TGA of Curcumin, MCM-41, Cur-MCM-41(1.7nm), Cur-MCM-41(2.1nm) 
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Figure 4.S5 (A) XRD pattern of Curcumin, physical mixture of curcumin and MCM-
41, Cur- MCM-41  (1.7nm), Cur-MCM-41 (2.1nm) and MCM-41, and (B) Differential 
Scanning Calorimetry of Curcumin, Cur-MCM-41 (1.7nm), Cur-MCM-41 (2.1nm) and 
MCM-41. 
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Figure 4.S6 (A) Nitrogen adsorption-desorption isotherms of Cur- MCM-41(1.7nm), 
Cur-MCM-41(2.1nm) and (B) pore size distribution plot of Cur- MCM-41(1.7nm), Cur-
MCM-41(2.1nm). 
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Figure 4.S7 (A) Nitrogen adsorption-desorption isotherms of MCM-41, Cap- MCM-
41 and (B) pore size distribution plot of MCM-41, Cap-MCM-41. 
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Figure 4.S8 TGA analysis of a) Captopril, b) Cap-MCM-41. 
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` 
Figure 4.S9 FTIR spectra of MCM-41, Captopril, Cap-MCM-41. 
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Figure 4.S10 A scheme showing the home-made Rosette rise apparatus. 
 
Table 4.S1 Physicochemical properties of MCM41 (1.7nm), Cur- MCM-41-1.7nm, 
MCM-41(2.1nm), Cur-MCM-41-2.1nm, MCM-41, Cap- MCM-41 
     
Sample Surface 
area 
(m2/g) 
Pore 
volume 
(cm3/g) 
Pore size 
(nm) 
Drug 
loading (% 
TGA) 
MCM41(1.7nm) 806 0.57 1.7  
Cur-MCM-
41(1.7nm) 
MCM-41(2.1nm) 
397 
1333 
0.24 
0.81 
1.7 
2.1 
20 
Cur-MCM-
41(2.1nm) 
MCM-41(2.1) 
751 
946 
0.46 
0.66 
2.1 
2.1 
20.9 
Cap- MCM-41 534 0.38 1.7 16.4 
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Table 4.S2 The compositions of floating tablets with bare MCM-41 
Formulati
on 
MCM-41 
(mg) 
HPMC 
K100M 
(mg) 
Sodium 
bicarbonate 
(mg) 
Zinc 
stearate 
(mg) 
Total weight 
of tablet (mg) 
 
F0   0   60   33     4.4 97.4  
FA   80   60   33     4.4 187.4  
FB 120 60 33 4.4 217.4  
FC 140 60 33 4.4 237.4  
FD 160 60 33 4.4 257.4  
 
 
Note: MCM-41 with a pore size of 2.1 nm was used. 
Table 4.S3 Composition of curcumin floating tablet 
 
Formu
lation 
MCM-
41(mg) 
Cur-
MCM-41 
(mg) 
Curc
umin 
(mg) 
HPMC 
K100M 
(mg) 
Sodium 
bicarbonate 
(mg) 
MCC 
(mg) 
Zinc 
stearate 
(mg) 
Total 
weight 
of tablet 
(mg) 
F1 0 100 0 60 33 0 4.4 197.4 
F2 80 0 20 60 33 0 4.4 197.4 
F3 0 0 20 60 33 80 4.4 197.4 
F4 0 100 0 60 33 0 4.4 197.4 
 
          
Note: In F2, F4, MCM-41 with a pore size of 2.1 nm was used. In F1, MCM-41 
with a pore size of 1.7 nm was chosen. 
Table 4.S4 Composition of captopril floating tablet 
 
Note: MCM-41 with a pore size of 2.1 nm was used. 
Formula
tion 
Cap-
MCM-41 
(mg) 
Captopr
il (mg) 
HPMC 
K100M 
(mg) 
Sodium 
bicarbon
ate (mg) 
MCC 
(mg) 
Zinc 
stearate 
(mg) 
Total weight 
of tablet 
(mg) 
F5    92      0    60    33     0      4.4 189.4 
F6 0 15 60 33 77 4.4 189.4 
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 Chapter 5 
Asymmetric silica nanoparticles 
with tunable head-tail structures 
enhances hemocompatibility and 
maturation of immune cells 
 
 
 
Asymmetric mesoporous silica nanoparticles (MSN) with controllable head-tail 
structures have been successfully synthesized. The head particle type is tunable 
(solid or porous) and the tail has dendritic large pores. The tail length and tail 
coverage on head particles are adjustable. Compared to spherical silica 
nanoparticles with a solid structure (Stöber spheres) or large-pore symmetrical MSN 
with fully covered tails, asymmetrical head-tail MSN (HTMSN) show superior 
hemocompatibility due to reduced membrane deformation of red blood cells and 
decreased level of reactive oxygen species. Moreover, compared to Stöber spheres, 
asymmetrical HTMSN exhibit a higher level of uptake and in vitro maturation of 
immune cells including dendritic cells and macrophage. This study has provided a 
new family of nanocarriers with potential applications in vaccine development and 
immunotherapy. 
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5.1 Introduction  
Asymmetric nanoparticles with polymeric, [1-3] inorganic, [4-6] and polymeric-
inorganic [7-10] hybrid compositions have attracted much attention in diverse fields. 
As an interesting family of porous materials with promising applications in 
therapeutic delivery, mesoporous silica-based nanoparticles (MSN) with asymmetric 
architectures have emerged only very recently.[10,11] Zhang et al. synthesized 
magnetic mesoporous Janus nanoparticles with aspect ratios from 2:1 to 7:1 and 
studied their magnetic properties.[5] Multicompartment MSN were synthesized via an 
epitaxial growth of hexagonally mesostructured silica branches on cubic mesoporous 
silica.[12] Asymmetric single hole mesoporous nanocages have been prepared by 
growth of cubic periodic mesoporous organosilica (PMO) on the surface of dense 
SiO2 nanoparticles followed by etching of SiO2. The particle was further 
functionalized with upconversion nanoparticles (UCNP) and used for a co-delivery 
system.[13] Recently, Kuroda and co-workers showed that MSN were asymmetrically 
capped by organosilica.[14] The asymmetric MSN reported so far were mainly 
prepared in aqueous systems, where relatively simple architectures with limited pore 
sizes (< 10 nm) can be obtained. Moreover, the advantage of asymmetric structures 
over symmetric ones has rarely been reported. 
Recently, dendritic mesoporous silica nanoparticles (DMSN) prepared in water/oil 
biphasic systems are emerging as a promising platform for biomedical applications. 
[15-19] The unique central-radial pore structures offer vast advantages, such as 
large pore size and highly accessible surface areas compared to conventional 
MSN.[20-22] To the best of our knowledge, constructing asymmetric MSNs with a 
highly controllable dendritic silica compartment with large pores has not been 
reported. 
 
5.2 Results and discussion 
In this work, head-tail mesoporous silica nanoparticles (HTMSN) with controllable 
structures have been successfully prepared for the first time using an oil/water 
emulsion system. As shown in Scheme 5.1, spherical silica head particles with either 
a solid or porous nature can be used to grow a dendritic tail with large pores (11-28 
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nm), forming asymmetrical HTMSN. The tail length and tail coverage on head 
particles are adjustable. Compared to solid head particles or MSN with fully covered 
 
Scheme 5.1 Illustration of synthesis of HTMSN and their advantages in 
hemocompatibility and maturation of immune cells. 
dendritic large pores, asymmetrical HTMSN show surprisingly higher 
hemocompatibility towards red blood cells. Further, HTMSN were analyzed for 
immunoadjuvant activity. Interestingly, we found that asymmetrical HTMSN exhibit a 
higher level of uptake and in vitro maturation of antigen presenting cells compared to 
spherical head particles. HTMSN were synthesized by dispersing monodispersed 
Stöber spheres[23] as head particles (Figure 5.S1) with a uniform size of ~ 200 nm in 
a water-chlorobenzene system, in which cetyltrimethylammonium chloride (CTAC) 
was used as a structure directing agent, tetraethylorthosilicate (TEOS) as a silica 
source and triethanolamine (TEA) as a catalyst (see Supporting Information). The 
calcined product is named as HTMSNV-t-H, where V represents the volume of TEOS 
(0.41, 1.25 and 3.75 mL), t is the reaction time (2, 3, 6, 9, 12 and 24 h) and H is the 
amount of head particles (0, 30 60,100, 200 and 400 mg). 
Figure 5.1 shows transmission electron microscope (TEM) and field-emission 
scanning electron microscopy (FE-SEM) images of HTMSN prepared with varied 
amount of TEOS V at a fixed t of 12 h and H of 60 mg. TEM images of HTMSNV-12-60 
(V=0.41, 1.25 and 3.75 mL, Figure 5.1A-C) clearly show a monodispersed 
asymmetric head-tail nanostructure with a uniform particle size of 377±5, 399±5, and 
427±5 nm, respectively. The particle size and tail coverage of HTMSNV-12-60  
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Figure 5.1 TEM and SEM images of HTMSN prepared at varied TEOS volume V. (A, 
D, G) HTMSN0.41-12-60, (B, E, H) HTMSN1.25-12-60, (C, F, I) HTMSN3.75-12-60. 
increased with increased TEOS amount V. Dynamic light scattering (DLS) 
measurements were used to further determine the particle size and polydispersity of 
HTMSNV-12-60 (Figure 5.S2). The size and polydispersity index (PDI) values of 
HTMSNV-12-60 (V=0.41, 1.25, 3.75 mL) were 392, 408, 478 nm and 0.18, 0.12, 0.20, 
respectively. The DLS sizes exceeded by 10-20 % of the particle diameters 
determined by TEM analysis due to the hydration of particles. The low PDI values 
suggest that HTMSNV-12-60 are monodispersed without significant aggregation. 
 
      
Figure 5.2 TEM images (A-E) of HTMSN1.25-t-60 collected at different reaction time 
(t=2, 3, 6, 9 and 24 h, respectively).  (F) The variation of tail length (black bar) and 
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head coverage (grey bar) as a function of t. Bars represent the mean ± SEM (n=20). 
Statistical analysis was performed using one-way ANOVA with Dunnett’s multiple 
comparisons test. (*) P < 0.05, (**) P < 0.01, (***) P < 0.001, (****) P < 0.0001, ns (P ≥ 
0.05) indicates no significant difference.  
The variation in TEOS volume V has a significant impact on the head-tail structure 
as shown by TEM images observed at higher magnifications. HTMSN0.41-12-60 
synthesized under a low TEOS amount have a tail length of ~ 80 nm (shown by a 
solid white line) and a uniform head coverage of porous shell (indicated by dotted 
circles) with a thickness of ~ 12 nm (Figure 5.1 D). The tail has a dendritic-like 
radially arrayed pore structure with large pores (> 10 nm), which are clearly seen 
under SEM observations (Figure 5.1G). The porous layer fully covered on the head 
has relatively smaller pores (< 3 nm, Figure 5.S3). When V is increased to 1.25 and 
3.75 mL, the length of both tail and head coverage is increased (summarized in 
Figure 5.S4). Increases in tail length and coverage also lead to tails with larger sizes, 
eventually an umbrella like structure is formed in HTMSN3.75-12-60 where the overall 
size of tail is larger than the head. For HTMSN1.25-12-60, radially aligned mesopores 
can be observed on the head surface with sizes similar to that in the tail region 
(Figure 5.1E). However, for HTMSN3.75-12-60, it appears that the mesopore sizes in 
both head and tail regions (Figure 5.1F) are smaller compared to HTMSN1.25-12-60. 
The relatively larger pore sizes in the head region can be observed for HTMSN1.25-12-
60 (Figure 5.1H), but not for HTMSN3.75-12-60 (Figure 5.1I). 
To characterize the porous nature of HTMSN, N2 sorption analysis was conducted. 
The nitrogen adsorption and desorption plots of three HTMSNV-12-60 (V=0.41-3.75) 
samples show type IV isotherms (Figure 5.S5A), the pore size distribution curves are 
shown in Figure 5.S5B. As summarized in Table 5.S1, all three samples have dual 
pores, one set of large pores (10-30 nm) and another set of small pores (1-3 nm). 
When V is increased from 0.41 to 1.25 and 3.75 mL, the pore sizes decrease for 
both large (28, 16 and 11 nm) and small pores (2.7, 2.1 and 1.8 nm). In contrast, 
both the surface area and pore volume increase with increasing V. 
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In order to elucidate the evolution of tail on the head, a time-resolved study was 
conducted. The collected samples at 2, 3, 6, 9 and 24 h are denoted HTMSN1.25-t-60 
(t=2-24 h). TEM images of the samples are shown in Figure 5.2A and Figure 5.S6 (at 
low magnification to show the uniform structures). As shown in Figure 5.2A, at 2 h a 
small tail with dendritic large pores (> 10 nm) and a length of ~ 20 nm was formed. 
When t was extended to 3 h, a thin layer with small mesopores (< 3 nm) uniformly 
covered on the head with a thickness of ~ 7 nm. At the same time the tail length 
increases to ~ 56 nm. When t was further increased (6-24 h), both the 
length/thickness of the tail/porous shell increased continuously (Figure 5.2F). When t 
was not longer than 9 h, only small mesoporous (< 3 nm) were observed in the 
porous shell covering the head particles (Figure 5.2D). Another dendritic porous 
layer with structures similar to that in the tails was formed after 12 h (Figures 5.1E 
and 2E).   
DLS measurements reveal a mean particle size of 255, 295, 342, 396, 458, and 531 
nm for HTMSN1.25-t-60 samples collected at 0, 2, 3, 6, 9 and 24 h (Figure 5.S7), 
consistent with both TEM (Figure 5.S6) and SEM (Figure 5.S8) results. N2 sorption 
analysis of HTMSN1.25-t-60 samples (Figure 5.S9) shows that large pores (> 10 nm, 
derived from the dendritic tail region) appeared at t = 2 h compared to solid silica 
head particles, in accordance with the SEM (Figure 5.S8B) and TEM (Figure 5.2A) 
observations. However, small sized mesopores (~ 2 nm) attributed to the head cover 
were generated at t = 3 h, also in agreement with the TEM results (Figure 5.2B). The 
BET surface area and pore volume both increased with increases in the tail length 
and thickness of head cover at prolonged t (Table 5.S2). 
The pore structures of HTMSN1.25-3-60 and HTMSN1.25-12-60 were studied by electron 
tomography (ET).[24-26] As shown by the ET slice, when t is 3 h a dendritic porous 
tail with large pores and a mesoporous layer homogeneously covering the head with 
smaller pores were observed (Figure 5.S10A). The small-sized mesopores also 
appeared in the inner layer of tail region. For HTMSN1.25-12-60 obtained at 12 h, it can 
be seen that bimodal mesopores were located on both head and tail nanostructures 
(Figure 5.S10B). The thickness of the small-sized mesoporous layer in the head and 
tail region is ~ 15 and > 50 nm, respectively. At the outer layer in both the head and 
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tail areas, dendritic large mesopores were also observed, in accordance with N2 
sorption results.  
We further studied the influence of the head amount on the final structures for 
sample HTMSN1.25-12-H by varying the head amount H from 0-400 mg in the reaction 
system while keeping the other synthesis conditions unchanged. Without adding 
dense silica spheres as the head (H=0), mesoporous silica nanoparticles with a 
spherical core-cone structure (MSN-CC) [27] were produced with ~ 200 nm in 
diameter (Figure 5.S11A). A mixture of MSN-CC and HTMSN particles was observed 
for HTMSN1.25-12-30 due to the limited number of head particles in the system for the 
production of HTMSN (Figure 5.S11B). The obvious difference in morphology of tail 
was observed between the samples prepared with 60 mg of head (HTMSN1.25-12-60, 
Figure 5.S11C) and greater than that (HTMSN1.25-12-100, HTMSN1.25-12-200 and 
HTMSN1.25-12-400). When the seed amount is larger than 60 mg, the head-tail 
morphology is not clear (TEM images Figure 5.S11D-F). HTMSN1.25-12-400 has a 
nearly spherical morphology with a fully covered dendritic shell and a mean particle 
size of ~300 nm (Figures 5.S7, 5.S11F, G), suggesting that the head particle amount 
is another important parameter to produce high yield HTMSN. 
In our synthesis system, the silica head particles were negatively charged before 
adding into reaction system ( potential: –31.9 mV). When the 
cetyltrimethylammonium cations (CTA+) were introduced into the aqueous solution 
containing silica nanoparticles, the surface of head particles changed to positively 
charged ( potential: +33.5 mV) due to electrostatic attraction. After the addition of oil 
(chlorobenzene) containing TEOS into the aqueous solution at a stirring speed of 
400 rpm, an oil-in-water emulsion (Figure 5.S12 A) was formed with an average oil 
droplet size of ~ 2-5 µm (Figure 5.S12 B). The identification of emulsion type was 
conducted by adding either oil or water. The added chlorobenzene was separated 
from the emulsion, indicating that oil is the dispersed phase. The emulsion remained 
stable after dilution with water, indicating that the continuous phase is water in the 
oil-in-water emulsion.  
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As reported in literature, [29] silica particles may arrange at the oil/water interface as 
an emulsifier to stabilize the emulsion droplet (Scheme 5.2A). Hydrolysis and 
condensation of TEOS leads to negatively charged silicate species, which 
cooperatively self-assemble with CTA+ as structure-directing agents to form the first 
mesostructured layer with relatively small pore sizes.[28] At the same time 
nucleation and growth of tails occurs preferentially on one side, possibly near the 
water phase, leading to the formation of HTMSN (Scheme 5.2B). 
 
Scheme 5.2 Schematic illustration of (A) an oil-in-water droplet stabilized by Stöber 
spheres and (B) the orientation of dendritic tail growth. 
To support the proposed mechanism, the emulsion in the HTMSN1.25-9-60 reaction 
system was directly treated by vacuum evaporation for 24 h for SEM observation. As 
shown in Figure 5.3A, some partially collapsed hollow spherical shapes can be 
observed. One clear hollow structure is shown in Figure 5.3B. The size of the hollow 
sphere is 2.5 µm, similar to the size of emulsion droplets. Interestingly, the wall of the 
hollow sphere is composed of one layer of asymmetric particles. Because the 
sample is not washed nor calcined in order to reduce the damage to sample, the tail 
structure is not that clear compared to the calcined samples. Nevertheless, the head-
tail morphology can still be distinguished with the spherical head towards the hollow 
cavity while the non-spherical tail outwards. The above observations are consistent 
with Scheme 5.2: Stöber spheres stabilize the oil-in-water emulsion droplets and the 
growth direction of dendritic tail is towards water.  
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Figure 5.3 SEM images of the HTMSN1.25-9-60 emulsion at low (A) and high (B) 
magnifications. 
The observation of MSN-CC without a head-tail asymmetrical morphology in the 
absence of head particles (H=0) is consistent with the above mechanism. To test 
whether the emulsion system is essential for the formation of head-tail structures, we 
also carried out reactions at a slower stirring speed (50 rpm) under which two 
phases were maintained. The TEM images of the resulting sample demonstrated a 
homogenous growth on the head (Figure 5.S13), suggesting that HTMSN cannot be 
prepared under conventional biphasic conditions.  
From the time-dependent growth studies, it is proposed that the formation of the 
large-pore dendritic tail is similar to what we reported before [27] and can be 
predicted by reference to the surfactant packing parameter (g). [28] It is reported that 
surfactant CTA+ presented in aqueous solutions forms spherical micelles,[29] thus at 
early reaction time (< 2 h) silica coated composite micelles aggregate together to 
form mesostructural coating on head region with small pores. The organic cosolvent 
(chlorobenzene in our case) diffuses into hydrophobic region of CTA+ micelles with 
time, leading to structural transformation to bilayered structures (g≈1).[30] Thus at 2 
h, large pore dendritic tail with a pore size of ~ 15 nm was observed (Figure 5.2A). 
The diffusion of chlorobenzene into CTA+ micelles is faster near the oil phase 
(where the nucleation of tails occurs) than in aqueous solution, therefore only 
composite micelles are coated at the head region until 9 h of reaction (Figure 5.2D), 
afterwards dendritic shell is also generated in addition to the dendritic tail (Figure 
5.2E). 
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The proposed mechanism can be used to explain the influence of TEOS amount. 
When the reaction time is kept at 12 h, reducing V from 1.25 to 0.41 mL leads to less 
silica source available in the system, thus further growth of dendritic shell in the head 
region is inhibited. When V is increased to 3.75 mL, HTMSN3.75-12-60 is formed with 
increased surface area and pore volume due to increased mesoporous 
compartments over dense silica head particles. 
Our approach to synthesize asymmetrical HTMSN can be applied to head particles 
with other structures. To demonstrate the formation of dendritic tails on porous head 
particles, dendritic MSNs (DMSNs) with an average particle size of ~ 150 nm (Figure 
5.S14) and a pore size ~ 4 nm (Figure 5.S15, Table 5.S4) were prepared according 
to a previous report [31] and used as head particles in our synthesis. Figure 5.4A 
clearly shows the formation of head-tail morphology with an asymmetrical 
architecture (named as HTDMSN1.25-12-60). The ET slice cutting from the centre of 
HTDMSN1.25-12-60 is displayed in Figure 5.4B, showing small mesopores in the head 
region and large pores (~ 16 nm) in the tail. The surface area and total pore volume 
of HTDMSN1.25-12-60 (303 m2/g and 0.47 cm3/g, Table 5.S4) with a short tail length 
were slightly higher than those of HTMSN1.25-6-60 with a solid head by a longer tail 
(295 m2/g and 0.35 cm3/g, Table 5.S2). These results suggest that our approach is 
versatile to grow dendritic tail on heads with either a solid or porous nature.  
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Figure 5.4 TEM image (A) and, ET slice (B) of HTDMSN1.25-60-12. 
In order to highlight the unique properties of asymmetrical HTMSN over symmetrical 
silica nanoparticles, their hemolytic activity was compared. HTMSN synthesized at 
different reaction time (HTMSN1.25-t-60, t=2, 3, 6, 9, 12 h) with tailored tail length 
(Figure 5.2) were chosen. For comparison, two symmetrical silica nanoparticles with 
only head or tail structure were included: the solid Stöber sphere and HTMSN1.25-12-
400 (fully covered by dendritic pores, Figure 5.S11F, G). All the samples included in 
this comparison share a similar surface zeta potential ranging from -30 to -40 mV 
(Table 5.S2, S5). A dose dependent hemolysis assay was conducted for all these 
samples. As shown in Figures 5.S16 and 5.S17, the hemolysis percentage increases 
as the particle concentration increases from 20 to 160 µg/mL for all these samples. 
To be noticed, only the symmetrical nanoparticles, Stöber spheres and HTMSN1.25-12-
400, show significantly higher hemolytic activity compared to all asymmetrical 
HTMSNs. 
By further increasing the particle concentration to 240 µg/mL (Figure 5.5), 
HTMSN1.25-12-400 show the highest hemolysis percentage of 92.0±1.7%, followed by 
Stöber spheres (26.2±0.7%). The hemolysis percentages of HTMSN1.25-t-60 (t= 2, 3, 
6, 9, 12, 24 h) exhibit a tail length dependent behaviour. Once the dendritic large-
pore tail is formed on Stöber spheres as head particles at 2 h (HTMSN1.25-2-60), the 
hemolysis percentage decreased rapidly from ~26% to 4.2±0.6%. With increasing 
reaction time and tail length the hemolysis percentages decreased (t=3 h, 4.1±0.8%, 
t=6 h, 2.9±1.0%), reaching the lowest value of 1.6±0.3% for HTMSN1.25-9-60. When 
the reaction time is prolonged to 12 h when the head particles were fully coated with 
dendritic structures (HTMSN1.25-12-60), the hemolysis percentage increased to 6.9± 
1.1%. The results demonstrate that the asymmetrical HTMSN have advantages over 
Stöber spheres by introducing a tail with large pores and reduced hemolysis, and 
also over HTMSN1.25-12-400 with large-pore but significantly high hemolysis. [32]  
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Figure 5.5 Hemolytic percentages of mouse RBCs upon incubation with different 
nanoparticles at 240 µg/milk D.I water and PBS was used as positive and negative 
control, respectively. Bars represent the mean ± SEM (n=3). All samples were 
compared with HTMSN1.25-12-400. 
The hemolytic activity of DMSNs, HTDMSN1.25-12-60 and MSN-CC was also studied. 
MSN-CC show a significant increase in hemolysis percentage from 3% at 20 µg/mL 
to 90% at 240 µg/mL (Figure 5.6, Figure 5.S18), similar to HTMSN1.25-12-400. For 
comparison, only a slight increase in hemolytic activity can be seen in both DMSN 
(from 3% to 7%) and HTDMSN1.25-12-60 (from 2 to 5%). The lower hemolytic activity of 
small-pore DMSN (4 nm) compared to large-pore MSN-CC (32.8 nm) is consistent 
with a literature report. [33] Nevertheless, the asymmetric HTDMSN1.25-12-60 with a 
large-pore dendritic tail also display highly improved safety with RBCs compared to 
MSN-CC (7% vs 90%). It is concluded that the asymmetric morphology significantly 
improves the hemocompatibility, and this concept is applicable in head particles with 
both solid and nonporous nature.  
The influence of surface charge, [34-36] shape and pore size, [37-38] particle size 
[33] and aspect ratio [32] of conventional MSNs on hemolytic activity has been 
reported. DMSN with highly accessible and large mesopores have emerged recently 
as promising carriers for intracellular delivery of large biomolecules. [20,27] 
However, their hemolytic activity has received less attention. Our studies have 
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demonstrated their potential risk causing high hemolysis. The fabrication of 
unsymmetrical HTMSN with large-pore tails and significantly improved 
hemocompatibility provides new candidates and approaches to overcoming this 
limitation. 
 
Figure 5.6 Hemolytic percentages of mouse RBCs upon incubation with different 
particles at various concentrations. 
To understand the underlying reason of the particle symmetry dependent 
hemocompatibility, symmetrical particles Stöber spheres, HTMSN1.25-12-400 and one 
asymmetrical particle HTMSN1.25-12-60 were chosen to study two possible 
contributions: extracellular reactive oxygen species (ROS) generation[39] and the 
contact mode of nanoparticles with RBC membrane.[38,40] It has been reported that 
Si-O three-membered rings can be formed on amorphous silica nanoparticle surface 
after high temperature calcination, and will further cleave and react with water 
molecules thus inducing hydroxyl free radicals in solution.[36] ROS generated by 
silica nanoparticles could result in peroxidation of cell components of RBCs, causing 
cell lysis. Figure 5.7A shows that HTMSN1.25-12-400 with the highest hemolysis 
percentages have a significantly higher extracellular ROS level than HTMSN1.25-12-60, 
suggesting the ROS level contributes to hemolytic activity of HTMSN1.25-12-400. 
However, there is no significant difference in ROS level between Stöber spheres and 
HTMSN1.25-12-60. Considering the large difference in hemolytic activity between 
Stöber spheres and HTMSN1.25-12-60 (Figure 5.5), we speculate that the low ROS 
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level is not the only important parameter for the excellent hemocompatibility of 
unsymmetrical HTMSN1.25-12-60.  
The interaction between silanol groups on silica surface and RBC membrane is 
recognized as one of the main reason for hemolysis. As reported by Slowing et al, 
compared to a solid silica sphere, a mesoporous silica nanosphere could have 
reduced silanol density contacting with RBCs, thus decreased hemolytic activity.[41] 
However, in our study, HTMSN1.25-12-400 with symmetrical coverage of large 
mesopores show much higher hemolysis than solid Stöber spheres and HTMSN1.25-
12-60, which indicates that the silanol groups interacting with RBCs may not be the 
dominant reason to explain for the hemolysis difference in our particles. 
SEM image shows the intact biconcave disks of free RBCs (Figure 5.S19A). A 
number of HTMSN1.25-12-400 (Figure 5.7B) were engulfed by RBC membranes, 
inducing a strong local membrane deformation. The Stöber spheres (Figure 5.7C) 
mainly adhered to RBC membranes with slight local membrane deformation. In the 
case of HTMSN1.25-12-60 (Figure 5.7D), the asymmetric particles lie flatly on the 
surface of RBC with no obvious membrane deformation (indicated by red arrows). 
Although a large number of HTMSN1.25-12-60 were found attached to the RBCs (Figure 
5.S19 B,C) similar to Stöber spheres and HTMSN1.25-12-400, the normal biconcave 
shape is maintained similar to control RBCs (Figure 5.S19A). 
To quantify the cellular uptake performance of Stöber spheres, HTMSN1.25-12-60, and 
HTMSN1.25-12-400 in RBCs, fluorescein isothiocyanate (FITC) was conjugated to silica 
particles and incubated with RBCs for 2 h for flow cytometry analysis. Almost all 
RBCs (98.7%) are positive to FITC-HTMSN1.25-12-400 (Figure 5.S20), suggesting 
strong interaction between HTMSN1.25-12-400 and RBCs. In contrast, FITC positive 
percentages of RBCs are significantly lower after incubation with FITC-HTMSN1.25-12-
60 (76.8%) and FITC-Stöber spheres (60.9 %). The overall trend in RBC uptake 
performance is in good agreement with SEM observations.  
It is suggested that the unique head-tail morphology makes it difficult for the particle 
to contact the RBC membrane in a vertical manner, either through the head or the 
tail region. Instead, the "flat" mode is preferred, leading to reduced contact sites and 
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surface area compared to symmetrical particles. Nanoparticle encapsulation by 
RBCs is dependent on the binding energy of nanoparticles toward RBC membranes 
and bending energy of RBC membranes. [40] The successful particle encapsulation 
occurs when the released binding energy conquers the desired bending energy. The 
reduced contact sites and surface area of asymmetric HTMSN1.25-12-60 than 
symmetric particles (HTMSN1.25-12-400, Stöber spheres and MSN-CC) toward RBC 
membrane determines less binding energy, leading to decreased particle penetration 
inside RBCs and subsequent cell membrane deformation. It is concluded that both 
the ROS level and contact mode with RBC membrane are important for the 
hemolytic property of nanoparticles. 
In recent years, engineered MSN have been extensively studied as a new class of 
adjuvants, stimulating robust antibody [42-45] or cellular immunity responses [46-49] 
of antigens with a great potential in disease and cancer treatment. For example, a 
recent report revealed that hollow mesoporous silica nanospheres acted as effective 
cancer vaccine adjuvants, significantly inhibiting tumour growth compared to the 
 
Figure 5.7 (A) Extracellular ROS generation of three nanoparticles and SEM images 
of RBCs incubated at room temperature for 2 h with (B) HTMSN1.25-12-400, (C) Stöber 
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spheres and (D) HTMSN1.25-12-60. Scale bar is 10 µm. Scale bar is 10 µm. In (A), bars 
represent the mean ± SEM (n=3). 
commercial adjuvant Alum. [47] However, it is not clear to date whether the shape of 
MSN will have influence on modulating immunological response, even though there 
are some reports on the shape effect on adjuvanticity of non-silica nanomaterials. 
[50-52] 
We compared the uptake level of asymmetrical HTMSN0.41-12-60 and HTDMSN1.25-12-
60, symmetric Stöber spheres, MSN-CC and DMSN, using DCs and macrophages. 
Fluorescein isothiocyanate (FITC) was conjugated to silica particles and incubated 
with freshly isolated mouse splenocytes in which DCs and macrophages were 
marked with CD11c-A600 and F4/80-APC-Cy7 antibodies, respectively. The 
resultant cell-associated fluorescence was measured by flow cytometer (Figure 
5.S21). As shown in Figure 5.8, the positive percentages of DCs and macrophage 
cells for Stöber spheres and DMSN are only ~40-50%. However, up to 92±0.1%, 
77±0.4 % DCs and 91±3.2%, 85±1.6% macrophages are positive to HTMSN0.41-12-60 
and HTDMSN1.25-12-60. The uptake of MSN-CC (48±2.8% in DCs, and 68±3.3% in 
macrophages) was slightly higher than Stöber spheres in macrophages, but also 
lower than asymmetric structures.  
 
Figure 5.8 Flow cytometric analysis showing FITC positive (A) CD11c+ DCs and (B) 
F4/80+ macrophages treated with FITC conjugated Stöber spheres HTMSN0.41-12-60, 
HTDMSN1.25-12-60, MSN-CC and DMSN. Bars represent mean ± SEM (n=3). 
The head-tail particles (HTMSN0.41-12-60 and HTDMSN1.25-12-60) significantly enhance 
APC uptake compared to conventional symmetrical ones (Stöber spheres, MSN-CC 
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and DMSN), possibly because the head-tail morphology provides a geometry 
favourable for phagocytosis.[53] Enhanced uptake of non-spherical nanoparticles 
than spherical ones was also observed in non-phagocytic human cervical cancer 
cells (HeLa).[54] The difference in the uptake of asymmetric structures between 
APCs and RBCs may be attributed to their different roles because macrophages and 
other APCs are professional scavengers to internalize foreign particles. Our results 
have shown that controlling the morphology of nanoparticles is an alternative 
approach to achieve targeting towards APCs, even without any targeting ligands, 
which is important for applications such as vaccines and immunotherapy.  
Next, we studied the maturation of APCs induced by these particles in the presence 
or absence of a model antigen (ovalbumin, OVA) to highlight the potential application 
of asymmetrical nanoparticles as potent immunoadjuvants. Splenocytes were 
incubated with bare particles and OVA loaded particles followed by specific 
fluorochrome-coupled antibody staining for analysing the expression of costimulatory 
molecules (CD40 and CD86), which are important signals for triggering CD4+ and 
CD8+ T lymphocytes. The cell population of DCs and macrophage was determined 
by CD11c+ and F4/80+ mean fluorescent intensity (MFI) during FACS analysis, 
respectively. 
For bare particles, asymmetric HTMSN0.41-12-60 and HTDMSN1.25-12-60 induced 
averagely higher levels of CD40 and CD86 expression on DCs and macrophages 
than symmetric Stöber spheres, MSN-CC and DMSN, although the difference is not 
always significant (Figure 5.9). The provoked APC maturation by asymmetric 
particles over symmetric ones can be explained by their enhanced cellular uptake 
(Figure 5.8). [51,55]  
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Figure 5.9 Flow cytometry analysis of maturation marker CD40 (A, C) and CD86 (B, 
D) expression levels on CD11c+ DCs (A, B) and F4/80+ macrophages (C, D) 
triggered by Stöber spheres, HTMSN0.41-12-60, HTDMSN1.25-12-60, MSN-CC and 
DMSN. Bars represent mean ± SEM (n=3). 
For comparison, APC maturation level stimulated by Alum was also studied. As 
shown in Figure 5.S22A, Alum shows significantly higher maturation level in both 
DCs and macrophages than asymmetric HTMSN0.41-12-60. However, the numbers of 
live DCs and macrophages treated with Alum are much lower than those treated with 
asymmetric HTMSN0.41-12-60 (Figure 5.S22B), indicating a significantly higher toxicity 
of Alum to APC. Our asymmetric HTMSN0.41-12-60 or HTDMSN1.25-12-60 presents a 
promising adjuvant with a balanced adjuvant efficiency and safety. Alum has been 
widely used as adjuvants in prophylactic vaccines in human but show weaker 
therapeutic efficacy in anticancer activity comparing with silica materials.[47] Our 
HTMSN with improved safety have a great potential as promising adjuvants in 
therapeutic cancer vaccines. We also investigated the capability of OVA (20 µg/mL) 
loaded particles (200 µg/mL) in triggering CD40 and CD86 expression on APCs 
(Figure 5.S23) and the observation is consistent with the data obtained from the 
blank nanoparticles. However, the overall expression level of CD40 and CD86 
triggered by OVA loaded particles is much higher than bare particles, which is 
consistent with previously reported results.[56] Delivery of encapsulated antigen in 
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nanoparticles provides synergistic effect in surface marker upregulation compared to 
either soluble antigens or bare nanoparticles.[57] These results suggest that the 
asymmetrical particles are more potent adjuvants to trigger the APC maturation than 
conventional symmetrical particles.  
 
5.3 Conclusion 
In conclusion, asymmetric HTMSNs with a unique head-tail morphology, adjustable 
large-pore dendritic tail structures (tail length and tail coverage) and tunable head 
structures (solid or dense) have been successfully synthesized for the first time using 
an oil/water emulsion system. The HTMSNs showed a tail length dependent 
hemolytic activity, which is dramatically lower than conventional symmetric 
nanoparticles with solid or dendritic mesoporous structures. The superior 
hemocompatibility was attributed to the reduced ROS generation and the “flat” 
contact mode to RBCs membrane. As a proof of concept, we further demonstrated 
the enhanced uptake of HTMSN into APCs compared to that of Stöber spheres, 
which in turn led to higher level of maturation. Our contribution provides a new family 
of asymmetric large-pore MSNs with potential applications as efficient 
immunoadjuvants and delivery vehicles for antigens or therapeutic biomolecules. 
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Supporting information 
Materials and Methods 
5.S1. Materials  
Chemicals: Cetyltrimethylammonium chloride (CTAC) solution (25 wt% in H2O); 
triethanolamine (TEA); chlorobenzene and tetraethylorthosilicate (TEOS, >98%), 3-
aminopropyl triethoxysilane (APTES), fluorescein isothiocyanate (FITC), ammonia 
aqueous solution (28 wt%) and ethanol were purchased from Sigma-Aldrich. 
PE/CY7-CD11c, BV605-F4/80, FITC-CD40 and, APC-CD86 were from BD 
Biosciences. All chemicals were used as received without further purification. 
 
5.S2. Synthesis of dense SiO2 head nanoparticles 
Uniform nonporous silica nanoparticles with a smooth surface were synthesized 
using a well-known method developed by Stöber et al. [1] Typically, absolute ethanol 
(50 mL) was mixed with deionized water (3.8 mL) and ammonium hydroxide solution 
(2 ml, 28%) at 308 K. Then, TEOS (2.8 mL) was added to the solution under 
vigorous stirring. After 6 h, the as-synthesized nanoparticles were separated by 
centrifugation, and washed with ethanol and deionized water. The final product was 
obtained by drying at 373 K overnight. 
 
5.S3. Synthesis of dendritic nanoparticles 
Dendritic mesoporous silica nanoparticles were synthesised according to literature 
with slight modification. [2] At first, 0.18 g of TEA was weighed in 100 ml round 
bottom flask. To flask 24 mL of CTAC (25 wt%) solution and 36 Ml of water were 
added and stirred slowly at 60 °C for 1 h. After 1 h, 16 mL of cyclohexane and 4 mL 
of TEOS was slowly added from sides of the flask and left the reaction under slow 
stirring for 24 h. The particles were collected after 24 h by centrifugation and washed 
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for several times with ethanol. The surfactant was removed by calcination at 650 °C 
for 6 h. The calcined product were named as DMSN. 
 
5.S4. Synthesis of head-tail nanoparticles 
In a typical synthesis, 60 mg of Stöber silica spheres of ~200 nm size were 
dispersed in 6 mL of milliQ water and 0.035 g TEA by sonication for 15 min. Then, 4 
mL of CTAC (25 wt%) solution was added into the solution and kept at 60 °C at a 
stirring speed of 400 rpm for 1 h. After stirring for 1 h, 8.75 mL of chlorobenzene and 
a pre-determined volume of TEOS (V=0.41, 1.25, 3.75 mL) was added into the 
above solution. The reaction was continued at 60 °C for 12 h. Particles were 
collected by centrifugation at 15,000 rpm, washed with water and ethanol twice and 
dried at 50 °C overnight. The calcined products were named as HTMSNV-t-H, where V 
represents the volume of TEOS, t is the reaction time and H is the amount of head 
particles. In this synthesis, the final products were labelled as HTMSN0.41-12-60, 
HTMSN1.25-12-60, HTMSN3.75-12-60, respectively. We also conducted experiments to 
study the influence of reaction time and head amount. The particles synthesized at 
reaction time (t=2, 3, 6, 9, 12 and 24) and head amount (H=0, 30, 60, 100, 200 and 
400 mg).  
The synthesis of HTDMSN1.25-12-60 was similar to that of HTMSN1.25-12-60, where 60 
mg of uncalcined DMSN were dispersed in 6 ml of milliQ water and 0.035 g TEA by 
sonication for 15 min. Then, 4 mL of CTAC (25 wt%) solution was added into the 
solution and kept at 60 °C at a stirring speed of 400 rpm for 1 h. After stirring for 1 h, 
8.75 mL of chlorobenzene and a 1.25 mL of TEOS was added into the above 
solution. The reaction was continued at 60 °C for 12 h. Particles were collected by 
centrifugation at 15,000 rpm, washed with water and ethanol twice and dried at 50 
°C overnight. The surfactant was removed by calcination at 650 °C for 6 h. The 
calcined product were named as HTDMSN1.25-12-60. 
 
5.S5. Amino group modification of silica nanoparticles 
Amino silane was grafted onto the surface of Stöber spheres, HTMSN0.41-12-60, 
HTDMSN1.25-12-60, DMSN, and MSN-CC to create positive charge particles. 200 mg 
Chapter 5 
Asymmetric silica nanoparticles with tunable head-tail structures enhances 
hemocompatibility and maturation of immune cells 
 
- 120 - 
 
of particles was suspended in 30 mL of toluene, and sonicated for 10 min, and then 
0.19 mL APTES was added and the mixture was refluxed at 110 °C for 20 h. The 
product were collected by centrifugation and washed twice with ethanol and water 
and dried at 50 ˚C for overnight. 
 
5.S6. Grafting of 5(6)-isothiocyanate dye (FITC) 
50 mg of amino modified particles were suspended in 20 mL of ethanol with 
sonication for 10 min. Afterwards, 5 mg of FITC was added and stirred the 
suspension for overnight in dark. FITC tagged particles were collected by 
centrifugation followed by 3 times washing with ethanol to remove the free dye. FITC 
is the original fluorescein molecules functionalized with an isothiocyanate reactive 
group (-N=C=S). This derivative is reactive towards nucleophiles such as amine and 
sulfhydryl groups on protein. 
 
5.S7. Characterization  
Nitrogen adsorption-desorption measurements were conducted at 77 K with a 
Micromeritcs Tristar ІІ system, before testing the samples were degassed at 453 K 
overnight on a vacuum line. The total pore volume was calculated from the amount 
adsorbed at a maximum relative pressure (P/P0) of 0.99. The Barrett-Joyner-
Halenda (BJH) method was used to calculate the pore size of samples from the 
adsorption branches of the isotherms. The Brunauer-Emmett-Teller (BET) method 
was utilized to calculate the specific surface areas. 
The SEM images were obtained using JEOL JSM 7800 field-emission scanning 
electron microscope (FE-SEM) operated at 1-1.5 kV using gentle bean mode. For 
FE-SEM measurements, the samples were prepared by dispersing the powder 
samples in ethanol, after which they were dropped to an aluminium foil piece and 
attached to conductive carbon film on SEM mount. Then the samples were dried in a 
vacuum oven at 60 °C for 12 hours and the samples were observed without any 
coating.   
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TEM images were obtained using JEOL 1010 and FEI Tecnai F30 operated at 100 
kV and 300 kV, respectively. Dynamic light scattering (DLS) were carried out at 298 
K using a Zetasizer Nano-ZS from Malvern Instruments. 
The ET experiment was performed in bright-ﬁeld TEM mode on a FEI Tecnai F30 
operated at 300 kV. All TEM images were recorded digitally at a given defocus in 
bright-ﬁeld mode to show the mass–thickness contrast. The ET specimens were 
prepared by dispersion of the samples in ethanol under ultrasonication for 5 min, and 
then deposition directly onto a formvar ﬁlm supported by a copper grid (3×1 mm slot, 
Electron Microscopy Science). Colloidal gold particles (10 nm) were deposited on 
both surfaces of the grid as ﬁducial markers for the subsequent image alignment. 
The tomographic tilt series were carried out by tilting the specimen inside the 
microscope in dual axis ranging from +65 ° to -65 ° at an even increment of 1°. 
Tomograms revealing the fine structures of nanoparticles were obtained by using the 
software of IMOD. [3]  
For the optical microscopy measurement the samples were prepared by adding 
emulsion on to a glass slide mounted with cover slip and the samples were observed 
under optical microscopy (Olympus BX51).  
 
5.S8. Uptake of nanoparticles by dendritic and macrophages in in-vitro model 
Briefly, mice spleens were passed through a cell strainer to obtain single cell 
suspension, and red blood cells were lysed using erylysis buffer (Sigma–Aldrich). 
The resulting cells were seeded in a 96-well plate at a density of 2x 105 cells/well in 
phenol free IMDM Glutamax medium (Gibco®, Life technologies), supplemented with 
10% fetal bovine serum  (FBS), 50 µM 2-mercaptoethanol (Gibco®, Life 
technologies), 100 U/mL penicillin, and 100 lg/ml streptomycin (Gibco®, Life 
technologies). Dextran-FITC (positive control) and samples (Stöber spheres, 
HTMSN0.41-12-60, HTDMSN1.25-12-60, MSN-CC and DMSN) labelled with FITC were 
added to the wells and incubated for 6 h. The adherent cells were scraped from the 
plate and incubated with Fc-block for 20 min at 4°C, centrifuged and resuspended in 
a buffer containing CD11c (eBioscience), F4/80 (BioLegend, Pacific Heights Blvd, 
San Diego, CA, USA) antibodies for 30 min at 4°C. The cells were then centrifuged 
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and resuspended in 0.5 mL of FACS buffer (PBS, 0.02% sodium azide, 0.5% bovine 
serum albumin (BSA)) and analyzed using LSR II flowcytometer (BD Biosciences). 
The fluorescence intensities of dendritic cells and macrophages treated with PBS 
were also measured as a negative control. The actual uptake was calculated as the 
percentage of cells double positive for FITC and CD11c and FITC and F4/80. 
 
5.S9.  Maturation study of dendritic and macrophages in in-vitro model 
Briefly, mice spleens were passed through a cell strainer to obtain single cell 
suspension, and red blood cells were lysed using erylysis buffer (Sigma–Aldrich). 
The resulting cells were seeded in a 96-well plate at a density of 2x 105 cells/well in 
phenol free IMDM Glutamax medium (Gibco®, Life technologies), supplemented with 
10% FBS, 50 µM 2-mercaptoethanol (Gibco®, Life technologies), 100 U/mL 
penicillin, and 100 lg/ml streptomycin (Gibco®, Life technologies). Stöber spheres, 
HTMSN0.41-12-60, HTDMSN1.25-12-60, MSN-CC and DMSN loaded with ovalbumin (20 
µg/mL) loaded particles (200 µg/mL) were added to the wells and incubated for 24 h. 
The adherent cells were scraped from the plate and incubated with Fc-block for 20 
min at 4 °C, centrifuged and resuspended in a buffer containing CD11c 
(eBioscience), F4/80, CD40, CD86 (BioLegend, Pacific Heights Blvd, San Diego, 
CA, USA) antibodies for 30 min at 4 °C. The cells were then centrifuged and 
resuspended in 0.5 mL of FACS buffer (PBS, 0.02% sodium azide, 0.5% BSA) and 
analyzed using LSR II flowcytometer (BD Biosciences). 
 
5.S10. Hemolysis Assay 
Ethylenediamine tetraacetic acid (EDTA)-stabilized mouse blood was provide by 
Australian Institute for Bioengineering and Nanotechnology Animal Facility, 
University of Queensland Biological Resources, Australia. Whole blood was 
centrifuged at 1600 rpm for 5 min, and the supernatant was discarded. After further 
washing RBCs with PBS until the supernatant was clear, 200 µL of packed RBCs 
was diluted to 4 mL with PBS (5% hematocrit). The diluted RBCs suspension (0.2 
mL) was mixed with 0.8 mL of varied nanoparticles at concentration of 20, 40, 
80,120, 160, 240 µg/mL. PBS and deionized water were used as negative and 
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positive control, respectively. The mixtures were gently vortexed and incubated at 
room temperature for 2 h. 
After centrifugation at 1600 rpm for 5 min, the absorbance of the supernatant was 
measured at 541 nm using a Synergy HT microplate reader. The percent hemolysis 
of RBCs was calculated based on following equation. 
Percent hemolysis = ((sample absorbance - negative control absorbance)/(positive 
control absorbance - negative control absorbance)) × 100. 
5.S11. SEM observation of RBC samples 
The diluted RBC suspension (0.2 mL) was mixed with 0.8 mL of varied nanoparticles 
at concentration of 240 µg/mL and incubated at room temperature for 2 h. The 
samples were fixed by adding 40 µL of glutaraldehyde solution (25 %) into 1 mL of 
above solutions. After incubation at 37 °C for 1.5 h, the RBCs samples were washed 
with PBS for 3 times, followed by postfix with 1% osmium tetroxide for 1.5 h, and 
then washing with PBS for three times. The RBCs were then dehydrated in 
increasing concentrations of ethanol (50, 60, 70, 80, 90, 95 and 100%) for 5 min 
each. Cell suspensions were dropped onto plastic coverslips, dried, and coated with 
Au and then viewed under JEOL 7001F. 
 
5.S12. Extracellular ROS study 
The measurement of extracellular ROS was conducted using H2DCF (2,7-
dichlorofluorescein). H2DCF working solution was prepared by dissolving 50 µg of 
H2DCF in 17.3 µL of ethanol. 0.01 M sodium hydroxide solution was added to the 
stock solution and placed at room temperature for 30 min. Later, 3.5 mL of 
phosphate buffer (pH=7.1) was added to neutralize the reaction. 200 µg/mL of 
nanoparticle solution was added to H2DCF stock solution and incubated at room 
temperature for 3 h. The fluorescence was measured at Ex497/Em527 using 
microplate reader. 
 
5.S13. Test to identify the emulsion type 
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2-4 mL of chlorobenzene or water was slowly added to 2-4 mL of emulsion under 
static condition.  
 
 
5.S14. Flow cytometry analysis of RBCs  
The diluted RBC suspension (0.2 mL) was mixed with 0.8 mL of FITC conjugated 
Stöber spheres, HTMSN1.25-12-60, and HTMSN1.25-12-400 at a concentration of 40µg∙mL-
1 and incubated at room temperature for 2 h. PBS was used as negative control. 
After 2 h, RBCs were analysed by accuri C6 flow cytometer. 
 
 
 
 
 
Supplementary Figures and Tables 
 
Figure 5.S1 TEM image of the dense stöber spheres as head with size ~ 200 nm.
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Figure 5.S2 Partice size distribution curves of a) HTMSN0.41-12-60, b) HTMSN1.25-12-60, 
c) HTMSN3.75-12-60 by DLS measurement. 
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Figure 5.S3 A TEM image showing the small mesopores in the porous layer fully 
covering the head region in HTMSN0.41-12-60. Scale bar: 100 nm. 
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Figure 5.S4 Tail length and head coverage length of samples HTMSN0.41-12-60, 
HTMSN1.25-12-60, and HTMSN3.75-12-60. Statistical analysis was performed using one-
way ANOVA with Dunnett’s multiple comparisons test. Data were considered 
significant different at (*) P < 0.05, (**) P < 0.01, (***) P < 0.001, (****) P < 0.0001, ns 
(P ≥ 0.05) indicates no significant difference. Bars represent the mean ± SEM (n=5). 
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Figure 5.S5 N2 sorption isotherms (A) and the BJH pore size distribution curves derived 
from adsorption branch (B) of a) HTMSN0.41-12-60, b) HTMSN1.25-12-60 and, c) 
HTMSN3.75-12-60.  
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Figure 5.S6 TEM images of  A) Stöber spheres; B) HTMSN1.25-2-60; C) HTMSN1.25-3-
60; D) HTMSN1.25-6-60 ; E) HTMSN1.25-9-60; F) HTMSN1.25-24-60. 
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Figure 5.S7 Particle size distribution of a) HTMSN1.25-0-60; b) HTMSN1.25-2-60; c) 
HTMSN1.25-3-60; d) HTMSN1.25-6-60 ; e) HTMSN1.25-9-60; f) HTMSN1.25-24-60. 
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Figure 5.S8 SEM images of  A) Stöber spheres; B) HTMSN1.25-2-60; C) HTMSN1.25-3-
60; D) HTMSN1.25-6-60 ; E) HTMSN1.25-9-60; F) HTMSN1.25-24-60. 
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Figure 5.S9 N2 sorption isotherms (A) and BJH pore size distribution curves derived 
from adsorption branch (B) of a) Stöber spheres; b) HTMSN1.25-2-60; c) HTMSN1.25-3-
60; d) HTMSN1.25-6-60 ; e) HTMSN1.25-9-60; f) HTMSN1.25-24-60. 
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Figure 5.S10 ET slices of A) HTMSN1.25-3-60 and, B) HTMSN1.25-12-60. 
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Figure 5.S11 TEM images of A) HTMSN1.25-12-0; B) HTMSN1.25-12-30; C) HTMSN1.25-12-
60; D) HTMSN1.25-12-100; E) HTMSN1.25-12-200; F) HTMSN1.25-12-400, SEM image of G) 
HTMSN1.25-12-400.  
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Figure 5.S12 Digital image of emulsion (A1) after addition of chlorobenzene to 
HTMSN1.25-9-60 emulsion, (A2) after addition of water to HTMSN1.25-9-60 emulsion, (B) 
optical image of emulsion. 
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Figure 5.S13 TEM image of MSN1.25-60-12 sample prepared at 50 rpm. 
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Figure 5.S14 TEM image of DMSN 
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Figure 5.S15 N2 sorption isotherms (A) and the BJH pore size distribution curves 
derived from adsorption branch (B) of dendritic particles (a) and HTDMSN1.25-60-12 (b). 
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Figure 5.S16 Hemolytic percentages of mouse RBCs upon incubation with Stöber 
spheres, HTMSN1.25-t-60 (t= 2, 3, 6, 9, 12), and HTMSN1.25-12-400 at different 
concentrations. D.I water (+) and PBS (-) were used as controls. Bars represent the 
mean ± SEM (n=3). Samples were compared with HTMSN1.25-12-400 under all tested 
concentrations. 
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Figure 5.S17 Hemolysis results. Photographs of RBCs treated with HTMSN at 
different concentrations. The released haemoglobin from the damaged cells in the 
supernatant can be seen from the photographs. (-) and (+) controls are the RBCs in 
PBS and water, respectively. 
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Figure 5.S18 Hemolysis results. Photographs of RBCs treated with DMSN, 
HTDMSN and MSN-CC at different concentrations. The released haemoglobin from 
the damaged cells in the supernatant can be seen from the photographs. (-) and (+) 
controls are the RBCs in PBS and water, respectively. 
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Figure 5.S19 SEM image of (A) free RBCs and (B, C) RBCs incubated with 
HTMSN1.25-12-60. 
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Figure 5.S20 Flow cytometry analysis showing FITC positive RBCs incubation with 
Stöber spheres, HTMSN1.25-12-60, and HTMSN1.25-12-400 for 2 h.   
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Figure 5.S21 Flow cytometer analysis of the uptake of A) Stöber spheres and B) 
HTMSN0.41-12-60 (C) HTDMSN1.25-12-60 (D) MSN-CC, (E) DMSN in dendritic cells (left 
panel) and macrophages (right panel). Q2 represents the percentage of dendritic 
cells positive for silica nanoparticles, Q2-1 represents the percentage of 
macrophages cells positive for silica nanoparticles.  
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Figure 5.S22 A) Flow cytometry analysis of maturation marker CD40 and CD86 
expression levels on CD11c+ DCs and F4/80+ macrophages triggered by HTMSN0.41-
12-60 and Alum, (B) live cell numbers of CD11c+ DCs and F4/80+ macrophages 
treated with Alum and HTMSN0.41-12-60. 
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Figure 5.S23 Flow cytometry analysis of maturation marker CD40 (A, C) and CD86 
(B, D) expression levels on CD11c+ DCs (A, B) and F4/80+ macrophages (C, D) 
triggered by OVA loaded Stöber spheres, HTMSN0.41-12-60, HTDMSN1.25-12-60, MSN-
CC and DMSN. Bars represent mean ± SEM (n=3). 
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Table 5.S1 Physical properties of samples HTMSN0.41-12-60, HTMSN1.25-12-60, 
HTMSN3.75-12-60. 
Samples S 
(m2/g) 
V (cm3/g) D 
(nm) 
PDI Mean 
particle 
diameter 
(nm) 
HTMSN0.41-12-60 
HTMSN1.25-12-60 
HTMSN3.75-12-60 
198 
369 
406 
0.40 
0.46 
0.49 
2.7, 28 
2.1, 16 
1.8, 11 
0.183 
0.128 
0.236 
387 
408 
466 
Note: S is BET surface area, V is total pore volume, and D is the pore size. 
 
Table 5.S2 Physical properties of stöber; HTMSN1.25-2-60; HTMSN1.25-3-60; 
HTMSN1.25-6-60; HTMSN1.25-9-60; HTMSN1.25-24-60. 
Samples S 
(m2/g) 
V 
(cm3/g) 
D 
(nm) 
PDI Mean 
particle 
diameter 
(nm) 
-
Potential 
(mV) 
Stöber spheres 
HTMSN1.25-2-60 
HTMSN1.25-3-60 
HTMSN1.25-6-60  
HTMSN1.25-9-60 
HTMSN1.25-24-60 
15 
73 
219 
295 
380 
403 
0.07 
0.17 
0.32 
0.35 
0.38 
0.44 
0 
15 
1.8, 18 
1.9, 18 
2.1, 18 
2.1, 13 
0.092 
0.197 
0.153 
0.237 
0.224 
0.125 
289 
297 
347 
406 
462 
540 
37.8 
-36.4 
-35.9 
-35.6 
-36.1 
-40.8 
Note: S is BET surface area, V is total pore volume, and D is the pore size. 
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Table 5.S3 Physical properties of HTMSN1.25-12-60 prepared at a stirring speed of 150 
rpm. 
Sample S (m2/g) V (cm3/g) D (nm) 
HTMSN1.25-12-60   234 0.34 2.5, 16 
Note: S is BET surface area, V is total pore volume, and D is the pore size. 
 
Table 5.S4 Physical properties of DMSN and HTDMSN1.25-12-60 
Samples S (m2/g) V (cm3/g) D (nm) -Potential 
(mV) 
DMSN 
HTDMSN  
162 
303 
0.40 
0.47 
4 
3, 16 
-32.6 
-35.45 
Note: S is BET surface area, V is total pore volume, and D is the pore size. 
 
 
Table 5.S5 Physical properties of HTMSN1.25-12-400 and MSN-CC 
Sample S(m2/g) V 
(cm3/g) 
D (nm) PDI Mean 
particle 
diameter 
(nm) 
-Potential        
(mV) 
HTMSN1.25-12-400   
MSN-CC 
182 
612 
0.36 
1.51 
2.1, 
16.5 
32.8 
0.17 
0.25 
338 
293 
-33.6 
-30.8 
Note: S is BET surface area, V is total pore volume, and D is the pore size. 
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Reference: 
[1] W. Stöber, A. Fink, E. Bohn, Controlled growth of monodispersed silica spheres 
in micron size range. J. Colloid Interface Sci. 1968, 26, 62-69. 
 
[2] Shen, D. Yang, J. Li, X, Biphase stratification approach to three-dimensional 
dendritic biodegradable mesoporous silica nanospheres. Nano Lett. 2014, 2, 923-32. 
 
[3] Kremer, J. R.; Mastronarde, D. N.; McIntosh, J. R. Computer visualization of 
three-dimensional image data using IMOD. Journal of Structural Biology 1996, 116, 
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 Chapter 6 
 
Core-shell-structured dendritic 
mesoporous silica nanoparticles 
for combined photodynamic 
therapy and antibody delivery 
 
 
 
Multifunctional core-shell-structured dendritic mesoporous silica nanoparticles with a 
fullerene doped silica core and a dendritic silica shell with large pores have been 
prepared. The combination of photodynamic therapy and antibody therapeutics 
significantly inhibits the cancer cell growth by effectively reducing the level of anti-
apoptotic proteins.    
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6.1 Introduction 
In the past decades, with the rapid development of nanotechnology, a variety of 
nanoparticles such as polyesters and polyacrylamide, [1] liposomes, [2-4] 
dendrimers, [5, 6] magnetic [7, 8] and other inorganic nanoparticles [9-11] have been 
widely used as carriers for photodynamic therapy (PDT). The combination of chemo 
and photodynamic therapy[12] is an effective approach for many cancer treatments 
with further enhanced therapeutic efficacy.[13-15] However, conventional 
chemotherapy using small molecular weight anti-cancer drugs has caused drug 
resistance and this problem exists in combinational therapy.[16] One promising 
alternative to chemotherapy for cancer treatment is antibody therapy. The combined 
PDT and antibody delivery is discovered as a promising strategy for cancer 
treatment by conjugating photosensitizers [17] with monoclonal antibodies (mAbs). 
However, there are some intrinsic issues, such as technical difficulty of chemical 
coupling and reduced phototoxicity. [18-22] Design of suitable carriers holds promise 
for improved combination therapy of photosensitizers and protein / antibody 
therapeutics by addressing these problems. 
Recently, mesoporous silica nanoparticles (MSN) have attracted attention mainly 
due to their easy functionalization, large surface area and high pore volume for high 
payload of therapeutic agents and effective cellular delivery.[23,24] Monodispersed 
MSN with small pores have applications limited to small drug delivery.[25] The 
discovery of dendritic mesoporous silica nanoparticles (DMSN) with large and open 
pore channels makes them attractive candidates for delivering large 
biomolecules.[26,27] Lin et al. reported the advantage of magnetic DMSN for 
doxorubicin hydrochloride (DOX) delivery.[28]  Later, Zhao and co-workers reported 
the synthesis of 3D-DMSN grown on gold and silver nanoparticles.[29] The 
composite DMSN fabricated so far have been used for real time fluorescence 
imaging, magnetic resonance imaging,[30] adsorption[31] and protein delivery.[29] 
However, to the best of our knowledge, there is no report using DMSN as a 
multifunctional platform for both PS with monoclonal antibodies (mAbs).  
Herein, we report the synthesis of a multi-functional core-shell structured 
nanoparticle consisting of a solid silica-fullerene core and a dendritic silica shell with  
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large pores (Scheme 6.1). The silica core doped with fullerene (C60) acts as PS and 
fluorescent agents for imaging. The large-pore dendritic silica shell after hydrophobic 
C18 modification is used to load a therapeutic mAb anti-pAkt. After intracellular 
delivery, the doped fullerene in the core generates single oxygen (1O2) and 
fluorescence under UV light excitation, whereas anti-pAkt provokes cell inhibition by 
blocking pAkt and downstream anti-apoptotic protein Bcl-2. [32] Compared to 
antibody treatment itself, the combination of PDT and antibody treatment significantly 
promote cell inhibition by reducing the downstream anti-apoptotic protein levels. 
Scheme 6.1 Schematic illustration of preparation procedure of FD for applications in 
imaging and combined protein-/photodynamic therapy. 
6.2 Results and discussion 
Solid silica-fullerene nanoparticles were prepared using a literature method [33] and 
used as core particles to generate a large-pore dendritic shell in an emulsion system 
(Scheme 6.1, see details in Experimental section, ESI). The templates were 
removed using solvent extraction and the sample is named FD. Modification with 
octadecyl groups resulted in a hydrophobic sample named FD-C18. Both FD and 
FD-C18 samples were used for combinational PDT and protein therapy. 
Transmission electron microscopy (TEM) images of FD and FD-C18 are shown in 
Figure 6.1A, B. Both nanoparticles are highly uniform and monodispersed with a 
diameter of 116 ± 2 and 119 ± 1 nm, respectively (n=50). A distinct dendritic  
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structure on fullerene loaded solid silica core can be clearly observed from TEM 
images. The large pore openings can be seen directly from scanning electron 
microscopy images (Figure 6.1C, D). The dynamic light scattering (DLS) 
measurement revealed that FD and FD-C18 has a hydrodynamic diameter of 122 
and 121 nm, respectively (Figure 6.S1, Table S1). The particle sizes of FD and FD-
C18 are close to those of TEM measurement. The successful modification of 
octadecyl groups is evidenced by two peaks at 2858 and 2929 cm-1 in the Fourier 
transform infrared (FTIR) spectra. As shown in Figure 6.1C, D, the pore openings 
and spherical morphology is well preserved after C18 modification. 
 
Figure 6.1 TEM and SEM images of (A,C) Fullerene dendritic (FD), B,D) Fullerene 
dendritic-C18 (FD-C18).  
The nitrogen adsorption/desorption isotherms of FD and FD-C18 are shown in 
Figure 6.S3. Both samples show similar type IV isotherms and capillary 
condensation steps at relative pressure (P/P0) higher than 0.9, indicative of large 
mesopores. From the pore size distribution curves, both FD and FD-C18 show a 
broad pore size centered at 28 nm. The Brunauer-Emmett-Teller surface area and 
pore volume of FD is 328 m2/g and 1.11 cm3/g (Table 6.S1, SI). After hydrophobic 
modification, the surface area and pore volume of FD-C18 decrease to 294 m2/g and  
Chapter 6 
Core-shell-structured dendritic mesoporous silica nanoparticles for combined photodynamic 
therapy and antibody delivery 
- 154 - 
 
 
1.01 cm3/g due to the grafted layer of silica-octadecyl-groups. The structural 
parameters of both FD and FD-18 are summarized in Table 6.S1 for comparison. 
The presence of C60 in FD and FD-C18 was studied according to a literature report. 
Pure solid silica (SS) nanoparticles without C60 were used as a control group. Figure 
6.S3C shows the UV-absorption spectra of SS, FD and FD-C18.  FD and FD-C18 
show peaks at 234, 217, 308 nm, which indicate the presence of C60. [33] TGA 
analysis was further used to quantitatively measure the C60 content in FD and FD-
C18 (Figure 6.S4). Silica dendritic [34]    and SD-C18 without C60 were used as 
control groups. The weight loss for SD and SD-C18, FD and FD-C18 was 0.6, 7.5, 
5.3 and 11.6 %, respectively. The C60 amount of FD and FD-C18 was calculated by 
subtracting the weight loss (%) obtained from SD and SD-C18, respectively. The C60 
amount in FD and FD-C18 was 4.7 and 4.1 %, respectively (Table 6.S2).  
To verify the generation efficiency of singlet oxygen (1O2) produced by FD and FD-
C18, 100 µL of 9,10-anthracenediyl- bis(methylene) dimalonic acid (ABDA, a 1O2 
sensor) solution (2 mg/mL) was mixed with FD (1 mg/mL) and FD-C18 (1.136 
mg/mL). The C60 concentration was kept the same (65 µg) in two positive groups 
and pure ABDA solution was used as a control group. ABDA after chemical reaction 
with 1O2 will bleach to endoperoxide, which results in a decrease in optical density 
(OD) at 376 nm. The change of OD in the ABDA control group was negligible in the 
absence of C60 (Figure 6.2A). For FD (Figure 6.2B), with increase in the UV 
exposure time the OD decreased, suggesting an increased amount of 1O2 produced 
by the FD over time. A similar trend was observed for the FD-C18 (Figure 6.2C), 
suggesting that both FD and FD-C18 have good 1O2 generation efficiency. Figure 
6.2D is the normalized OD values shown in Figures 6.2A-C, showing that the 
bleaching of ABDA is time dependent under UV illumination in the presence of C60. 
However, the 1O2 generation of FD-C18 was slightly less than FD. 
 
 
 
Chapter 6 
Core-shell-structured dendritic mesoporous silica nanoparticles for combined photodynamic 
therapy and antibody delivery 
- 155 - 
 
 
Figure 6.2 Photobleaching of ABDA by 1O2 generated by (A) pure D20, (B) FD, (C) 
FD-C18, (D) decay curves of pure D20, FD, and FD-C18 at 376 nm as a function of 
UV irradiation time. 
Confocal microscopy was used to investigate the cellular uptake capability of 
nanoparticles. As C60 has fluorescent activity, external conjugation of fluorescent 
dyes onto nanoparticles for cellular imaging can be eliminated. The fluorescence 
images of FD and FD-C18 treated MCF-7 cells were captured after 4 h post 
incubation. The cytoskeleton of the cell was marked with Alexa Fluor® 488 phalloidin 
(green), while the nucleus is stained with DAPI (blue). As shown in Figure 6.S5, cells 
without nanoparticle treatment have no red fluorescence. However, cells treated with 
FD and FD-C18 show red fluorescence in the cytoplasmic region, indicating that 
nanoparticles were internalized successfully into cells. Inductive coupled plasma 
optical emission spectroscopy (ICPOES) was used to quantify the cellular uptake 
efficiency of FD and FD-C18 by incubating 50 µg/mL particles with MCF-7 cells for 4 
h. As shown in Figure 6.S6, 64 pg FD/cell while 120 pg FD-C18/cell (50% increase) 
was detected. The significant improvement in cellular uptake performance of FD-C18 
is attributed to the hydrophobic modification, which was similar to the literature 
report. [32]   
In order to study the in vitro efficacy of our designed particles, the cell toxicity of FD 
and FD-C18 as a function of particle concentration was tested in a MCF-7 cell line. 
As shown in Figure 6.S7, the cell viability decreased with increasing dose. At low  
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concentrations of 20, 40 and 80 µg/mL, the cell viability of FD and FD-C18 was 
similar (96 vs 96 %, 84 vs 83 %, and 80 vs 79%, respectively). At higher dose of 120 
and 180 µg/mL, FD-C18 caused slightly higher toxicity to MCF-7 cells than FD. The 
cell viability of FD and FD-C18 was 82 vs 75 % and 69 vs 60 %, respectively. The 
toxicity of FD-C18 at the highest concentration is similar to that of C18 modified 
dense silica particles reported in literature. [35] 
To demonstrate the PDT efficacy of FD and FD-C18, the cancer cell inhibition as a 
function of UV irradiation time was tested (Figure 6.3). Under UV light exposure, the 
cancer cell inhibition was negligible within 5 min, while 20% cell inhibition was 
observed at 10 min irradiation time. The cell viability in the presence of FD (110 
µg/mL) and FD-C18 (125 µg/mL) was UV light exposure time dependent. The cell 
Figure 6.3 Cell viability of MCF-7 cells treated with FD and FD-C18 under different 
UV irradiation time. 
viability of FD and FD-C18 after exposing to UV light was 81% and 72% for 2 min, 76 
% and 55 % for 5 min, while 47% and 42% for 10 min. The higher cell inhibition (FD-
C18 over FD) is mainly attributed to the higher cellular uptake of FD-C18 (50% 
higher than FD), although its 1O2 generation efficacy is slightly lower than FD. 
Because the cell toxicity is relatively high caused by a longer UV exposure time such 
as 10 min, therefore we selected 5 min as a suitable UV exposure time for 
conducting combination therapy studies. It was reported that cooperative, synergistic 
therapies using dual or multiple therapy types can produce remarkable therapeutic 
efficacy and help various types of therapies effectively play coordinate roles in 
cancer therapy. The synergistic effects of PDT and therapeutic mAb anti-pAkt were  
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investigated using anti-pAkt, FD-C18 + anti-pAkt and FD-C18 + anti-pAkt + UV 
groups at different particle and protein concentrations. FD-C18 was chosen for 
combined therapy studies because it has high uptake into MCF-7 cell line than FD 
and good loading capacity of 12 µg/mg.  Efficient cellular uptake performance of 
nanoparticles is a prerequisite for successful cellular delivery. As shown in Figure 
6.4, free anti-pAkt at various concentrations showed little effect on cell viability. The 
cell viability at the highest anti-pAkt concentration of 1.5 µg/mL was 94 %. However, 
FD-C18 + anti-pAkt group in the absence of UV light exhibited cell viability of ∼ 85%, 
72% and 45% at particle concentrations of 35, 90, and 125 µg/mL, respectively. After 
UV light treatment for 5 min, the cell viability was further dropped to ∼ 51%, 33% and 
23%. This may be because of efficiency delivery of FD-C18 into the cells. 
 
 
Figure 6.4 Treatment of nanoparticles and anti-pAkt at various concentrations in the 
presence or absence of UV irradiation for 5 min. 
 
To study the knockdown efficiency of downstream Bcl-2 protein in MCF-7 cells after 
treatment, western-blot analysis was conducted (Figure 6.5). GAPDH serves as an 
internal standard. Bcl-2 protein regulates the cell death or apoptosis.[36]  Compared 
to the blank control group, anti-pAkt  treatment group showed similar levels of Bcl-2, 
in accordance with previous results,[37]  indicating that anti-pAkt mAb alone cannot 
enter into the cells and further showing the significance of nanoparticles in cellular 
delivery of anti-pAkt mAb. For FD-C18 + anti-pAkt group, suppression in Bcl-2 level 
was observed compared to the control and anti-pAkt groups. The results suggest 
that activation of caspases, and inhibition of cancer cell growth by blocking pAkt in  
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the cells can be achieved by successful uptake of nanoparticles loaded with anti-
pAkt antibodies. After treatment with FD-C18 + anti-pAkt + UV, the Bcl-2 protein 
level was significantly decreased compared to all the other groups. The combination 
of protein and photodynamic therapy showed significant reduction of Bcl-2 protein 
than single therapy, indicating that cell growth inhibition is associated with the 
cytosolic delivery of FD-C18 and efficient blocking of pAkt by PSs and mAbs and 
further reducing the level of Bcl-2. 
 
Figure 6.5 Western-blot analysis of Bcl-2 protein in MCF-7 cells after 5 min UV 
irradiation in blank control, anti-pAkt, FD-C18 + anti-pAkt and FD-C18 + anti-pAkt + 
UV groups. Blots presented are representative of typical results. GADPH served as 
an internal standard. 
 
6.3 Conclusion 
In conclusion, we have fabricated a new class of core-shell-structured dendritic 
mesoporous silica nanoparticles with multifunctions for combined PDT and antibody 
therapy. The C60 dispersed in the silica core led to efficient PDT and fluorescence for 
intracellular tracking. The dendritic shell with hydrophobic modification is utilized for 
intracellular delivery of large therapeutic mAbs. The combined treatment of antibody 
/ photodynamic therapy in MCF-7 cancer cells have shown significantly improved 
cancer cell inhibition by reducing the level of anti-apoptotic proteins. The 
nanoparticles developed in this work have the potential to be used diverse 
combination therapies. 
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Materials and reagents 
6.S1. Materials 
Cetyltrimethylammonium chloride (CTAC) solution (25 wt% in H2O); triethanolamine 
(TEA); chlorobenzene and tetraethylorthosilicate (TEOS, >98%), C60 fullerene (99%), 
cyclohexane, 1-hexanol, Triton X-100, n-octadecyltrimethoxysilane (n-ODMS, 90%),  
9,10-anthracenediyl-bis(methylene) dimalonic acid (ABDA), (3-4,5-dimethylthiazol-2-
yl]-2,5 diphenyltetrazolium bromide), ammonium hydroxide (28 wt%, 240 mL) were 
purchased from Sigma-Aldrich. Toluene was purchased from Merck. Dulbecco’s 
Modified Eagles Medium (DMEM), penicillin-streptomycin (10,000 U/mL) and trypsin-
EDTA (0.25 %) were purchased from GIBCO or Invitrogen, Life Sciences, Life 
Technologies. Monoclonal antibodies (rabbit source) to Bcl-2, and GAPDH and HRP-
linked anti-rabbit IgG antibody were purchased from cell signalling. MCF-7 (HTB-
22™) cell line was purchased from American Type Culture Collection (ATCC). All 
chemicals were used as received without further purification. 
6.S2. Synthesis of SSF and SS nanoparticles 
Uniform solid silica fullerene (SSF) nanoparticles were synthesized according to 
literature method. [1] In a typical synthesis, 16 mg of C60 fullerene was well 
dispersed in toluene by sonication. The dispersed fullerene solution was mixed , with 
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microemulsion solution composed of cyclohexane (20 mL), 1-hexanol (8 mL), 
distilled water (2 mL), and Triton X-100 (6.8 mL) under stirring for 30min. 400 µL of 
TEOS was added into the above mixture and stirred for another 30 min before 
addition of ammonium hydroxide (28 wt %, 2.4 mL). The mixture was continuously 
stirred at room temperature for 24 h, followed by addition of 40 mL of ethanol to 
break the microemulsion. The particles were collected by centrifugation at 20,000 
rpm for 10min and then washed with ethanol twice.  
Solid silica (SS) nanoparticles without fullerene was prepared using the same 
procedure as SSF in the absence of fullerene. 
 
6.S3. Synthesis of FD and SD  
In a typical synthesis, 60 mg of SSF was dispersed in 6 mL of milliQ water with 
dissolved 0.035 g of TEA by sonication for 15 min. Then, 4 mL of CTAC (25 wt%) 
solution was added into the solution and stirred at 60°C with a stirring speed of 400 
rpm. After stirring for 1 h, followed by addition of 8.75 mL of chlorobenzene and 1.25 
mL of TEOS. The reaction was continued at 60°C for 12 h. Particles were collected 
by centrifugation at 20,000 rpm for 10min, washed with water and ethanol twice. The 
final fullerene dendritic (FD) nanoparticles were obtained by vacuum drying 
overnight. Solid dendritic (SD) nanoparticles were prepared using the same 
procedure as FD, except the replacement of SSF with SS. 
 
6.S4. C18 modification of FD and SD 
60 mg of FD or SD was suspended in 9 mL of toluene, and sonicated for 10 min. 
Then 150 µL of n-ODMS was added into the mixture and refluxed at 110°C for 20 h. 
The final products (FD-C18 and SD-C18) were obtained by centrifugation, washing 
twice with ethanol and water and vacuum dried overnight.  
 
6.S5. Characterization 
Transmission electron microscopy (TEM) images were obtained with JEOL 1010 
operated at 100 kV. Scanning electron microscopy (SEM) images were taken using 
JEOL 7800 operated at 1kV. Dynamic light scattering (DLS) was carried out in D.I. 
water at 298 k using a Zetasizer Nano-ZS from Malvern Instrument. Nitrogen 
adsorption-desorption measurements were conducted at 77 K with a Micromeritcs 
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Tristar ІІ system, before testing the samples were degassed at 310 K overnight on a 
vacuum line. The total pore volume was calculated from the amount adsorbed at a 
maximum relative pressure (P/P0) of 0.99. The Barrett-Joyner-Halenda (BJH) 
method was used to calculate the pore size of samples from the adsorption branches 
of the isotherms. The Brunauer-Emmett-Teller  method was utilized to calculate the 
specific surface area. Thermogravimetric analysis (TGA) measurements were 
performed by TGA/DSC Thermogravimetric Analyser (Mettler-Toledo Inc) with a 
heating rate of 2°C /min in air flow. Fourier transform infrared (FTIR) spectra of FD 
and FD-C18 were recorded on ThermoNicolet Nexus 6700 FTIR spectrometer 
equipped with Diamond ATR (attenuated total reflection) crystal. UV-vis 
transmittance spectra were measured with a shimadzu UV-2450 double beam 
spectrophotometer. 
 
6.S6. Detection of singlet oxygen 
The generation of singlet oxygen was detected using 9,10-anthracenediyl-bis 
(methylene) dimalonic acid (ABDA) reagent. In our experiment, ABDA was chosen to 
monitor the release of singlet oxygen into solution (deuterium water) by recording the 
decrease in absorption of ABDA at 376 nm via UV-vis spectroscopy. 100 µL of 
ABDA solution (2 mg/mL) was mixed with FD (1 mg/mL) and FD-C18 (1.136 mg/mL) 
and analysed with UV-vis spectroscopy. ABDA dissolved in deuterium water was 
used as control sample. The absorption intensity of ABDA at 376 nm was monitored 
under different UV exposure times. 
 
6.S7. Cell culture 
MCF-7 cells were maintained as monolayer cultures in Dulbecco’s Modified Eagle’s 
Medium (DMEM), supplemented with fetal bovine serum (FBS) and 1 % penicillin-
streptomycin in a 5% CO2 incubator at 37°C. The media was changed for every 2-3 
days and the cells were trypsinized after reaching 80 % confluence.  
6.S8. Cellular uptake assay (Confocal) 
MCF-7 cells were seeded onto 24-mm glass coverslip in a 6-well plate with a density 
of 1×105 cells / well, one day before the assay. FD or FD-C18 nanoparticles was 
added into the cells with a concentration of 160 µg/mL and incubated for 4 h in 
serum free media. Afterwards, cells were washed twice with PBS and fixed with 4 % 
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formaldehyde solution for 30 min, followed by washing with PBS twice. The 
cytoskeleton of cells was stained with Alexa Fluor® 400 phalloidin (Life technologies, 
Australia) according to the vendor protocol. The coverslip was washed twice with 
PBS and mounted onto glass slides by fluoroshield with DAPI (sigma). The prepared 
slides were observed under confocal microscopy (LSM 710, ZEISS).  
 
6.S9. Cellular uptake assay (ICPOES) 
The cellular uptake of FD and FD-C18 nanoparticles was measured quantitatively 
using inductive coupled plasma optical emission spectrometry (ICPOES). MCF-7 
cells were seeded in a 6-well plate at 1×105 cells per well, one day before the assay. 
FD and FD-C18 nanoparticles was added into cells at a concentration of 50 µg/mL 
and incubated for 4 h in serum free media. The cells were then washed twice with 
PBS to remove the remaining particles and dead cells, and harvested with trypsin. 
The number of cells was recorded and the cell pellets were washed twice with PBS, 
followed by sonication in DI water to break the cells. The pellets were collected by 
centrifugation and the supernatant containing cell components were discarded. 
Fresh aqueous NaOH solution (1 M) was added into the pellets to dissolve silica 
components. The silicon concentration was measured by ICPOES, and the amount 
of silica per cell was calculated. 
 
6.S10. Cytotoxicity assay 
The MTT assay was used to determine the cell viability of MCF-7 cells treated with 
FD and FD-C18 nanoparticles. MCF-7 cells were seeded in 96 well plates at a 
density of 8×103 cells / well, one day before the assay. The cells were exposed to FD 
and FD-C18 nanoparticles with various concentrations (20, 40, 80, 120, 180 µg/mL) 
and incubated in 200 µL of serum containing medium for 24 h at 37 °C in a 
humidified atmosphere with 5% CO2. Afterwards, 20 µL of MTT solution (5 mg/mL) 
was added into each well and incubated for another 4 h. After removing media, 200 
µL of DMSO was added to each well. The absorbance at 540 nm was measured 
using a Synergy HT microplate reader. The cells without treatment were used as a 
control. All experiments were performed in triplicates for each group. Data was 
shown as the mean±SEM. 
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6.S11. The combined therapeutic effect of antibody and fullerene 
The combined therapeutic effect of anti-pAkt and fullerene delivered by FD-C18 was 
evaluated in MCF-7 cells. Cells were seeded in a 96-well plate with a density of 
8×103 cells / well one day before the assay. Cells were then treated with different 
concentrations of free anti-pAkt antibody, FD-C18 + anti-pAkt antibody for 4 h in 
culture medium. After 4 h’s incubation, cell culture media were replaced with PBS 
and the cells treated with FD-C18+anti-pAkt antibody were exposed to UV light for 5 
minutes. PBS in the UV exposed and non-exposed plates was replaced with culture 
media. After 24 h incubation the cell viability was measured using MTT assay as 
described above.  
 
6.S12. Western-blot analysis 
MCF-7 cells were plated in a 6 well plate at a seeding density of 2×105 cells/ well. 
The anti-pAkt antibody was incubated with FD-C18 in PBS at 4°C for 4 h for loading. 
The final concentration of FD-C18 was 125 µg/mL and anti-pAkt was 1 µg/mL. The 
cells were then treated with free anti-pAkt or anti-pAkt-FD-C18 complex for 4 h. 
Media were replaced with PBS and the cells treated with FD-C18+anti-pAkt antibody 
were exposed to UV light for 5 min. PBS in the UV exposed and non-exposed plates 
was replaced with culture media. After 24h incubation, cells were washed with cool 
PBS and lysed. The lysed cells were denatured at 95°C for 5 min followed by 
characterization by SDS-PAGE. Obtained bands were transferred to a PVDF 
membrane. Bcl-2 bands were targeted using Bcl-2 monoclonal antibody (mAb) as 
the primary antibody, and HRP-linked anti-rabbit IgG antibody as the secondary 
antibody. GAPDH mAb was used as internal standard. Bands were visualized using 
ChemiDoc MP System (Bio-Rad). 
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Supporting Figures and Tables 
 
Figure 6.S1 Particle size distribution curves of FD and FD-C18 in distilled water. 
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Figure 6.S2 FTIR spectra of a) FD and, b) FD-C18. The two peaks at 2924 and 
2854 cm-1 was attributed to asymmetric and anti-symmetric –CH2- stretching, 
respectively, indicating the successful attachment of octadecyl groups. 
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Figure 6.S3 N2 adsorption-desorption isotherms of  FD and FD-C18 (A), 
corresponding pore size distribution curves calculated from adsorption branches 
using the BJH method (B), and UV-Vis absorption spectra of the SS, FD and FD-C18 
(C). 
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Figure 6.S4 Weight loss curves of SD, SD-C18, FD and, FD-C18 using TGA 
analysis.  
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Figure 6.S5 Confocal microscopy images of MCF-7 cells without treatment (a), 
treatment with FD (b), FD-C18 (C) at a concentration of 160 µg/ml for 4 h. The 
cytoskeleton and nuclei of cells were stained by Alexa Fluor® 488 phalloidin (green) 
and DAPI (blue), respectively. Scale bar 50 µm. 
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Figure 6.S6 Cellular uptake performance of FD and FD-C18 measured by ICPOES. 
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Figure 6.S7 Cytotoxicity of FD and FD-C18 as a function of particle concentration in 
MCF-7 cells after 24 h. 
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Table 6.S1 Structural properties of FD and FD-C18  
Sample SBET 
(m2/g) 
Pore 
volume 
(cm3/g) 
Pore 
size 
(nm) 
Diameter (nm) 
TEM Mean 
particl
e 
FD 327.5 1.11 28 116±2 122.4 
FD-C18 294.3 1.01 28 119±1 121 
 
 
Table 6.S2 Fullerene content in FD and FD-C18  
Sample Weight loss (%) % of fullerene 
SD 0.6 - 
SD-C18 7.5 - 
FD 5.3 4.7 
FD-C18 11.6 4.1 
 
 
 
References: 
[1] J. Jeong, M. Cho, Y. T. Lim, N. W. Song and B. H. Chung, Synthesis and 
Characterization of a Photoluminescent Nanoparticle Based on Fullerene-Silica 
Hybridization. Angew Chem Int Edit, 2009, 48, 5296-5299.
                 Chapter 7 
                                                          
Conclusion and outlook 
 
 
The research that I have accomplished during my PhD is presented in this 
dissertation provides a useful guide for the formulation and development of solid 
dosage forms, and fabrication of new nanocarriers. Currently, there are many 
research attempts in the design and modification of nanocarrier for efficient drug 
delivery and treating disease. In this thesis MSN based floating tablets with long 
retention time in acidic medium was successfully formulated. A series of head-tail 
silica nanoparticles, fullerene dendritic MSN has been successfully synthesised and 
studied for hemocompatibility, antigen presenting cells uptake, maturation of 
dendritic cells for former particles, and  demonstrated the advantage of dual therapy 
using antibodies and photosensitiser for cancer treatment for later.  
 
7.1 Conclusions 
1. A new generation of floating tablets based on MSNs for the localised drug delivery 
was developed. Calcined MCM-41 type MSNs with two different pore size (2.1 and 
1.7 nm) were used in the preparation of tablets. The loading of Curcumin into MCM-
41 was confirmed by XRD and DSC analysis and the loading percentage is 20.0% 
and 20.9 % in MCM-41 with the pore size of 1.7 and 2.1 nm, respectively. In 
addition, the loading of captopril into MCM-41 with the pore size of 2.1 nm was 
confirmed by TGA with the loading efficiency of 16.4%. Floating tablets with 
curcumin or captopril loaded MCM-41 was prepared by tablet compression machine. 
The homogenous distributed and retention of MCM-41 in the tablet was even evident 
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after 12 h of dissolution process. The percentage of curcumin release from the 
formulation prepared with MCM-41 (1.7nm) was 42.8 % at 20 h, which was 
comparatively higher than the formulation prepared with MCM-41 (2.1nm), without 
MCM-41 and physical mixture. In addition, captopril release from the floating tablet 
prepared with captopril loaded MCM-41, was only 60 % at 6 h and it was 100% at 
the same time point for conventional captopril floating tablet. (Relevant content: 
Chapter 4) 
2. The second major contribution of this work is synthesis of head tail dual pore 
mesoporous silica nanoparticles, via emulsion system. Although, there are few 
literatures on the synthesis of asymmetric silica nanoparticles, but still there is dearth 
for synthesis of safe, dual pore asymmetric silica nanoparticles for biomedical 
application. Stöber spheres with a fixed head particle of ~200 nm, with different tail 
length and head coverage were fabricated by changing the reaction time, silica 
source and amount of head particles. With increase in the reaction time from 2 to 24 
h, the tail length was increased from 20 nm to 18 nm, respectively. In addition, with 
increase in the silica source the tail length can be tuned from 97 to 176 nm. All head 
tail nanoparticles (HTMSN) contain a dual pore with the pore size of ~ 2nm and 28 
nm. We further replaced the dense silica head with the porous silica nanoparticle for 
generation of porous head tail MSN. To the best of our knowledge this is the first 
report on the synthesis of asymmetric silica nanoparticles with tuneable tail lengths. 
All head tail nanoparticles has good hemocompatibility with less than 8 % hemolysis 
after 4 h of incubation. However, symmetric particles have > 90 % hemolysis at 
similar time point. In addition, to hemocompatibility, head tail nanoparticles have high 
efficient uptake by APC than stöber spheres. Furthermore, the dendritic cell 
expression of CD40 and CD86 induced by stöber spheres was slightly lower than 
head-tail silica nanoparticles. (Relevant content: Chapter 5) 
3. Utilizing the emulsion system, fullerene core large pore dendritic silica 
nanoparticles was synthesised (FD-MSN). The advantage of combined 
photodynamic and antibody therapy in treatment of cancer was demonstrated by FD-
C18. The synthesized FD-C18 has a unique feature in terms of its structure, porosity. 
The synthesised nanoparticles are about the size of 100-120 nm, with the fullerene 
core size of 50 nm and the dendritic shell size of 70 nm. The FD-C18 exhibited a 
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surface area of 327.5 m2/g, pore size of 28 nm and pore volume of 1.11 cm3/g. After 
hydrophobic modification the surface area came down to 294.3 m2/g. The 
hydrophobic modified particles were successfully loaded with anti-pAKt antibody. 
The hydrophobic modified and unmodified particles was efficient in generating 
reactive oxygen species under light excitation. The fluorescence generated due to 
the dispersed fullerene in the core of FD-C18 was used for intracellular tracking of 
particles in MCF-7 cell line. The FD-C18 facilitated the intracellular delivery of 
therapeutic protein anti-pAKt antibody, and has good fluorescence generating 
activity. The combined antibody/photodynamic therapy were conformed in cancer 
cells, leading to cell viability down to ~21 % at the concentration of 1.5 µg/ml of anti- 
pAKt antibody. (Relevant content: Chapter 6) 
 
7.2 Recommendations for future work 
This work has introduced the improvement in the formulation design of floating 
tablets, synthesis of head tail nanoparticles and symmetric dendritic fullerene core 
silica nanoparticles and its application in vaccines and cancer therapy. However, 
there is still room to develop for improving the efficiency of nanoparticles. 
 
7.2.1 Active targeting and fullerene solubility 
In chapter 5, we have shown the advantage of combined therapy in cancer 
treatment. However, conjugating targeted peptide can help in uneven accumulation 
of nanoparticles in the body. To make current nanoparticles more reliable targeting 
moiety like folic acid can help targeting the nanoparticles to the cancer cells. Thus 
attachment will greatly help in unwanted side effects and improve cell specificity. 
Pegah et.al.,[1] have conjugated folic acid/methionine for active targeting delivery of 
docetaxel to tumor. They observed that targeted delivery enhanced the antitumor 
efficacy for cancer therapy. 
 
7.2.2 Replacing head with various metal nanoparticles 
In chapter 2, we have shown the advantages of head-tail nanoparticles in 
hemocompatibility and as an adjuvant. We have also shown that solid head part can 
be replaceable with porous nanoparticles. In the similar way solid or porous head 
part can be replaced with silica coated gold or iron nanoparticles. The gold or iron 
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nanoparticle HTMSN not only serves as nanovaccine, it can also be used as 
diagnostic agents and in lateral flow immunoassays. Gold nanoparticles have high 
surface to volume ratios and can be functionalised to detect specific targets, offering 
lower detection limits and higher selectivity than conventional strategies.[2] Mirkin’s 
group were pioneers in using gold nanoparticles in molecular detection system. The 
product developed was used for warfarin metabolism and F5/F2/MTHFR mutations. 
7.2.3 In vivo studies 
Finally, in this thesis we have shown the advantages of asymmetric particles in the 
uptake and activation of antigen presenting cells. We also tested the in vivo efficacy 
of HTMSN loaded with J8 antigen. However, due to the limited time we did not 
include the in vivo data in this thesis. We tested the DMSN and HTDMSN 
nanoparticle shape influence on generating antibodies response in vivo by using J8 
as model antigen. Both the nanoparticles showed a J8 (model antigen) loading 
capacity of greater than 800 µg/mg of particles. The effect of particle shape on 
generating antibody response was studied, where HTDMSN showed high overall 
antibody titre and IgG1 than DMSN. This high antibody titre could be contributed 
from high uptake into macrophages. This finding helps in developing promising 
candidates in vaccine development. The influence of particle morphology (e.g., 
spheres versus rods) on immune response has been reported in silica,[3] aluminium 
oxyhydroxides,[4] and gold nanoparticles,[5] showing that the shape of nanoparticles 
is another important parameter on their adjuvanticity. 
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